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In multiple sclerosis (MS), clonally-expanded brain-resident B cells may sustain chronic 
disease, however their relative contributions versus recently recruited B cells is unclear. 
Furthermore, pro-inflammatory CD20+ T cells may also be involved in MS pathogenesis. 
This study aimed to characterise the cerebrospinal fluid (CSF) B cell response in MS and 
investigate the features of CD20+ T cells. 
CSF B cells and antibody-secreting cells (ASC) displayed an activated phenotype and were 
identified in MS CSF at a higher frequency than controls. In contrast to the periphery, CSF 
ASC almost exclusively expressed IgG and were strongly Ig-biased, whereas memory B 
cells displayed similar immunoglobulin expression profiles in both compartments. MS CSF 
antibodies were frequently reactive towards EBNA-1, which preferentially induced an Ig-
biased antibody response. Finally, CD20+ T cells displayed a highly activated effector 
phenotype and were present in the CSF, although their frequencies were no different between 
MS and other neurological disease groups. 
These findings suggest that most CSF B cells result from non-specific recruitment, whereas 
ASC are involved in a persistent Ig-biased antigen-driven immune response, which may 
primarily be directed towards EBNA-1. Despite their highly activated phenotype, a role for 
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Chapter 1: General Introduction 
1.1 Overview 
The ability of the human immune system to recognise and protect against an almost limitless 
range of antigens whilst simultaneously maintaining tolerance to self is a crucial property of 
adaptive immunity. Though mechanisms to prevent loss of tolerance exist, these checkpoints 
may be breached by autoreactive lymphocytes, and the failure to control aberrant responses 
by these cells can result in autoimmune conditions such as multiple sclerosis. The distinction 
between the instigators and propagators of autoimmune conditions, and the identification and 
characterisation of immune cell populations that are involved, can provide important 
information on the pathological mechanisms, along with the dynamics, of a disease course. In 
this thesis, I explore the possible contributions of B cells and T cells to the pathogenesis of 
multiple sclerosis.  
1.1.1 Innate Immunity 
The innate immune system is an ancient and evolutionary conserved system representing the 
first immunological line of defence following breach of a physical barrier such as the skin or 
mucosa. Cells of this system include macrophages, neutrophils, eosinophils and basophils. 
Innate immune cells utilise pattern recognition receptors (PRRs) to recognise structural 
pathogen components, termed pathogen-associated molecular patterns (PAMPs), which 
includes fungal and bacterial cell wall components and viral nucleic acids (Iwasaki and 
Medzhitov, 2015). PRRs divide into several families including toll-like receptors (TLR), C-
type lectin receptors (CLR) and retinoic acid-inducible gene-1 like receptors (RLR) which 
recognise both extracellular and intracellular microbial components (Thompson et al., 2011). 
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PAMP recognition induces numerous effector functions such as increased phagocytosis, 
increased antigen presentation and pro-inflammatory cytokine secretion; a response that is 
tailored to the type of pathogen recognised (Turvey and Broide, 2010). Importantly, PAMP 
recognition also leads to activation of the adaptive immune response.  
In addition to these cellular components, the innate immune system comprises the 
complement system, a collection of serum proteins which enhances pathogen removal. These 
proteins exist as inactive zymogens that are activated in the presence of bacterial products 
(alternative and lectin pathways) or in the presence of IgG or IgM immune complexes 
(classical pathway) (Sarma and Ward, 2011). Activation of either pathway results in a 
proteolytic cascade, which ultimately leads to formation of the membrane attack complex 
(MAC) and subsequent pathogen lysis (Tegla et al., 2011). 
1.1.2 Adaptive Immunity 
In many circumstances, innate immunity alone is not sufficient to fully eradicate pathogens 
from the body. Cells of the adaptive immune system are highly specialised in clearing 
pathogens by mounting a sophisticated antigen-specific response. In contrast to innate cells, 
adaptive cells utilise one type of antigen-recognition receptor, each with a single specificity 
that collectively can recognise an almost limitless number of antigens; this is achieved by 
gene segment recombination (see section 1.2.2).  
In addition to sophisticated antigen recognition, a hallmark of adaptive immunity is the ability 
of adaptive immune cells to provide long-lived protection by developing ‘memory’, allowing 
more rapid and efficient responses to previously encountered antigens. These properties, 




1.2 B cell biology 
1.2.1 B cell lineages  
B cells can be divided into two major lineages, B1 cells and B2 cells, which differ in 
ontogeny, phenotype and anatomical location. B1 cells are a self-renewing population 
generated in the foetal liver and are enriched in the peritoneal and pleural cavities (Lund, 
2008). B1 cells constitutively secrete high levels of IgM in the absence of infection, known as 
natural antibody, which is rapidly increased following activation. These antibodies are germ-
line encoded with limited diversity, they display high polyreactivity and autoreactivity and 
can recognise repeating non-protein antigens such as microbial components (Nagele et al., 
2013).  
B2 cells arise from bone marrow progenitors and are made up of follicular B cells and 
marginal zone (MZ) B cells. MZ B cells express the integrins αLβ2 and α4β1 and the 
sphingosine-1-phosphate receptors S1P1 and S1P3, which retain them in the marginal sinuses 
of the spleen, permitting continual surveillance for blood-borne pathogens (Weill et al., 2009). 
Like B1 cells, marginal zone B cells can respond rapidly when activated, differentiating into 
antibody-secreting cells (ASC) in just one to two days following stimulation (Lund, 2008). B1 
and MZ cells express TLR and can respond to PAMPs including carbohydrates and lipid 
antigens with or without B cell receptor (BCR) ligation (Cerutti et al., 2013). Thus, both B1 
and MZ cells possess innate-like features and are ideally located and equipped to rapidly 
respond to T-independent (TI) antigens.  
The other B2 lineage cell type, follicular B cells, are the predominant B cell population in the 
body and are considered the conventional B cells of adaptive immunity. These cells use the 
blood and lymph to re-circulate between the follicles of secondary lymphoid organs, where 
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the majority of these cells are located. Follicular B cells primarily respond to T-dependent 
(TD) antigens, processing proteins and presenting them to CD4+ T cells loaded onto Major 
Histocompatibility Complex (MHC) class II molecules, although they can respond to TI 
antigens (Hoffman et al., 2016; Nutt et al., 2015).  
1.2.2 B cell development and V(D)J recombination 
The extraordinary range of foreign antigens that the immune system may encounter during an 
individual’s lifetime demands a highly diverse antibody repertoire able to recognise more than 
5x1013 different antigens (Pieper et al., 2013). This diversity is achieved by V(D)J 
recombination, in which variable (V), diversity (D) and joining (J) germline gene segments 
are spliced and rearranged to generate antibodies with almost endless specificities from a 
limited set of pre-existing gene segments. This process is carried out by enzymes encoded by 
recombination-activating genes (RAG1 and RAG2) which introduce breaks in conserved 
regions of DNA expressed adjacent to each segment, known as recombination signal 
sequences (RSS).  The segments are liberated and re-joined using DNA repair mechanisms to 
yield a contiguous V(D)J region, where additional diversity is created through nucleotide 
deletion and the addition of palindromic (P-) or non-template encoded (N-) nucleotides 
(Market and Papavasiliou, 2003; Nadel and Feeney, 1997).  
The generation of mature naïve B cells expressing functional BCRs is summarised in Fig. 1.1. 
Following migration of common lymphoid progenitors (CLP) to the bone marrow and 
expression of Paired box protein 5 (Pax5) to determine B lineage commitment, RAG 
expression is induced in progenitor (pro)-B cells to rearrange heavy chain V, D and J 
segments on the first chromosome (Cobaleda et al., 2007). Another enzyme, terminal 
deoxynucleotidyl transferase (TdT), is also expressed at this stage. TdT helps to generate 
diversity by adding N-nucleotides to the V, D and J segments and like RAG-1 and RAG-2 
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enzymes is expressed only during somatic mutation (Melchers, 2015). If gene segment 
rearrangement is unsuccessful, the B cell attempts to rearrange segments on the second 
chromosome and if it fails, the cell dies. If successful rearrangement occurs, RAG genes are 
down-regulated and the heavy chain is expressed on the cell surface with surrogate light chain 
proteins λ5 and VpreB, marking the start of the pre-B cell phase (Grawunder et al., 1995). At 
this stage, B cells undergo their first central tolerance checkpoint to eliminate potentially 
autoreactive B cells, and any pre-B cell receptor with strongly reactive heavy chains are 
deleted (Basten and Silveira, 2010). Following a proliferative phase in which pre-B cells 
become large pre-B cells, these cells exit the cell cycle to become small pre-B cells; at this 
stage, the light chain gene loci are opened, and RAG genes are re-expressed (Nemazee, 2006). 
Immunoglobulin light chains may be either kappa (Ig) or lambda (Ig) isotypes. V and J 
Figure 1.1. B cell development and the generation of a functional B cell receptor. Within 
the bone marrow, B cells undergo a series of developmental stages marked by gene 
rearrangement and editing of heavy and light chains. This either results in apoptosis or 
expression of a unique and fully functional BCR which does not recognise self-antigens. 




segments of the kappa light chain are rearranged first, however if this produces a non-
functional product, the kappa locus is removed by the kappa deleting element (KDE) and 
rearrangement of the lambda light chain commences (Das et al., 2009). If successful, the light 
and heavy chains associate and the BCR is expressed on the cell surface; the cell is now an 
immature B cell. Here, cells are met by another central tolerance checkpoint. Immediate 
apoptosis would be a biologically costly and energy demanding process at this late 
developmental stage, therefore immature B cells with moderate to high avidity for their 
cognate antigen undergo receptor editing, in which RAG genes are reactivated and 
immunoglobulin (usually light chain) gene segments are further rearranged in an effort to 
generate a non-self-reactive BCR (Basten and Silveira, 2010). Despite these stringent central 
tolerance checkpoints, resulting in the elimination of over 85% of immature B cells in the 
bone marrow, some autoreactive B cells still evade these processes (Gururajan et al., 2014; 
Melchers, 2015).  
Recently generated immature B cells migrate from the bone marrow to the spleen and 
undergo transitional stages (T1 and T2) where they encounter self-antigens that may not have 
been present in the bone marrow (Basten and Silveira, 2010). These peripheral tolerance 
checkpoints are essential for B cells considering their ability to hypermutate their receptors 
following activation and their ability to respond to antigens in the absence of T cell help. B 
cells binding to their cognate antigen with high avidity undergo clonal deletion, whereas those 
binding with low avidity undergo a state of non-responsiveness, characterised by desensitised 
BCR signalling, known as anergy (Goodnow et al., 1988; Nemazee and Bürki, 1989). Upon 
BCR ligation, these cells migrate to the T cell zone in search for T cell help, but do not 
receive the necessary co-stimulation required for full activation (Basten and Silveira, 2010). 
At this stage, B cell survival is dependent upon BAFF, and greater BAFF responsiveness is 
7 
 
achieved by BAFF receptor upregulation following BCR stimulation; however, weak BCR 
signalling and insufficient BAFF responsiveness in anergic B cells leads to cell death (Lesley 
et al., 2004; Stadanlick and Cancro, 2008). Peripheral tolerance is also achieved through the 
action of the B cell siglecs CD22 and Siglec-G. These inhibitory receptors bind sialic acids 
commonly expressed on mammalian but not microbial cells, thus dampening reactivity by 
setting a ‘threshold’ to self-antigens (Macauley and Paulson, 2014).  
1.2.3 B cell activation  
B cells can acquire soluble or particulate antigens from macrophages or follicular dendritic 
cells (FDC) within the secondary lymphoid organs via the BCR (Yuseff et al., 2013). The 
BCR comprises membrane-bound immunoglobulin molecules coupled with Igα (CD79a) and 
Igβ (CD79b) heterodimers, which transmit intracellular signals through immunoreceptor 
tyrosine-based activation motifs (ITAMs) in their cytoplasmic tails. A co-receptor complex 
comprising CD19, CD21 (complement receptor 2) and CD81 also plays a role by augmenting 
signal transduction (DeFranco, 1996; Fujimoto et al., 2000). Antigen binding and BCR cross-
linking results in ITAM phosphorylation and activation of kinases including Lyn, Syk and Btk 
that mediate an intracellular signalling cascade and activate downstream signalling pathways 
affecting differentiation, survival and proliferation (Harwood and Batista, 2010; Hobeika et 
al., 2015). The BCR-antigen complex is internalised and processed in endocytic vesicles 
where the antigen is digested and the resulting peptides are loaded onto MHC class II 
molecules and expressed on the cell surface. Antigen-loaded B cells migrate towards the T 
cell zone of the lymphoid follicle, where they distribute alone the B/T border (Pereira et al., 
2010). On recognition by their cognate T follicular helper (TFH) cell, B cells are activated 
through MHC class II engagement, co-stimulation via CD40-CD40L and the provision of 
cytokines such as interleukin (IL)-4 (IL-4) and IL-21 (Yuseff et al., 2013). Some of these B 
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cells will immediately 
differentiate into early 
plasmablasts to provide low-
affinity antigen-specific antibody 
in the early phases of the immune 
response, and a small fraction will 
be released into the periphery as 
germinal centre -independent 
memory B cells, possibly to 
maintain a broad range of antigen-
specific B cells (Kurosaki et al., 
2015). Alternatively, B cells enter 
the germinal centre reaction, 
where they are referred to as centroblasts. Germinal centres (GC) are specialised structures 
within secondary lymphoid organs that develop over several days following antigen 
encounter, with the goal of producing large numbers of clonal B cell populations and high 
affinity antibodies (Fig. 1.2). Entry of activated B cells into the germinal centre is controlled 
to favour high affinity B cells expressing the most antigen, whilst the entry of low affinity B 
cells is restricted (Crotty, 2014; Schwickert et al., 2011). Here, B cells undergo repeated 
rounds of proliferation and somatic hypermutation of their immunoglobulin genes within the 
dark zone, before migrating to the light zone, where FDCs select those with the highest 
affinity and allow their survival (Allen et al., 2007; Schwickert et al., 2011). B cells may also 
change their antibody isotype during class switching, following interaction with their cognate 
TFH cell (Zhang et al., 2016).  Following the germinal centre reaction, centroblasts may re-
Figure 1.2. The germinal centre reaction. Repeated 
rounds of proliferation and somatic hypermutation in the 
dark zone followed by affinity selection and class 
switching in the light zone generates B cells with a high 
affinity for antigen (Heesters et al., 2014). Reproduced 
with permission of the copyright owner. 
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enter the germinal centre to allow further affinity maturation, or they may exit as memory B 
cells or ASC (Heesters et al., 2014).  
 1.2.4 Affinity Maturation 
Affinity maturation is an essential component of adaptive humoral immunity and involves 
secondary diversification of the antibody repertoire to produce higher affinity antibodies; this 
is achieved following repeated exposure of the B cell to its cognate antigen as described 
above. Somatic hypermutation occurs when point mutations are introduced into the V regions 
by the enzyme activation-induced cytidine deaminase (AID), that converts C:G base pairs into 
U:G mismatches, which may then be excised, replicated or repaired (Muramatsu et al., 1999; 
Luo et al., 2004). The mutational frequency induced by AID activity is reportedly 1,000,000 
times higher than the rate of spontaneous mutations in other genes (Briney and Jr, 2013).       
In addition to modifying the V regions through somatic hypermutation, B cells can further 
modify antibody function by switching the C region in a process known as isotype switching, 
which alters the effector function of the antibody. Isotype switching is achieved through class-
switch recombination (CSR) in which heavy chain encoding sequences are looped out and 
deleted by a process involving AID and re-joined by DNA repair enzymes (Stavnezer and 
Schrader, 2014). The decision of an activated B cell to undergo isotype switching is governed 
by CD4+ T cell-derived cytokines, particularly IFN (IgG2a and IgG3), IL-4 (IgE, IgG1 and 
IgG4) and TGFβ (IgA and IgG2b), and in the presence of multiple cytokine signals there is a 
hierarchy (IFN>IL-4>TGFβ) which allows the B cell to make logical decisions in a complex 
milieu (Tangye et al., 2002; Deenick et al., 2005). B cells may also undergo isotype switching 
in the absence of T cell help; this is best characterised in the gut, where intestinal epithelial 
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cells and FDC stimulated by commensal bacteria secrete cytokines that induce isotype 
switching to IgA (He et al., 2007; Suzuki et al., 2010; Chorny et al., 2010). 
1.2.5 Antibodies  
 A unique feature of B cells is the production of antibodies. Antibodies are the secreted form 
of the BCR and are exclusively produced by ASC. Antibodies contain two identical heavy 
chains and two identical light chains linked by disulphide bonds. Five antibody isotypes exist 
based on their heavy chain class (IgG, IgM, IgA, IgD, IgE), and IgG (IgG1, IgG2, IgG3, 
IgG4) and IgA (IgA1, IgA2) may be further subdivided into several subclasses. The heavy 
and light chain V regions collectively form the antigen-binding (Fab) region of the antibody, 
composed of two identical antigen binding sites, and the C regions form the fragment 
crystallisable (Fc) region, which induces effector mechanisms by activating components of 
the innate immune system (Hoffman et al., 2016). The Fc region can activate the classical  
 
Immunoglobulin Isotype 
IgG1 IgG2 IgG3 IgG4 IgM IgA IgE 
Adult serum levels (mg/dl) 900 300 100 50 150 300 0.03 
Heavy chain 1  2  3  4  α ε 
Molecular Mass (kDa) 146 146 165 146 970 160 188 
Serum half-life (days) 21 2 7 21 10 6 2 
Polysaccharide antigens + +++ +/- +/- ++ ++ ++ 
Protein antigens ++ +/- ++ ++ + + + 
Complement activation ++ + +++ - ++++ - - 
Fc receptor binding + - + +/- - + + 
Mast cell/basophil activation + - + - - - ++++ 
Table 1.1. Properties and functions of immunoglobulin isotypes.  
– to +++ indicates the relative absence or presence of activity or response. (Hoffman et al., 2016). 




complement pathway, resulting in lysis of bacterial cell walls, and bind Fc receptors 
expressed by macrophages, leading to phagocytosis of opsonised pathogens (Wang et al., 
2007; Hoffman et al., 2016).   
 The heavy chain is responsible for antibody effector functions and different heavy chain 
isotypes possess different properties (summarised in table 1.1). For example, IgM is a strong 
activator of the complement pathway due to its pentameric structure and low avidity, whereas 
IgE is excellent at binding FcR1 on mast cells and basophils (Hoffman et al., 2016).  
1.4 B cell subsets: characteristics and phenotypic features 
 1.4.1 Naïve and memory B cells  
In humans, naïve B cells comprise a large proportion (60-70%) of the circulating B cell pool 
and co-express IgM and IgD on the surface (Perez-Andres et al., 2010). Naive and memory B 
cells express high levels of BCR-associated molecules such as CD19, CD20 and CD45, and 
molecules associated with a T-dependent response such as CD40 and MHC class II (Perez-
Andres et al., 2010). During the generation of memory B cells, intrinsic developmental 
changes occur that enable a more rapid secondary response to antigen compared to naïve B 
cells encountering antigen for the first time, with enhanced magnitude and proliferative 
capacity (Tangye and Tarlinton, 2009). These properties can be attributed to the selection of 
higher affinity B cells during the primary response, the placement of memory B cells at 
antigen-draining sites that allows earlier antigen contact than naïve B cells, and a higher 
expression of co-stimulatory markers that facilitates rapid T cell help (Good and Tangye, 
2007). Around 50% of circulating memory B cells have undergone CSR, with around half of 
the memory B cell pool expressing unswitched IgM+IgD+ or IgM alone (Perez-Andres et al., 
2010). As with class-switched memory B cells, unswitched memory B cells can be 
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phenotypically distinguished from naïve B cells by the high expression of CD27, a tumour 
necrosis factor receptor (TNFR) family member involved in B cell differentiation into ASC 
(Klein et al., 1998).  
1.4.2 Antibody-secreting cells 
1.4.2.1 Characteristics and identification  
Antibody-secreting cell (ASC) is an umbrella term encompassing plasmablasts and plasma 
cells. Plasmablasts are highly proliferative, recently generated cells peaking at day 7 
following infection; nonetheless, around 90% of these cells will die within 2-3 weeks (Fink, 
2012). Regardless of their origin, any activated B cell, including naïve, marginal zone or 
memory, may become a plasmablast, though it is unclear whether cells from all these origins 
have the capacity to become plasma cells (Radbruch et al., 2006). Despite low steady-state 
levels, plasmablasts can be detected in the peripheral blood of healthy humans at 
approximately 2 cells/µl and typically represent 1-3% of the total B cell pool (Morbach et al., 








Figure 1.3. Morphological features distinguishing B cells and antibody-secreting cells. B cells 
are small round cells which express surface-bound immunoglobulin and display a high nucleus to 
cytoplasm ratio (left image). Antibody-secreting cells display eccentric (non-central) nuclei with 
condensed chromatin, and abundant cytoplasmic constituents (such as golgi apparatus and 
endoplasmic reticulum) involved in rapid antibody synthesis (right image).  
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Morphologically, ASC display eccentric (non-central) nuclei, condensed chromatin and 
abundant golgi apparatus and endoplasmic reticulum (ER; Fig. 1.3), making them well 
equipped for secreting large quantities of antibody (Miller, 1931). ASC display a distinct 
phenotype that coincides with their progressive differentiation from short-lived plasmablasts 
to long-lived plasma cells. This includes gradual downregulation of molecules involved in B 
cell receptor signalling and antigen presentation, and upregulation of activation markers (e.g. 
CD27 and CD38) and homing molecules (e.g. CXCR4 and CD138; table 1.2). Steady-state 
circulating plasmablasts express CD19 and are CD27+CD38+, with up to half expressing 
CD138 (Syndecan-1), a heparin sulphate associated with a more mature phenotype compared 
to CD138- plasmablasts (Caraux et al., 2010). The requirement of CD138 for long-term 
survival suggests that CD138- plasmablasts are destined to remain short-lived, whereas 
CD138+ plasmablasts have the potential to become plasma cells if a suitable niche is found.  





Lifespan ++ + + ++++ 
Proliferation - ++ - - 
CD27, CD38, CD138* and 
CXCR4 expression 
- + ++ +++ 
CD19, CD20, CD45, MHC 
class II and sIg expression 
+++ ++ +/- +/- 
Location L.O. L.O., P.B. L.O., B.M. B.M. 
BLIMP1 expression - + + ++ 
+/- indicates low or heterogeneous expression. sIg = surface immunoglobulin, L.O. = lymphoid 
organs, P.B. = peripheral blood, B.M. = bone marrow. *CD138 expression is heterogeneous within 
the plasmablast population. Adapted from (Nutt et al., 2015). Reproduced with permission of the 
copyright owner. 
 
Table 1.2. Summary of antibody-secreting cell maturation. +/- indicates low or heterogeneous 
expression. sIg = surface immunoglobulin, L.O. = lymphoid organs, P.B. = peripheral blood, B.M. 
= bone marrow. *CD138 expression is heterogeneous within the plasmablast population. Adapted 
from (Nutt 2015).  




Different ASC populations have been identified and characterised within human lymphoid 
tissues. Based on phenotypic markers (see table 1.2), CD19- ASC are the most terminally 
differentiated and have been shown to maintain a long-lived antibody response to mumps and 
measles viruses over 40 years after infection, and thus can be considered long-lived plasma 
cells (Halliley et al., 2015). Consistent with these observations, Landsverk et al (2017) 
showed that within a year of transplanting human duodenal tissue, the CD19- ASC population 
remained stable, indicating substantial longevity, whereas a third of donor CD19+ ASC had 
been replaced by recipient CD19+ ASC, indicating that CD19+ ASC represent short-lived 
plasmablasts (Landsverk et al., 2017). This group also measured carbon-14 levels from the 
genomic DNA of ASC subsets in intestinal biopsy samples and showed that CD19- but not 
CD19+ ASC were extremely long-lived, with a median age of 22 years (Landsverk et al., 
2017). Long-lived plasma cells are not replenished by the memory B cell pool, as their long-
term depletion does not affect ASC frequency, but their longevity could be achieved by low 
levels of homeostatic proliferation, as despite being regarded as terminally differentiated, low 
levels of the proliferation marker Ki-67 has been observed in these cells (Ahuja et al., 2008; 
Macallan et al., 2005). As such, the ASC pool represents a heterogeneous population of short-
lived (i.e. plasmablasts) and long-lived (i.e. plasma cells) ASC which can largely be 
distinguished based on CD19 and CD138 expression. 
 1.4.2.2 Survival niches 
The majority of survival niches are found in the bone marrow; however, a proportion of 
niches are found within the spleen, lymph nodes or inflamed tissues (Radbruch et al., 2006). 
Arrival at a survival niche is a critical stage for plasmablast differentiation into plasma cells. 
Survival niche homing is governed by chemokines which direct plasmablasts to different 
anatomical locations. For example, CXCR4 is important for homing to the bone marrow, 
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which is the largest plasma cell niche in the body; however, CXCR3, which binds 
inflammatory chemokines such as CXCL9 and CXCL10, can direct plasmablasts to ectopic 
sites of inflammation (Radbruch et al., 2006; Hauser et al., 2002).  
Niches are served by several accessory cells that contribute to the survival and maintenance of 
the plasma cell pool (Fig. 1.4) such as dendritic cells (DC), macrophages and eosinophils, 
which secrete important growth factors including BAFF, a proliferation inducing ligand 
(APRIL), IL-6 and CXCL12 (Chu et al., 2011; Jego et al., 2001; Nutt et al., 2015). Plasma 
cells are retained within the niche via adhesion molecules, including CD44, which binds 
hyaluronic acid and other extracellular matrix components, very late antigen-4 (VLA-4; 
CD49d), the ligand for vascular cell adhesion molecule-1 (VCAM-1; CD106) which is 
expressed by stromal cells, and 
CD138, which mediates 
adhesion to several extracellular 
matrix components, and is also 
a receptor for APRIL (Ingold et 
al., 2005; Radbruch et al., 2006; 
Nutt et al., 2015). As the 
number of niches within the 
body is finite, recently 
generated plasma cells compete 
for survival by dislodging long-
lived plasma cells from their 
niche (Odendahl et al., 2005).  
Figure 1.4. The plasma cell survival niche. Antibody-
secreting cells are dependent on a range of survival factors, 
which includes chemokines and adhesion molecules, secreted 
by stromal cells and accessory cells (Nutt et al., 2015). 
Reproduced with permission of the copyright owner. APRIL; a 
proliferation inducing ligand, BCMA; B cell maturation 
antigen, MCL1; myeloid cell leukaemia 1, ZBTB20; zinc finger 
and BTB-containing domain protein 20, VLA4; very late 
antigen 4, VCAM1; vascular cell adhesion molecule 1 
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1.5 T cell biology 
1.5.1 T cell development  
Like B cells, T cells undergo a series of distinct differentiation stages to produce mature, fully 
functional naïve cells that are released into the periphery (summarised in Fig. 1.5). 
Developing thymocytes undergo VDJ recombination in a similar fashion to B cells, 
rearranging gene segments to produce a functional T cell receptor (TCR) before receiving 
important selection signals before their release into the periphery. Lymphoid progenitors from 
the bone marrow migrate to the cortico-medullary junction of the thymus, where they are 
referred to as CD4-CD8- double negative thymocytes (Zuniga-Pflucker, 2004). These cells 
migrate through the cortex, interacting with cortical thymic epithelial cells whilst undergoing 
a number of developmental stages which results in expression of the pre-T cell receptor 
(TCR) complex; in the majority of T cells this consists of the TCRβ chain and the pre-TCRα 
Figure 1.5. T cell development and generation of the T cell receptor. T cells rearrange their V, 
D and J segments to produce a functional antigen-specific TCR which is associated with single 
positive CD4+ or CD8+ cells following positive selection. Gene recombination of the first receptor 
chain often gives rise to αβ T cells but can also give rise to γδ T cells. Adapted from (Nemazee, 




chain. Loss of IL-7 and notch ligand signals allows differentiation into double positive 
(CD4+CD8+) thymocytes with expression of a complete TCR (Rothenberg et al., 2008). The 
thymocytes then migrate to the medulla where they undergo central tolerance checkpoints to 
assess TCR affinity towards self-proteins. These proteins, referred to as tissue-specific self-
antigens, are promiscuously expressed by medullary thymic epithelial cells, and their 
expression is mediated by the autoimmune regulator (AIRE) transcription factor, which is 
thought to act by opening chromatin to allow the transcription of normally-repressed genes, 
thus allowing ectopic expression of self-proteins (Derbinski et al., 2001; Anderson et al., 
2002). Strong binding to self-peptide-MHC complexes results in elimination (negative 
selection), whereas T cells displaying intermediate affinity towards self-peptide-MHC-
complexes are allowed to mature into single positive CD4+ or CD8+ T cells (positive 
selection) and are released into the periphery (Germain, 2002; Klein et al., 2014).  
1.6 T cells in the immune response  
1.6.1 The T cell receptor and T cell subsets  
The TCR is a heterodimeric structure consisting of two peptide chains linked together by a 
disulphide bond, and is anchored to the cell surface by a hydrophobic transmembrane domain. 
Around 95% of T cells express TCRs with an α and β chain and are thus referred to as αβ T 
cells; most of these recognise peptide fragments bound to MHC molecules, but a minority of 
unconventional αβ T cells recognise antigens via alternative methods. These cells, though not 
well characterised, display limited diversity and recognise bacterial components and lipid 
antigens (Attaf et al., 2015).  
Another group of T cells express γ and δ polypeptide chains to form the TCR- these are 
referred to as γδ T cells and, like the unconventional αβ T cell subsets, do not recognise 
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peptide antigens. δ T cells constitute 1-10% of the peripheral T cell pool but are considerably 
enriched in epithelial tissues; this reflects their function as rapid responders using restricted 
TCR as pattern recognition receptors to recognise bacterial antigens entering the skin (Attaf et 
al., 2015; Vantourout and Hayday, 2013).  
The αβ TCR is associated with four invariant membrane-bound accessory chains on the cell 
surface, comprised of two ε, one δ and one γ chain, which collectively make up the CD3 
complex. The cytoplasmic domains of each CD3 accessory chain, along with an intracellular 
homodimer of ζ chains, contain ITAMs which are phosphorylated following TCR 
engagement, allowing zeta-associated protein kinase (ZAP)-70 binding and a subsequent 
signalling cascade (Wang et al., 2010).  
1.6.2 States of T cell differentiation  
Circulating T cells can be identified based on their differentiation status, allowing them to be 
split into naïve, central memory (TCM), effector memory (TEM) and revertant effector memory 
(TEMRA) subsets. 
Naïve T cells circulate between secondary lymphoid organs in search for their cognate 
antigen. These cells extravasate through high endothelial venules and enter the lymph nodes 
using the adhesion molecule L-selectin (CD62L) and CCR7 (Brinkman et al., 2013). Within 
the T cell zones of the lymph nodes, recognition of antigen presented by DC leads to T cell 
activation. Naïve T cells can be distinguished by the expression of CD45RA, a protein 
tyrosine phosphatase involved in cell signalling. On differentiation, memory T cells express 
an alternatively spliced isoform, CD45RO, which alters the sensitivity of the cell to external 
stimuli and improves the efficiency of TCR signalling (Earl and Baum, 2008).  
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TCM, which are responsible for maintaining the memory pool, also home to secondary 
lymphoid organs where they rapidly proliferate and differentiate into TEM on antigen 
recognition (Sallusto et al., 2004). TEM, which downregulate CD62L and CCR7 to prevent re-
entry to the lymph nodes, migrate to peripheral tissues using alternative homing receptors 
such as CXCR3, where they elicit their effector functions in the presence of inflammation 
(Sallusto et al., 2004; Willinger et al., 2005). TEMRA are terminally differentiated memory T 
cells that retain their potent effector functions but have switched back to expressing CD45RA 
to limit their activation. Mainly found in the CD8+ T cell compartment, TEMRA are pre-
senescent and lack proliferative capacity, displaying the shortest telomeres amongst T cells, 
which marks their end-stage differentiation status (Henson et al., 2012; Mahnke et al., 2013).  
1.6.3 Limiting T cell activation  
In addition to TCR ligation (signal 1), T cells require co-stimulation, typically via CD28 
(signal 2) which binds CD80 or CD86 on the antigen presenting cell (APC), and cytokine 
priming (signal 3). These events result in T cell activation, proliferation and differentiation 
(Smith-Garvin et al., 2009). However, because of their potential damaging consequences, 
these functions are highly regulated. T cells may be subjected to several peripheral tolerance 
mechanisms such as suppressed activation by regulatory T cells (Treg), peripheral deletion 
following high affinity self-peptide engagement, or conversion to Treg following low-affinity 
self-peptide engagement (Xing and Hogquist, 2012). Anergy may also be induced in 
peripheral T cells, in which TCR ligation is received in the absence of co-stimulation, 
rendering the cell non-responsive. This may occur in the absence of inflammation due to a 
lack of pro-inflammatory cytokines, which are required for the expression of co-stimulatory 
molecules on DC (Mueller, 2010). In addition, activated or autoreactive T cells can be 
inhibited by the expression of inhibitory receptors, which induce a non-responsive state 
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within peripheral tissues. These include programmed cell death receptor 1 (PD-1), T cell 
immunoglobulin mucin 3 (TIM-3) and cytotoxic T lymphocyte-associated protein 4 (CTLA-
4) which block intracellular activation signals through immunoreceptor tyrosine-based 
inhibition motifs (ITIMs) (Fuertes Marraco et al., 2015).   
1.7 T cell subsets 
The TCR co-receptors CD4 and CD8 promote signal amplification during antigen recognition 
(Artyomov et al., 2010). CD4 is expressed by T helper (Th) cells and interacts with peptides 
bound to MHC class II molecules expressed by antigen presenting cells, which have been 
sampled from exogenous proteins (Blum et al., 2013). CD8 is expressed by cytotoxic T cells 
and interacts with MHC class I molecules, which are expressed by all nucleated cells. MHC 
class I molecules bear endogenous peptides derived from cytosolic proteins, such as viral 
components, permitting identification of infected host cells that require elimination (Blum et 
al., 2013). 
 1.7.1 CD4+ T cells 
Naïve CD4+ T cells are uncommitted precursors with a high level of plasticity, playing a 
central role in T cell-mediated immunity through their proliferation and differentiation into 
distinct subsets following activation. This process is governed by cytokines which induce 
specific transcription factors, leading to a switch in the gene expression profile that is 
responsible for the subsequent phenotype of that cell. The original model involved 
differentiation into Th1 cells or Th2 cells (Murphy and Reiner, 2002). Th1 cells 
predominantly secrete IFN and are responsible for cell-mediated immunity, responding to 
intracellular pathogens such as viruses and bacteria; conversely, Th2 cells secrete IL-4 
(amongst other cytokines) and contribute to humoral immunity, providing protection against 
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extracellular parasites such as intestinal 
helminths (Murphy and Reiner, 2002). 
Both subsets also play a role in 
pathological responses, with Th1 cells 
associated with autoimmune diseases 
and Th2 cells associated with allergy and 
asthma (Murphy and Reiner, 2002).  
Besides Th1 and Th2, naïve CD4+ T 
cells can follow alternative 
differentiation pathways (Fig. 1.6). 
Contrary to conventional T helper cells, 
Tregs modulate the immune response by 
downregulating T cell activation, 
predominantly through IL-10 secretion 
and the expression of CTLA-4, a homologue of CD28, which acts through the co-stimulatory 
molecules CD80 or CD86 (Corthay, 2009).  
Th17 cells play a role in pathogen clearance at mucosal surfaces predominantly through 
secretion of IL-17, IL-21 and IL-22 (Crome et al., 2010). Previously believed to be a distinct 
subset for their inability to secrete other lineage-defining cytokines, it is now appreciated that 
Th17 cells can produce IFN, a Th1-associated cytokine, or IL-10, a Treg-associated 
cytokine, depending on the pathogen encountered (Zielinski et al., 2012). Aberrant Th17 cell 
responses have been linked to several chronic inflammatory conditions including psoriasis, 




Figure 1.6. CD4+ T cell differentiation. Naïve 
CD4+ T cells (Th0) can differentiate into a variety 
of T helper subsets following activation (Russ et 




 1.7.2 CD8+ T cells 
Cytotoxic CD8+ T cells eliminate target cells through direct cell-cell contact via death 
receptor signalling or perforin-mediated killing, or indirectly through the production of pro-
inflammatory cytokines (Andersen et al., 2006).  
The primary mechanism by which CD8+ T cells exert their cytotoxicity is through the 
perforin pathway. This rapid-acting mechanism, which is calcium-dependent, involves the 
secretion of pre-formed effector molecules within cytoplasmic granules, namely perforin and 
granzymes (granule enzymes). Following target cell identification, an immunological synapse 
is formed and the CD8+ T cell becomes polarised, transporting secretory granules to the cell 
surface through the action of microtubules. These granules fuse with the cell membrane and 
release their contents into the synaptic cleft, where perforin assembles into multimeric 
complexes and form pores in the target cell membrane (Voskoboinik et al., 2015). Granzymes 
then diffuse into the target cell, translocate to the nucleus and initiate cell death through 
proteolytic cleavage of substrates that induce apoptosis (Chowdhury and Lieberman, 2008). 
Granzymes are stored in an inactive form due to the acidity of the granules, which is lost on 
degranulation; however, the CD8+ T cell is protected from self-damage by expression of 
protease inhibitors known as serpins (Regner and Mullbacher, 2004; Ashton-Rickardt, 2012).  
Granzymes are a family of five of serine-proteases homologous to trypsin, constituting five 
members in humans. Granzymes A and B are the most abundant and well-studied, while 
granzymes K, H and M are less understood and are referred to as orphan granzymes 
(Voskoboinik et al., 2015). Granzyme A-mediated cell death is independent of caspase 
recruitment, involving reactive oxygen species (ROS) generation and subsequent recruitment 
of ER-associated nucleases, leading to DNA cleavage (Beresford et al., 2001). Unlike other 
granzymes, granzyme B can cleave after aspartate residues in the same way as caspases and 
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can therefore activate cell death through direct cleavage of caspase substrates, although it can 
also act through caspase-dependent mechanisms (Pinkoski et al., 2001; Chowdhury and 
Lieberman, 2008). As well as granzymes, granulysin, a small protein that targets bacteria by 
rupturing their membranes, may also be delivered into target cells (Stenger et al., 1998).  
The death receptor pathway is mediated by TNF-family members, namely Fas ligand (FasL), 
which binds Fas on target cells, or TNF-related apoptosis-inducing ligand (TRAIL), which 
binds its receptors TRAIL-R1 or TRAIL-R2 (Falschlehner et al., 2009). Trimerisation of the 
signalling complex leads to formation of the death-inducing signalling complex (DISC) and 
recruitment of Fas-associated death domain (FADD), which initiates an intracellular caspase 
cascade leading to apoptosis (Falschlehner et al., 2009).   
Triggering of pro-inflammatory cytokine release by CD8+ T cells, such as TNFand IFN, is 
induced on TCR ligation and promotes resolution of infection through multiple mechanisms. 
TNF binds its receptor on the target cell and initiates an intracellular signalling cascade 
involving the adaptor protein TNF receptor type 1-associated death domain (TRADD), 
leading to apoptosis (Pobezinskaya and Liu, 2012). IFN acts on host cells by upregulating 
Fas expression and antigen presentation through MHC class I, increasing the likelihood of 
recognising infected cells and allowing faster eradication (Andersen et al., 2006). IFN also 
induces the transcription of proteins involved in the inhibition of viral replication, and recruits 
macrophages to promote enhanced effector function (Samuel, 2001; Rauch et al., 2013). 
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1.8 Multiple sclerosis 
1.8.1 General overview 
 ‘Why this deliberate, slow-moving malignity? Perhaps it is a punishment for the impudence 
of my desires. I wanted everything so I get nothing ... I am not offering up my life willingly – 
it is being taken from me piece by piece, while I watch the pilfering with lamentable eyes.’  
~ W.N.P. Barbellion, The Journal of a Disappointed Man (early 20th century) 
Personal accounts of multiple sclerosis (MS), including those documented in W.N.P. 
Barbellion’s journals published in 1919 following his death from the disease aged just 30 
years old, offer some insight into the plight of sufferers where detailed medical knowledge 
was limited and effective treatments absent. The first medical descriptions of MS have been 
traced back to around the 14th century, but it is the famous French neurologist Jean-Martin 
Charcot, often referred to as the father of modern neurology, who is largely credited with the 
first comprehensive description of MS in 1868. Charcot’s details of the pathological changes 
that occur in the MS brain and spinal cord, described as ‘la sclérose en plaques disseminées’, 
as well as recognising the disease course, symptoms and the correlation of clinical features 
with post-mortem findings, led to the recognition of MS as a distinct disease (Pearce, 2005; 
Kumar et al., 2011).  
Today, MS is the most common chronic inflammatory disease of the central nervous system 
(CNS) and is the primary cause of neurological disability affecting young adults in the 
Western world (Rodriguez et al., 1994). MS most often presents between 20 and 40 years of 
age and affects more women than men at an approximate ratio of 2:1 (Bostrom et al., 2013). 
Though the clinical course can vary considerably between affected individuals, the disease is 
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degenerative in most cases and in time generally progresses to irreversible disability of 
varying degrees (De Jager, 2011).    
1.8.2 Clinical features and disease phenotypes 
Most individuals initially present with a single acute neurological attack known as clinically 
isolated syndrome (CIS), representing the earliest symptomatic demyelinating event 
suggestive of MS (Fig. 1.7). A CIS may present in a wide range of clinical scenarios, 
including optic neuritis, transverse myelitis, a brainstem syndrome and sometimes diffuse 
cerebral dysfunction, causing a range of symptoms from visual disturbances to muscle 
weakness and sensory disturbance, depending on the site of demyelination (Polman et al., 
2011; Marcus and Waubant, 2013). A diagnosis of MS is generally made when a second 
clinical event (a relapse) is experienced. Initially these episodes spontaneously resolve 
(remit), with apparent improvement of disability and return to normal CNS function between 
episodes, thought to represent resolution of inflammation. 80-90% of these individuals will 
experience further future relapses at a variable rate, generally (but not necessarily) equating to 
around 0.5-2 per year; this is referred to as relapsing-remitting MS (RRMS) and is the most 
common form of the disease (Compston and Coles, 2008).  
Figure 1.7. The major clinical phenotypes of multiple sclerosis. Though MS is 
highly variable in nature, several common features have allowed the disease to be 




With increasing disease duration, recovery following relapses is less complete and increasing 
disability and a gradual decline in neurological function is often experienced; this disease 
state, termed secondary progressive MS (SPMS), affects around 70-80% of those with RRMS 
(Disanto et al., 2011; Nylander and Hafler, 2012). A subset of people with MS (10-15%) 
experience progressive disability from the onset of diagnosis without periods of remission, a 
form known as primary progressive MS (Miller and Leary, 2007). In addition, some 
individuals experience a comparatively benign disease course, and although the definition of 
benign MS has been varied, it is characterised by minimal disability accumulation as 
measured by the expanded disability status scale (EDSS) (Hawkins and McDonnell, 1999; 
Pittock et al., 2004). In a 10-year follow-up study of 161 cases, 17% of individuals had an 
EDSS of 2 or less with a <10% chance of developing significant disability (Pittock et al., 
2004). The variable manifestations of MS are testament to the heterogeneity of the disease, 
and underpin the difficulties with predicting prognosis, particularly early in the disease. This 
principle was demonstrated in a large follow-up study in which 42% of individuals had 
developed significant disability 20 years from disease onset with a median EDSS of 6.5, 
whereas 38% experienced a less severe outcome with a median EDSS of less than 3 (Fisniku 
et al., 2008).  
1.8.3 Risk factors 
Like many autoimmune conditions, MS is a complex disease with multiple contributing 
factors. It is important to note that some factors may play a more important role than others 
and the presence or absence of all the factors associated with MS does not guarantee disease 




Despite variable outcomes, twin studies suggest a positive influence of heritability in MS. A 
British Isles survey of MS in 105 pairs of twins found concordance in 25% of monozygotic 
twins compared to 3% of dizygotic twins, however a weaker genetic link was found in a large 
North American study of over 1,100 twins, which found a concordance rate of 13% for 
monozygotic and 5% (same sex) and 3.7% (opposite sex) for dizygotic twins (Thorpe et al., 
1994; Islam et al., 2006).  
Genome-wide association studies (GWAS) have consistently revealed a link between several 
HLA genes (particularly HLA-DRB1*1501) and associated single nucleotide polymorphisms 
(SNPs) with MS, implicating immune function as a disease-contributing mechanism (Lincoln 
et al., 2005; Alcina et al., 2012; Schmidt et al., 2007). Some MHC class I risk alleles are also 
associated with MS, including the HLA-A SNP rs6457110, which is also linked to increased 
susceptibility for infectious mononucleosis (Jafari et al., 2010). Aside from the strong HLA 
association, many of the 110 non-MHC risk variants identified are also immune related, 
notably the interleukin-2 receptor alpha (IL-2Ra) and interleukin-7 receptor alpha (IL-7Ra) 
encoding regions, and epigenetic mechanisms that regulate gene expression have also been 
suggested to play a role (Sawcer et al., 2011; Beecham et al., 2013; Didonna and Oksenberg, 
2015; Miyazaki and Niino, 2015). 
1.8.3.2 Infectious agents 
Of the many infectious agents linked to MS pathogenesis, Epstein-Barr virus (EBV) is the 
most strongly associated. Over 90% of adults have been infected with EBV, however the 
seropositivity in MS is thought to be over 99%, or even 100% where two independent EBV 
detection methods are used (Pakpoor et al., 2013; Burnard et al., 2017). In addition, most 
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studies have found a higher seroprevalence of anti-Epstein-Barr Nuclear Antigen 1 (EBNA-1) 
and anti-Viral Capsid Antigen (VCA) antibodies in MS compared to non-MS controls 
(Fernandez-Menendez et al., 2016; Almohmeed et al., 2013; Santiago et al., 2010). The 
presence of cerebrospinal fluid (CSF) antibodies towards EBV-related proteins, and of EBV-
infected B cells in the brain, has also been described in MS (Cepok et al., 2005b; Serafini et 
al., 2007). Using a highly sensitive in situ hybridisation technique, a recent study identified 
EBV in 90% of MS cases compared to 24% of controls with non-MS neurological disease 
(Hassani et al., 2018). Possible scenarios explaining the association of EBV with MS are 
molecular mimicry, where cross-reactivity results from sequence similarity of foreign and 
self-peptides, bystander damage, in which an EBV-specific CNS immune response causes 
inflammation and damage to host tissues, and the EBV-infected autoreactive B cell 
hypothesis, where defective T cell control of autoreactive EBV-infected B cells leads to their 
accumulation in the CNS (Márquez and Horwitz, 2015; Pender, 2003). 
1.8.3.3 Other environmental factors 
Lack of sunlight exposure and the associated reduction in vitamin D and melatonin levels in 
countries further from the equator is linked to an increased prevalence of MS (Ascherio and 
Munger, 2007; Farez et al., 2015). Support for the contribution of vitamin D comes from 
identification of four SNPs involved in vitamin D synthesis or metabolism, and both vitamin 
D and melatonin play roles in immune regulation (Mokry et al., 2015; Berge et al., 2016). 
Smoking, low testosterone levels and dysbiosis of the gut microbiota have also been linked to 




1.8.4 Diagnosis  
A diagnosis of MS is made based on medical history and physical examination using the 
regularly revised McDonald criteria, with the aid of clinical testing (Thompson et al., 2018). 
Magnetic resonance imaging (MRI) is useful in demonstrating CNS lesions disseminated in 
space (lesions affecting separate regions of the CNS) and in time (indicating chronic disease), 
and both conditions must be met to fulfil a formal diagnosis of MS (Inglese, 2006; Polman et 
al., 2011).  
For a more immediate indication, CSF analysis is useful in identifying inflammatory activity 
which along with clinical indications can provide strong support for a diagnosis of MS. 
Oligoclonal band (OCB) testing is considered the gold standard CSF test and detects the 
electrophoretic migration properties of free immunoglobulin in the CSF. Around 60-70% of 
CIS samples and more than 90% of clinically definitive MS samples demonstrate two or more 
OCB that are specific to the CSF, with more bands reportedly indicating a worse prognosis 
(Franciotta et al.; Marcus and Waubant, 2013). Similarly, the measurement of CSF free light 
chains (FLC), which are made in excess of heavy chains during rapid intrathecal antibody 
production, provide superior sensitivity and specificity than OCB and might also provide 
prognostic information, with high levels predicting earlier conversion from CIS to MS 
(Solling et al., 1981; Villar et al., 2012; Hassan-Smith et al., 2014).  
1.8.5 Disease management 
The variable and largely unpredictable disease course combined with a multitude of 
therapeutic options presents a challenge for the treatment of MS. Treatment may be restricted 
to symptomatic management of acute relapses using steroids, which may eventually involve 
additional treatment with a more potent therapy as the disease progresses; conversely, 
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individuals affected by MS may be started on the more potent disease-modifying therapies 
(DMT) from the onset in an effort to reduce disease severity in the long term, at the expense 
of potentially experiencing serious side effects (Gajofatto and Benedetti, 2015). Several 
DMTs are approved by the FDA Food and Drug Administration (FDA) and European 
Medicines Agency (EMA) for use in MS, all of which are immunomodulatory or 
immunosuppressive, including interferon beta (1a and 1b), glatiramer acetate, fingolimod, 
mitoxantrone, natalizumab and ocrelizumab (Vargas and Tyor, 2017). Some DMTs (e.g. 
fingolimod, natalizumab) block lymphocyte trafficking, whereas others (e.g. glatiramer 
acetate, interferon beta) induce a switch in the inflammatory response to a regulatory 
phenotype (Groves et al., 2013; von Glehn et al., 2012; Aharoni, 2013). 
Following its approval in 1997 for the treatment of non-Hodgkin Lymphoma, rituximab was 
the first anti-CD20 therapy to be successfully used in MS (Maloney et al., 1994; Hauser et al., 
2008; Bar-Or et al., 2008). By targeting CD20, which is expressed by mature B cells from the 
pre-B cell to plasmablast stage, these therapies deplete B cells via antibody-dependent cellular 
cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and antibody-dependent 
cell-mediated phagocytosis (ADCP), leading to significant reductions in relapse rates and 
lesion formation (Sorensen and Blinkenberg, 2016; Agahozo et al., 2016; Geland et al., 2017). 
For example, in the first B cell-depleting trial, rituximab led to a 91% reduction in the total 
number of gadolinium-enhancing lesions and a 50% reduction in the annualised relapse rate 
compared to placebo controls at 24 weeks (Hauser et al., 2008). More recent trials with 
ocrelizumab, a humanised anti-CD20 antibody, and ofatumumab, a fully human anti-CD20 
antibody, have also shown beneficial results (Sorensen et al., 2014; Kappos et al., 2011; 
Montalban et al., 2017). For example, lower rates of disease activity and disease progression 
was recently demonstrated in two identical phase 3 trials in RRMS (Hauser et al., 2017). 
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Additionally, ocrelizumab recently became the first DMT approved for treating PPMS 
(Montalban et al., 2017).  
Though the efficacy of anti-CD20 therapies have largely been attributed to the elimination of 
antigen presenting properties of B cells, a small population of CD20+ T cells is present in the 
blood of MS and healthy control groups which is also depleted by anti-CD20 therapies (Wilk 
et al., 2009; Palanichamy et al., 2014b). CD20+ T cells, which appear to exhibit an activated 
pro-inflammatory profile, have also been detected in chronic MS brain lesions and as such, 
their possible contribution to MS cannot be disregarded without further investigation (Holley 
et al., 2014; Schuh et al., 2016).  
1.9 Immunopathology of multiple sclerosis 
 1.9.1 Pathogenesis  
MS is widely considered an autoimmune disease which is thought to occur when peripherally 
activated T cells infiltrate the CNS and are re-activated upon encountering their cognate 
antigen, leading to activation of mononuclear phagocytes such as macrophages and microglia 
with subsequent inflammation and tissue damage (Weissert, 2013). Though CD4+ T cells are 
considered central to MS pathogenesis, other immune cell subsets such as CD8+ T cells, B 
cells and ASC are thought to play a role (Dendrou et al., 2015). 
CNS lesions are a hallmark of MS and represent sites of demyelination which are associated 
with inflammatory immune cell infiltrates. Demyelination and lesion formation is more likely 
to occur in the myelin-rich white matter areas of the CNS, particularly those with a high 
venous density such as the perivasclular and periventricular regions, although grey matter 
damage also occurs (Calabrese et al., 2015; Haider, 2015). Influx of inflammatory cells is an 
32 
 
early feature the disease, which likely begins many months or years prior to the onset of 
symptoms, but with disease progression the inflammatory component gradually subsides and 
neurodegenerative effects become more apparent as the mechanisms promoting neuronal 
plasticity become overwhelmed (Compston and Coles, 2008; Ksiazek-Winiarek et al., 2015). 
Key to the degenerative process is the accumulation of ROS and glutamate, inducing 
mitochondrial injury, which in turn leads to energy failure and neuronal cell death (Haider et 
al., 2011; Macrez et al., 2016).   
1.9.2 Lymphocyte migration into the CNS 
1.9.2.1 The concept of CNS immune privilege  
The concept of biological barriers between the blood and CNS was established over 100 years 
ago by Paul Ehrlich, who observed that a water-soluble dye infused into the circulation was 
unable to stain brain tissue, but that the same dye infused into the CSF could stain brain tissue 
(Liddelow, 2011). CNS barriers have since been well characterised, and their unique features 
combined with the limited CNS immune interactions have led to consideration of the CNS as 
an immunologically specialised site. Whilst this remains true, historical findings are 
constantly being challenged and redefined. Notably, the importance of CNS immune 
responses and the presence of a lymphatic drainage system connecting the CNS to the 
periphery have advanced the understanding of immune interactions in the CNS (Louveau et 
al., 2015a; Louveau et al., 2015b; Engelhardt et al., 2017).  
1.9.2.2 Anatomy of CNS barriers 
Three major access sites for leucocytes have been distinguished for CNS entry; the blood-
arachnoid barrier (BAB), the blood-brain barrier (BBB) and the blood-CSF barrier (BCSFB). 
These are eloquently summarised in Fig. 1.8.   
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1.9.2.3 Lymphocyte trafficking in health and disease 
Homeostatic lymphocyte trafficking is largely considered to occur across the BCSFB, where 
selectins and adhesion molecules necessary for migration are constitutively expressed, rather 
than across the BBB, where endothelial cells lack the necessary adhesion molecules required 
by T cells in the absence of inflammation (Goverman, 2009; Shechter et al., 2013).  
Figure 1.8. Anatomy of CNS barriers. The blood-arachnoid barrier (A) surrounds the entire CNS 
parenchyma and contains meningeal arteries (MA), meningeal vessels (MV) and meningeal lymphatics 
(ML). The BAB is composed of the arachnoid barrier and the pia mater, forming the inner two layers of 
the meninges known as the leptomeninges, which are separated by the CSF-filled sub-arachnoid space 
(SAS). Meningeal vessels traverse the sub-pial and sub-arachnoid spaces, which may provide 
opportunities for lymphocyte migration. The blood-brain barrier (B) is composed of tightly packed 
endothelial cells linked by tight junctions to form CNS microvessels, which are surrounded by pericytes. 
Astrocytic foot processes and the endothelial basement membrane form the glia limitans, which opens up 
at the post-capillary venules to form a perivascular space, where professional APC await migrated 
lymphocytes. The blood-CSF barrier (C) lines the cerebral ventricles and is composed of specialised 
choroid plexus epithelial cells that help maintain brain homeostasis and secrete CSF into the ventricles. 
The capillaries of the choroid plexus, which are fenestrated and lack tight junctions, are surrounded by a 
stromal network containing APC and a substantial vasculature. Adapted from (Englehardt et al., 2017). 




 In a P-selectin-dependent manner T cells extravasate from the blood into the choroid plexus 
parenchyma, where they can subsequently traverse the choroid plexus epithelium to enter the 
CSF (Engelhardt and Ransohoff, 2012). The precise mechanisms governing these processes 
are unclear, as adhesion molecules such as vascular cell adhesion molecule (VCAM)-1 
(CD106) and intercellular adhesion molecule (ICAM)-1 (CD54) are expressed on the apical 
surface of the choroid plexus and are not available to T cells. In terms of chemokine receptor 
requirements, animal models have shown that CCR6-expressing Th17 cells may traverse the 
BCSFB through binding CCL20, which is constitutively expressed by the choroid plexus 
epithelium (Vajkoczy et al., 2001; Laschinger et al., 2002; Reboldi et al., 2009). The 
importance of immunosurveillance is highlighted in those individuals with MS who develop 
progressive multifocal leukoencephalopathy (PML) following prolonged natalizumab 
treatment, which inhibits leucocyte trafficking into the CNS by targeting α4-integrin. PML is 
a rare and often fatal infection caused by John Cunningham virus (JCV), a common virus that 
is reactivated during immunosuppression; however, symptoms may be further exacerbated by 
rapid restoration of CNS trafficking which can lead to immune reconstitution inflammatory 
syndrome (IRIS), a condition associated with high morbidity and mortality rates (Metz et al., 
2012; Barber et al., 2012; Purohit et al., 2016). 
During inflammation, activated endothelial cells of the BBB or BAB upregulate selectins, 
including P-selectin, which interact with their glycosylated ligands, such as P-selectin 
glycoprotein ligand-1 (PSGL-1), expressed by lymphocytes. Subsequent tethering and rolling 
allows the lymphocyte to bind to chemokines expressed by the endothelium (such as 
CXCL12, the ligand for CXCR4, and CCL19/CCL21, the ligands for CCR7), increasing their 
binding capacity for endothelial adhesion molecules by causing conformational changes in the 
integrins expressed by the lymphocyte. Key molecules mediating lymphocyte arrest include 
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VCAM-1, which binds VLA-4, and ICAM-1 and -2 (CD102), which binds leucocyte 
function-associated antigen (LFA)-1 (CD11a). Firm arrest allows diapedesis, via either 
transcellular or paracellular routes, where they extravasate into the leptomeningeal or 
perivascular spaces (Shechter et al., 2013; Engelhardt and Ransohoff, 2012).  
Unless they re-encounter their specific antigen expressed by APC, T cells are unable to cross 
into the CNS parenchyma proper; this phenomenon has been elegantly demonstrated using 
intravital imaging of a rat model of experimental autoimmune encephalomyelitis (EAE), the 
animal model for MS, where T cells specific for brain antigens could enter the CNS but 
activated brain antigen-ignorant T cells were not permitted (Bartholomaus et al., 2009). 
Interaction with cognate APC induces pro-inflammatory cytokine secretion such as IFN, 
TNF and IL-17; this increases endothelial barrier permeability, allowing influx of additional 
immune cells, and induces matrix metalloproteinase (MMP) secretion, allowing breach of the 
glia limitans and access to the CNS parenchyma (Shechter et al., 2013; Engelhardt and 
Ransohoff, 2012). 
In contrast to T cells, very few B cells enter the healthy CNS for immune surveillance, 
however, B cell numbers are increased during neuroinflammation (Anthony et al., 2003; 
Cepok et al., 2005a). Although the specific molecules used by B cells are less well 
understood, it appears that many receptors and chemokines that facilitate T cell trafficking 
can also be used by B cells; these include ICAM-1, VLA-4 ligands, CXCL12 and CXCL13, 
with the latter considered a major player in CNS B cell recruitment (Alter et al., 2003; 
Lehmann-Horn et al., 2015; Blauth et al., 2015). CXCL13 is significantly elevated in the CSF 
during MS and other neuroinflammatory conditions, is expressed on inflamed endothelium 
and is strongly associated with B cell-related parameters (Krumbholz et al., 2006; Kowarik et 
al., 2012; Puthenparampil et al., 2017).  
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Though the mechanisms for B cell migration into the CNS are not fully clear, it has recently 
been demonstrated that B cells can undergo bidirectional exchange across the BBB in MS 
(Fig. 1.9C). This was achieved using advanced high-throughput sequencing, known as deep 
repertoire sequencing, of Ig heavy chain variable region genes. In matched CSF and 
peripheral blood samples, five of six donors with MS were found to harbour related clones in 
the CSF and periphery, although this was also true for some of the control samples (von 
Budingen et al., 2012). By analysing B cell antibody repertoires from matched CNS and 
peripheral tissues, related B cell clones were found between CNS compartments and the 
cervical lymph nodes, however most founding B cell clones were from the cervical lymph 
nodes, implicating the latter as the primary site of maturation for CNS B cells (Stern et al., 
2014). Applying deep sequencing to CSF cells and sorted peripheral blood B cell populations, 
Ig class-switched memory B cells were identified as the major B cell population involved in 
bidirectional exchange, although in some individuals, IgG+ plasma cells and CD27-IgD- B 
cells were also connected to both compartments (Palanichamy et al., 2014a).  
1.9.3 T cell involvement in MS 
Autoreactive T cells are a major player in the pathogenesis of MS. The active or passive 
induction of EAE in animals, by immunisation with myelin peptides or adoptive transfer of 
myelin-specific T cells, demonstrates the ability to induce a CNS demyelinating disease with 
the immunological, pathological and histological features of MS from a peripheral immune 
response (Kabat et al., 1948; Constantinescu et al., 2011; Legroux and Arbour, 2015). In 
addition, the association of several genes with MS pathogenesis that are involved in T cell 
responses, such as MHC class II, IL-2 and IL-21, suggests an important role for these cells in 
MS pathogenesis (Sawcer et al., 2011; Weissert, 2013).    
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Th1 and Th17 cells are considered the dominant T cell populations involved in MS 
pathogenesis. The Th1/Th17 phenotype shows an exaggerated inflammatory profile in MS, 
with elevated IFN and IL-17 secretion following ex vivo stimulation or in response to 
myelin-associated peptides (Edwards et al., 2010; Cao et al., 2015). Despite these findings, 
EAE studies suggest that there is no absolute requirement for either cytokine phenotype, 
although the presence of IL-23 does appear to be necessary as its deficiency in mice confers 
resistance to disease (Ferber et al., 1996; Haak et al., 2009; Langrish et al., 2005; Lovett-
Racke et al., 2011; Gyülvészi et al., 2009; Fletcher et al., 2010). In EAE, IL-23 permits 
homing of myelin oligodendrocyte protein (MOG)-specific T cells to the CNS, where 
recruitment into the CNS is regulated by CCR6 and its ligand CCL20 (Gyülvészi et al., 2009; 
Reboldi et al., 2009).    
In humans, CCR6+ T cells in the CSF are largely ex-Th17 (non-classic) Th1 cells that 
predominantly secrete IFN and GM-CSF, which activates CNS-resident microglia and 
infiltrating macrophages and causes polarisation to a pro-inflammatory M1 phenotype 
(Restorick et al., 2017; Mazzoni et al., 2015; Shiomi et al., 2016). Interestingly however, 
infiltrating lymphocytes are predominantly CD8+ T cells, with frequencies consistently 
dominating that of CD4+ T cells, sometimes by up to 50 times; this increased frequency has 
been observed in the parenchyma, perivascular cuffs, normal appearing white matter and CSF 
(Hauser et al., 1986; Salou et al., 2015; Jilek et al., 2007). 
In MS the majority of CD8+ T cells show high clonal expansion in lesional/non-lesional brain 
tissue and CSF, with identical clones found in different brain regions; related CD8+ T cell 
clones in MS CNS have also been identified in the peripheral blood (Skulina et al., 2004; 
Junker et al., 2007). Up to 35% of CD8+ T cells within the parenchyma are clonally related, 
whereas the CD4+ T cell infiltrate is more heterogeneous (Babbe et al., 2000). Infiltrating 
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CD8+ T cells show biased TCR V-β chain usage, which has also been identified in the 
peripheral blood T cell repertoire, where there is more skewing in the CD8+ compared to the 
CD4+ compartment (Babbe et al., 2000; Salou et al., 2015; Gran et al., 1998; Laplaud et al., 
2004). CD8+ T cells from MS peripheral blood exhibit exaggerated responses to myelin-
derived peptides, and their pathogenicity is supported by EAE studies where MOG-reactive 
CD8+ T cells induce severe clinical features throughout the disease course following adoptive 
transfer (Zang et al., 2004; Crawford et al., 2004; Sun et al., 2001; Ford and Evavold, 2005).  
1.9.4 B cell involvement in MS  
It has been shown that current MS therapies, which were believed to suppress disease activity 
by depleting T cells, also deplete memory B cells (Baker et al., 2017b). For example, 
cladribine induces a more marked depletion of B cells than any other immune subset, and 
anti-neoplastic agents such as mitoxantrone, teriflunomide and cyclophosphamide 
preferentially target B cells due to their enhanced proliferative capacity compared to T cells 
(Baker et al., 2017a; Gandoglia et al., 2017; Hurd and Giuliano, 1975; Fidler et al., 1986). In 
conjunction with the limited efficacy of CD4+ T cell depletion in RRMS, this implicates a 
strong pathogenic role for B cells in MS (van Oosten et al., 1997; Samijn et al., 2006). B cells 
have been identified within distinct CNS compartments including the meninges, cortex, 
normal-appearing white matter and CSF; they have also been observed in MS lesions, where 
their immunoglobulin proteomes and transcriptomes strongly overlapped with those in the 
CSF, indicating an active and dynamic B cell component (Lucchinetti et al., 2000; Owens et 
al., 2003; Lovato et al., 2011; Obermeier et al., 2011). The presence of B cell aggregates, 
referred to as ectopic lymphoid-like follicles, have been reported in the meninges of some 
SPMS post-mortem brain specimens (Fig. 1.9B). Though devoid of mantle zones, these 
structures display features of germinal centres and contain proliferating B cells organised 
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around a stromal niche, with FDC secreting the B cell chemoattractant CXCL13 (Serafini et 
al., 2004). These follicles appear to be functional structures containing a number of AID-
expressing B cells, providing evidence for class switching and somatic hypermutation; 
features of a sustained T cell-dependent B cell response (Serafini et al., 2007). Furthermore, 
detailed analysis of post-mortem tissue suggests that the development and maintenance of 
these follicles is associated with local neurodegeneration and cell loss, correlating clinical 
disability with B cell activity (Magliozzi et al., 2010). As such, these findings implicate the 
CNS as an environment conducive to long-term B cell survival.  
1.9.4.1 CSF analysis 
Class-switched CD27+, IgM-IgD- memory B cells accumulate in MS CSF, and short-lived 
plasmablasts have been identified as the main effector B cell subset in MS, constituting up to 
30% of the CSF B cell pool (Cepok et al., 2001; Cepok et al., 2005a; Winges et al., 2007). 
CSF plasmablasts correlate with intrathecal IgG levels and parenchymal inflammation, and 
are present throughout the disease course, in contrast to those with infectious neurological 
diseases where CSF plasmablasts disappear rapidly following resolution of inflammation 
(Cepok et al., 2005a). Some studies have also identified CSF ASC with a mature CD19- 
phenotype, implicating a continuum of CNS B cell differentiation that is detectable in the 
CSF (Corcione et al., 2004; Winges et al., 2007). In contrast, other groups have failed to 
identify these cells in the CSF (Cepok et al., 2005a; Kuenz et al., 2008). 
Several markers of B cell activity have been identified within the MS CSF. Notably, CXCL13 
shows the strongest association and is significantly elevated in the CSF but not the serum of 
individuals with CIS, RRMS and PPMS compared to non-inflammatory controls, also 
correlating with B cell counts, intrathecal IgG synthesis, MRI activity and relapse rate (Kuenz 
et al., 2008; Kowarik et al., 2012). Although other markers of B cell activity have also been 
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implicated, they are often associated with contradictory findings. BAFF levels are elevated in 
MS CSF compared to controls, with higher levels in those with progressive disease and 
during relapse, and shows positive correlations with CXCL13, IL-6, IL-10 and APRIL 
(Ragheb et al., 2011; Wang et al., 2012). In contrast, a recent study found significantly 
decreased BAFF levels in MS CSF, with the authors speculating the absorption of BAFF by 
local ASC in the earlier stages of disease (Puthenparampil et al., 2017). In addition, IL-15 and 
CXCL12 were elevated in some studies, but as a hallmark of MS, OCB remain the most 
consistent immunological feature of the disease (Krumbholz et al., 2006; Rentzos et al., 
2006).   
 
Figure 1.9. The involvement of B cells in multiple sclerosis. B cells may contribute to MS 
pathogenesis through various effector functions, such as antigen presentation, cytokine secretion and 
antibody production (A). B cells and antibody-secreting cells may survive in ectopic follicles within 
the CNS (B) and may undergo bidirectional exchange across the blood-brain barrier (C). In addition, 
the presence of CSF B cell markers, including antibodies and free light chains, is suggestive of B cell 
activity in MS (D).    
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1.9.4.2 Cytokine profiles of B cells in MS 
B cells may contribute to MS pathogenesis through several mechanisms (Fig. 1.9). The 
defining feature of B cell biology is the production of antibodies; however, the immediate 
benefits of anti-CD20 treatment, combined with the persistence of long-lived ASC and OCB, 
suggests that antibodies may not play a substantial role in MS pathology (Piccio et al., 2010). 
B cell-derived cytokines may contribute to disease pathology and are reportedly perturbed in 
MS. B cells from people with MS display elevated capacity to secrete pro-inflammatory 
cytokines including IL-6, lymphotoxin-, TNF and GM-CSF, and demonstrate a diminished 
capacity to secrete IL-10 compared to healthy controls (Barr et al., 2012; Duddy et al., 2007; 
Li et al., 2015). 
1.9.4.3 Antigen presentation by B cells in MS 
Since B cells are strong presenters of antigen, this function could be their major contribution 
to MS pathogenesis (Fig. 1.9A). Memory B cells from RRMS blood can induce activation and 
proliferation of cognate T cells in response to myelin-associated antigens (Harp et al., 2010). 
B cells from the blood and CSF of those with MS express higher levels of co-stimulatory 
molecules compared to controls, and express higher levels of HLA-DR, suggesting a stronger 
propensity for antigen presentation (Fraussen et al., 2016; Mathias et al., 2017). In addition, 
mice with a B cell-specific defect in MHC class II molecules are resistant to EAE induction, 
and B cell-mediated antigen presentation enhances EAE severity and is required for maximal 
disease (Molnarfi et al., 2013; Parker Harp et al., 2015).  
1.9.4.4 The contribution of antibodies to MS 
A hallmark of MS is the presence of CSF antibodies (Fig. 1.9D). Demyelinating type II 
lesions, which are associated with substantial IgG and complement deposition, are the most 
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common lesion type in MS (Lassmann et al., 2007). Antibodies in the brain are thought to 
bind Fc receptors expressed by phagocytes, which process and present the antigen in the 
context of MHC class II molecules which can subsequently activate cognate CD4+ T cells. In 
B cell-dependent EAE models, where disease is sub-clinical in B cell-deficient animals, 
autoreactive CD19+ plasmablasts contributed to disease pathology by producing autoreactive 
antibodies, and transfer of MOG-primed B cells is sufficient to induce disease in MOG-
immunised B cell-deficient mice (Chen et al., 2016a; Lyons et al., 2002). In humans, 
antibodies are prominent in active MS lesions where they associate with areas of myelin 
degeneration (Lucchinetti et al., 2000).  
1.9.4.5 Possible autoantigens associated with MS  
Candidate targets of MS antibodies have been extensively investigated over the years, with 
myelin sheath components such as MOG and myelin basic protein (MBP) frequently 
identified (Pittock et al., 2007; von Budingen et al., 2008; Menge et al., 2011). These proteins, 
along with several others, are distributed amongst lipids in the myelin sheath and their 
exposure allows them to be targeted by antibodies (Podbielska et al., 2013). In animals, 
antibodies towards myelin components are capable of inducing demyelination and 
augmenting T cell-mediated EAE (Linington et al., 1988; Schluesener et al., 1987). Elevated 
reactivity of serum and CSF immunoglobulin towards myelin proteins has been observed in 
MS but not controls, and B cells specific for MOG and MBP have been identified in the 
periphery of those with MS (Xiao et al., 1991; Markovic et al., 2003; Reindl et al., 1999; Harp 
et al., 2010). Conversely, using various technological methods, several other studies have 
shown that CSF antibodies were either not reactive to myelin antigens, or were characterised 
by very low affinity binding; these included histological analysis of MS brain sections, 
western blotting, protein arrays and immunoprecipitation, using serum or CSF antibodies or 
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recombinant antibodies produced from CSF-derived ASC (O'Connor et al., 2003; Kuhle et al., 
2007; Owens et al., 2009; Ayoglu et al., 2016; Levin et al., 2013). Additionally, the presence 
of equivalent levels of functional anti-MBP antibodies in healthy individuals, and the 
presence of anti-MOG antibodies in several other CNS conditions such as neuromyelitis 
optica (NMO) and acute disseminated encephalomyelitis (ADEM), indicates that myelin is 
not the primary autoimmune target for B cells in MS (Xiao et al., 1991; Hedegaard et al., 
2009; Mader et al., 2011; O'Connor et al., 2007). 
Many other candidate autoantigens have been described in MS; these include those directed 
towards structural and molecular components, including neurofilament light chain, anoctamin 
2 and neurofascin, small molecules, such as alpha-B crystallin, and microbial antigens, such 
as EBV, measles, rubella and zoster (MRZ) viruses and Chlamydia pneumoniae (Amor et al., 
2014; Ayoglu et al., 2016; Mathey et al., 2007; van Noort et al., 1995; Felgenhauer et al., 
1985; Nociti et al., 2010; Sriram et al., 1999). The search for MS target antigens has also been 
extended to lipids. It has been reported that up to 60% of people affected by MS demonstrate 
serum and CSF reactivity towards myelin-derived lipids, particularly sulfatide, ganglioside 
and cerebroside (Brennan et al., 2011; Ilyas et al., 2003; Kanter et al., 2006). Lipid reactivity 
is also associated with IgM, which correlates with a more aggressive disease course (Villar et 
al., 2015). However, the inconsistent reproducibility between studies, and the generally low 
proportion of individuals with autoantibodies of a given specificity, implicate a real need for 
further investigating the antibody response in MS, especially considering the potential impact 
of identifying common autoantigens that are specific to MS. 
1.9.4.6 Features of the antigen-driven B cell response  
Irrespective of their antigen specificities, evidence suggests an antigen-driven B cell response 
in MS. Extensive somatic hypermutations of IgG heavy and light chain V regions, particularly 
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in the complementarity-determining region (CDR)3, with overrepresentation of VH4 and 
VH2 gene segments, is a key feature of B cells in MS brain lesions (Baranzini et al., 1999; 
Owens et al., 1998) and in the CSF (Owens et al., 2007; Colombo et al., 2000; Qin et al., 
1998). VH4 and VH2 germline sequences share related sequence homology and since the 
VH4 bias appears earlier than the VH2 bias in MS, this could represent an evolving immune 
response from one to several antigenic targets (Bennett et al., 2008; Kirkham et al., 1992). 
Though less frequently studied, CSF light chain sequences also demonstrate high levels of 
homology, with remarkably similar Vregions identified in CSF B cells from three out of 
three MS CSF samples; this was particularly evident within the kappa light chain CDR, which 
forms part of the antigen binding site (Blalock et al., 1999). In addition to suggesting a 
restricted antigen response that is shared between affected individuals, this study also 
supports the contribution of light chains to MS pathogenesis.   
Light chains have long been associated with MS pathogenesis. Studies spanning nearly 50 
years have reported elevated FLC in MS CSF, with preferential bias towards kappa light 
chain usage (Link and Zettervall, 1970; Zeman et al., 2012; Presslauer et al., 2014; Hassan-
Smith et al., 2014). A normal serum kappa to lambda light chain ratio is approximately 1.6:1 
in favour of kappa light chain but can be skewed in either direction during persistent 
immunological challenges such as chronic inflammation or autoimmunity (Barnidge et al., 
2014). This bias presumably relates to a restricted antigen response, caused by monoclonal or 
oligoclonal expansion of antigen-specific B cell clones. An immunohistochemistry study 
using post-mortem MS brain tissue demonstrated biased expression of kappa light chains in 
active ASC-containing lesions at a ratio of 2.3:1, compared to a ratio of 1.6:1 in non-active 
lesions (Esiri, 1977). A more recent study identified a kappa light chain bias of over 10:1 in 
blast-like CD19+ B cells in three MS CSF samples from individuals who went on to develop 
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MS (Vafaii and DiGiuseppe, 2014). This evidence points to the phenomenon of a kappa light 
chain bias in MS patients, indicative of a clonal B cell response.   
1.10 Project Aims 
It is appreciated that B cells play a role in MS pathogenesis, but their precise features in MS 
CSF remain to be determined. B cells and ASC have been identified in MS CSF, and some 
studies have reportedly identified mature ASC, indicative of a sustained B cell response, 
although this has been disputed by others. Additionally, the identification of clonal B cell 
populations in MS brain compartments, and their ability to traffic between the CNS and 
periphery, raises questions as to the relative contributions of CNS-expanded B lineage cells, 
which may sustain disease, versus peripheral B cells, which may gain access to the CNS 
through an inflamed BBB. The presence of clonally expanded B cell populations, in addition 
to the elevated ratio of kappa light chains (Igto lambda light chains (Ig) in MS CSF, 
implicate the involvement of a dominant autoantigen capable of inducing an Ig-biased 
antibody response. As such, the initial aims of this thesis were to: 
1) Identify, characterise and quantify B cells and ASC in the CSF and peripheral 
blood of CIS, established MS and control groups. 
2) Investigate the heavy and light chain isotypes on B cells and ASC in the CSF and 
peripheral blood of CIS, established MS and control groups. 
Despite extensive investigations, the antigen specificity of CSF antibodies in MS remains 
elusive and not well-characterised, however the availability of increasingly sophisticated 
applications allows the use of high-throughput approaches to investigate potential 
autoantigens in autoimmunity. With the assumption that CSF antibodies are pathogenic, 
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identification of the antigen responsible for inducing an Ig-biased antibody response, which 
is a key feature of MS CSF, could have important implications for understanding how MS is 
triggered and how it could be treated. The antigen specificities of antibodies bearing Ig 
versus those with Ig light chains have not before been investigated, therefore, using high-
density protein arrays, the next aim of this investigation was to: 
3) Investigate the antigen specificities of CSF antibodies from CIS, established MS 
and control groups and investigate whether certain antigens induce a skewed 
kappa light chain response. 
In addition to the ongoing interest in CSF antibody specificity, the rapid and sustained clinical 
benefits of anti-CD20 therapeutics in reducing inflammatory brain lesions and relapse rates 
has been attributed to the removal of antibody-independent functions mediated by CD20+ B 
cells, since CSF antibody remains largely unaffected (Hauser et al., 2008; Bonnan, 2014). 
Intriguingly, while CSF B cells are almost fully eliminated by anti-CD20 therapeutics, CSF T 
cell numbers also show a marked reduction in frequency (Cross et al., 2006). One possibility 
for this phenomenon is the contribution of CD20-expressing T cells to MS pathogenesis. 
These cells, which are reportedly increased in MS blood versus controls and are present in 
MS brain tissue, were shown to be removed following rituximab treatment, implicating 
possible involvement in disease (Wilk et al., 2009, Palanichamy et al., 2014b; Holley et al., 
2014). In addition, the elusive nature of this pro-inflammatory T cell population warrants 
further investigation into their phenotype and function in health and disease (Schuh et al., 
2016). Therefore, the final aim of this thesis was to: 
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4) Investigate the frequency and phenotype of CD20+ T cells in the peripheral blood 





























Chapter 2: Methods 
2.1 Materials 
Table 2.1 Common laboratory reagents.  
Description Components 
PBS 
Phosphate buffered saline (8g/l NaCl, 0.26g/l KCl, 1.15g/l Na2HPO4, 
0.2g/ml KH2PO4); prepared as 1 tablet in 100ml distilled H20 (Oxoid, 
Basingstoke, UK) 
FACS buffer PBS with 2% Bovine Serum Albumin (BSA; Sigma Aldrich, Dorset, UK) 
RPMI medium 
RPMI 1640 medium (Sigma Aldrich) with 1% GPS (2mM L-glutamine, 
100U/ml penicillin, 100ug/ml streptomycin; HyClone, Northumberland, 
UK) and 1% HEPES (Sigma Aldrich) 
RPMI + 10% FCS 
RPMI-1640 medium with 10% heat-inactivated foetal calf serum (FCS; 
Biosera, Ringmer, UK) 
MACS buffer 
PBS, 0.5% BSA and 2mM ethylenediaminetetraacetic acid (EDTA; 
Sigma Aldrich) 
 
Sort buffer 1:1 RPMI-1640 medium with heat-inactivated foetal calf serum 
Planar array assay 
buffer  
PBS + 0.1% tween + 3% BSA + 160µg/ml His6-ABP  
Planar array wash 
buffer 
PBS + 0.1% tween  
Suspension bead array 
assay buffer 
PBS + 0.1% tween + 3% BSA + 160µg/ml His6-ABP 
Suspension bead array 
wash buffer 








Table 2.2 Primary monoclonal antibodies used to detect surface and intracellular 
proteins by flow cytometry. 
 
Specificity Fluorochrome Company Cat. No Clone Dilution 
 
CD19 
Alexa Fluor 488 BioLegend 302219 HIB19 1/20 
Bv605 BioLegend 302244 HIB19 1/320 
 
CD20 
Bv421 BioLegend 302330 2H7 1/40 
Bv711 Biolegend 302342 2H7 1/80 
PE Biolegend 302306 2H7 1/20 
CD27 APC-Cy7 BioLegend 302816 O323 1/40 
CD138 
PE BioLegend 356504 MI15 1/20 
Alexa Fluor 700 Biolegend 356511 MI15 1/20 
CD38 PE-Cy7 BioLegend 356608 HB-7 1/200 








IgA VioBright FITC 
Miltenyi 
Biotec 




562538 G18-145 1/80 
IgM Bv650 BioLegend 314526 MHM-88 1/320 




















CD54RA PE-Texas Red 
BD 
Biosciences 
562298 HI100 1/800 
CCR7 Alexa Fluor 488 BioLegend 353206 G043H7 1/20 
IFNγ PE eBioscience 12-7319 4S.B3 1/20 




CCR6 APC Biolegend 353416 G034E3 1/20 
CD25 PerCP-Cy5.5 eBioscience 45-0259 BC96 1/20 
CD69 APC-Cy7 Biolegend 310914 FN50 1/40 
CD107a FITC Biolegend 328606 H4A3 1/20 
Perforin PE Biolegend 308106 dG9 1/20 
Granulysin PE eBioscience 12-8828 DH2 1/20 
Granzyme A PE-Cy7 eBioscience 25-9177 CB9 1/20 






NOK-1 564261 1/20 
CTLA-4 
(CD152) 
PE Biolegend 349906 L3D10 1/20 
PD-1 PE Biolegend 329906 EH12.2H7 1/20 










IL-4 PE eBioscience 12-7049-42 8D4-8 1/20 























Table 2.3 Isotype controls used for flow cytometry.   
Specificity Fluorochrome Company Cat. No 
Mouse IgG2b  Bv421 BioLegend 400342 
Mouse IgG2b PE BioLegend 400314 
Mouse IgG1κ PE Biolegend 400112 
Rat IgG2aκ PE-Cy7 Biolegend 400521 
Rat IgG2aκ PE Biolegend 400508  
Rat IgG1κ PE eBioscience 12-4031 
 
 
Table 2.2 Primary monoclonal antibodies used to detect surface and intracellular proteins by 
flow cytometry. Shown for each antibody is the antigen specificity, fluorochrome, order details, 
clone and dilution used. Abbreviations: Brilliant violet (Bv), phycoerythrin (PE), fluorescein 
isothiocyanate (FITC), allophycocyanin (APC), peridinin chlorophyll protein cyanine 5.5 (PerCP-
Cy5.5), cyanine 7 (Cy7), intracellular (IC).  
Appropriate isotype controls were used on the same fluorochrome and at the same concentration of 
their matched antibody. On occasions where no appropriate isotype control was available, gates 
were set using a fluorescence minus one (FMO) panel, in which the antibody of interest was 
omitted. Flow cytometry gates were set at 1% positivity on the isotype control/FMO, except for 
when gating on CD20+ T cells, which were set at 0.5% positivity or less.  
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2.3 Samples and Ethics 
Individuals undergoing elective diagnostic lumbar puncture with a suspected or confirmed 
diagnosis of MS, or control patients undergoing diagnostic or therapeutic lumbar puncture, 
were prospectively recruited from the Queen Elizabeth Hospital, University Hospitals 
Birmingham NHS Foundation Trust (QEHB) for matched peripheral blood and CSF. For 
studies requiring large numbers of cell-free CSF samples (i.e. the antigen arrays), historical 
banked CSF was used, which was collected between 2011 – 2016.  
Individuals were stratified into the following groups according to clinical criteria based on the 
diagnosis of MS: clinically isolated syndrome (CIS), relapsing-remitting (RRMS), primary 
progressive (PPMS) and those with MS recently ceasing natalizumab therapy (NAT). A 
combination of RRMS and PPMS was collectively referred to as clinically definitive MS 
(CDMS). Individuals with other neurological diseases (OND) and other neurological 
inflammatory diseases (ONID) were also included in the study. The OND cohort consisted of 
individuals diagnosed with headaches and headache-related disorders, hydromyelia, non-
epileptic attacks, anxiety and diabetic neuropathy. The ONID cohort were more 
heterogeneous, with diagnoses including autoimmune neuropathy, Behcet’s syndrome, 
neurosarcoidosis and transverse myelitis. 
Individuals were recruited after obtaining informed written consent and ethical approval was 
provided under study ‘Molecular and Cellular Studies on Inflammation in Multiple Sclerosis’ 
(UKCRN ID 13585). For healthy controls, peripheral blood was taken from donors recruited 
at the University of Birmingham, with ethical approval under ‘Immune mechanisms in the 
ocular microenvironment’ (UKCRN 4654) or ‘Adaptive immunity in multiple sclerosis’ 
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(ERN_15-1608A). For each results chapter within this thesis, the clinical information can be 
found within Appendices I-III. 
2.4 Preparation of Cerebrospinal fluid  
CSF was collected following non-traumatic diagnostic or therapeutic lumbar puncture from 
consenting individuals at the QEHB. CSF was centrifuged at 600xg for 8 min and the cell-free 
CSF was collected and stored at -80°C for later analysis. The CSF cell pellet was stained for 
surface and/or intracellular markers, either directly or following in vitro stimulation.  
 
2.5 Peripheral blood mononuclear cell (PBMC) isolation 
Peripheral blood was collected into EDTA-containing tubes (Greiner Bio-One, 
Gloucestershire, UK) and was diluted 1:1 with serum-free RPMI. Up to 18ml blood was 
layered onto 7ml Ficoll-paque (GE Healthcare Bio-Sciences, Uppsala, Sweden) and 
centrifuged at 400xg for 30 min with no brake applied. For PBMC isolation from lymphocyte 
cones (National Blood Service, Birmingham), blood was diluted to a volume of 30ml and 
15ml was layered onto 15ml Ficoll-paque in two 50ml falcon tubes. Mononuclear cell layers 
were harvested and washed in RPMI at 300xg for 8 min, then at 200xg for 8 min to remove 
platelets. For PBMC isolation from lymphocyte cones, red cell lysis buffer (Sigma Aldrich; 3-
4ml for up to 5 min) was used to deplete red blood cells present in the pellet. PBMC were re-
suspended in 10ml RPMI + 10% FCS and counted with the addition of trypan blue dead cell 
exclusion dye (Sigma Aldrich). PBMC were washed a final time at 300xg for 8 min and were 
resuspended at the required volume for further applications.  
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2.6 Fluorescence Activated Cell Sorting (FACS) 
Prior to isolating CD20- and CD20+ CD8+ memory T cells by fluorescence activated cell 
sorting (FACS), PBMC from lymphocyte cones were first stained with eFluor™ 450 Cell 
Proliferation Dye (eBioscience, Leicestershire, UK). PBMC were twice centrifuged in 10ml 
PBS at 300xg for 4 min and were resuspended in an appropriate volume of PBMC to yield 
20x106 cells/ml. This was added 1:1 to a 1/500 dye solution, to yield a final dye concentration 
of 10M. The cell suspension was thoroughly mixed and incubated at 37ºC for 10 min in the 
dark. The labelling reaction was quenched by adding a 4-5x volume of cold RPMI + 10% 
FCS and incubating on ice for 5 minutes. Cells were then centrifuged 3 times at 300xg for 4 
min. PBMC were then pre-enriched for CD8+ memory T cells using a negative selection 
magnetic isolation kit (Miltenyi Biotec, Surrey, UK) following the manufacturer’s 
instructions. For 107 cells, PBMC were incubated in 40µl MACS buffer with 10µl biotin-
antibody cocktail against CD4, CD11c, CD14, CD15, CD16, CD19, CD34, CD36, CD45RA, 
CD56, CD57, CD61, CD123, CD141, TCR γ/δ, and CD235a for 10 min at 4ºC. PBMC were 
washed in 1-2ml MACS buffer and incubated with 80µl MACS buffer plus 20µl anti-biotin 
microbeads for 15 min at 4ºC. PBMC were resuspended at the recommended volume and 
were passed through a pre-rinsed LS column (Miltenyi Biotec) on a magnetic MidiMACS™ 
separator. The unlabelled CD8+ memory T cell fraction was eluted and stained with surface 
markers for 20 min on ice, along with the appropriate single colour compensation controls. 
Cells were washed and resuspended in 2ml RPMI + 10% FCS. Cell sorting was performed on 
a MoFlo Astrios Flow Cytometer Cell Sorter (Beckman Coulter, High Wycombe, UK) using 




2.7 Cell culture 
In vitro cell culture assays were carried out in 96 well round-bottom plates, using RPMI + 
10% FCS as the assay media, with a total volume of 200µl per well.  
2.7.1 T cell stimulation assays 
For assessment of cytokine secretion by T cells from MS (CIS, RRMS or PPMS) and OND 
groups, samples were prepared as described above and both PBMC (adjusted to 1x106 cells 
per well) and CSF cells were resuspended in RPMI + 10% FCS and stimulated at 37ºC for 3 
hours with phorbol 12-myristate 13-acetate (PMA; 50ng/ml) and ionomycin (750ng/ml) in the 
presence of brefeldin A (0.1µg/ml; all from Sigma Aldrich) to inhibit intracellular protein 
transport. These were subsequently prepared for flow cytometry (section 2.8).  
For longer term T cell stimulation, isolated CD20+ and CD20- T cells were prepared as in 
section 2.6 and seeded at 2x104 cells per well in RPMI + 10% FCS with the addition of 
recombinant human IL-2 at 25U/ml (PeproTech, London, UK). Where required, 1.8x105 
PBMC were added to give a 10:1 ratio. Cultures were stimulated with Dynabeads® Human T-
Activator CD3/CD28 beads (Life Technologies, Paisley, UK) at a 1:1 cell to bead ratio, or 
ImmunoCult™ Human CD3/CD28 T cell activator (StemCell Technologies, Cambridge, UK) 
using 25l per 1ml cell suspension, as instructed by the manufacturer. Alternatively, cells 
were left unstimulated. Cultures were incubated for 4 days at 37 ºC and were subsequently 
stained for CD8 and CD20, with a corresponding FMO/isotype control used, and analysed by 
flow cytometry (section 2.8).    
 2.7.2 Degranulation assays 
To assess the ability of T cells to release cytotoxic molecules in response to stimulation, 
expression of CD107a (also known as lysosomal-associated membrane protein-1 or LAMP-1) 
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and perforin were analysed simultaneously on an hourly basis for a total of 3 hours. PBMC 
were stimulated as described in the presence of FITC-conjugated anti-human CD107a and 
brefeldin A. PBMC were then stained for surface markers to allow the identification of 
CD20+ T cells within T cell subsets, fixed and stained for intracellular perforin. Flow 
cytometry gates were set on stimulated control wells in the absence of CD107a and perforin.   
 
2.8 Multi-colour Flow Cytometry 
 2.8.1 Surface staining 
1-5x106 cells (depending on application) were washed in FACS buffer by centrifugation at 
300xg for 4 min. Where required, cells were first stained with Zombie AquaTM Fixable 
Viability dye diluted in cold PBS (1/400; BioLegend, London, UK) on ice for 20 min and 
washed in FACS buffer at 300xg for 4 min. Cells were stained with 50µl fluorescently 
labelled antibodies to detect surface markers for 20 min on ice in the dark. 100µl FACS buffer 
was added and cells were centrifuged at 300xg for 4 min. For immediate analysis by flow 
cytometry, cells were resuspended in a final volume of 300µl FACS buffer, or were 
alternatively fixed, either for later analysis or for intracellular staining (see below).  
 2.8.2 Intracellular staining 
Cells were fixed in medium A (FIX & PERM® cell fixation kit, Life Technologies) for 15 
min at room temperature (RT) and washed in FACS buffer by centrifugation at 300xg for 4 
min. Cells for surface marker staining only were re-suspended in 100µl FACS buffer and 
stored at 2-8°C for later analysis. Cells were resuspended in 50µl permeabilisation buffer 
(medium B), containing fluorescently labelled antibodies to detect intracellular markers, for 
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20 min at RT. Cells were washed in 100µl FACS buffer by centrifugation at 300xg for 4 min, 
and were resuspended in 300µl FACS buffer for immediate analysis, or were resuspended in 
100µl and stored at 2-8°C for later analysis. 
Table 2.4 Antibody panels used for flow cytometry analysis. 
Panel Description Antibodies 
B cell phenotyping  
 
CSF and peripheral blood, 
MS/control groups 
CD19, CD20, CD27, CD38, 
CD138, Igκ, Igλ, IgG, IgM, IgA 
CD20+ T cell cytokine secretion – 
3h stimulation 
CSF and peripheral blood, 
MS/control groups 
CD3, CD8a, CD20, CD45RA, 
CCR7, IFNγ, CCR6, IL-17A 
CD20+ T cell phenotyping - 
resting or 3h stimulation 
Peripheral blood, healthy 
donors 
CD3, CD8a, CD45RA, CCR7 plus 
various surface or intracellular 
markers for phenotyping 
CD20+ T cell sort/post-culture 
panel 
Peripheral blood, healthy 
donors 
CD8a, CD45RA, CD20 
CD20+ T cell degranulation 
assay 
Peripheral blood, healthy 
donors  
CD3, CD8a, CD45RA, CD107a, 
perforin 
Tetramer panel  Healthy donors  
APC-labelled tetramer, CD3, CD8, 
CD20 
 
2.8.3 Tetramer staining 
Tetramer staining was performed using APC-labelled tetramers towards two common EBV 
lytic cycle peptides, GLC (amino acid sequence: GLCTLVAML) or YVL (amino acid 
Shown are antibody panels used throughout the thesis along with a description of samples they were 





sequence: YVLDHLIVV) (Moosmann et al., 2010). Frozen PBMC from three HLA-A*02-
positive donors were thawed, washed in 15ml RPMI + 10% FCS and counted. PBMC were 
resuspended at 2-3x106 cells per well and were stained with the APC-labelled tetramers for 30 
min at 37ºC at a dilution of 1/25 in FACS buffer. PBMC were washed in FACS buffer at 
300xg for 4 min and were stained with surface antibodies towards CD3-Bv510, CD8-
eFluor™ 450 and CD20-PE for 20 min at RT, washed at 300xg for 4 min and resuspended in 
300µl FACS buffer. Cells were then analysed using flow cytometry.  
PBMC and tetramers were kindly donated by Dr Heather Long, Institute of Immunology and 
Immunotherapy, University of Birmingham.   
2.8.4 Flow cytometry data analysis 
Samples were ran on a BD LSR Fortessa™ flow cytometer (BD Biosciences, Oxford, UK) or 
a Cyan ADP flow cytometer (Beckman Coulter, High Wycombe, UK). Single colour 
compensation was achieved using surface-stained PBMC or OneComp eBeads (eBioscience). 
Data was analysed using Kaluza Flow Cytometry Analysis Software v1.2 (Beckman Coulter). 
 
2.9 Free light chain quantification  
FLC concentrations were measured by nephelometry using the latex particle-enhanced, 
Freelite® κ and λ immunoassays on a Dade-Behring BN ™ II Analyser (Bradwell et al., 
2001). Assays were performed by The Binding Site Group Ltd (Birmingham, UK), using 
anonymised coded samples. The limit of detection for the κ FLC assay was 0.06 mg/l and 




2.10 CXCL13 Luminex assay 
A Luminex assay for CXCL13 was performed using the Bio-Plex Pro™ reagent kit III (cat.no 
171304090M) following manufacturer’s instructions. All reagents were purchased from Bio-
Rad Laboratories Ltd, Hertfordshire, UK. The standard (Bio-Plex Pro™ human chemokine 
standard, cat.no 171-DK0001) was reconstituted and serially diluted four-fold to produce 
eight standards. Blank wells containing wash buffer were also included. 50µl neat CSF from a 
OND and MS groups were incubated with 50l coupled magnetic beads (Bio-Plex Pro™ 
human chemokine BCA-1/CXCL13 set, cat.no 171BK12MR2) for 1 hour on a shaker at RT. 
The plate was washed 3 times with 100µl wash buffer before adding 25µl of the detection 
antibody to each well. The plate was incubated for 30 min on a shaker in the dark and washed 
3 times with 100µl wash buffer. 50µl of streptavidin-PE antibody was added to each well and 
the plate was incubated as previously for 10 min. The plate was washed 3 times with 100µl 
wash buffer and each well was resuspended in 125µl assay buffer. The plate was covered and 
placed on a shaker for 30 seconds prior to running on a Bio-Rad Bio-Plex 200 machine.    
 
2.11 Quantitative Polymerase Chain Reaction (qPCR) 
2.11.1 mRNA isolation from sorted lymphocyte subsets  
Sorted cell subsets (B cells, CD20- T cells and CD20+ T cells) were washed in cold PBS at 
400xg for 8 min. Cell sorts yielding <1,000 cell equivalents per reaction were discarded. 
mRNA was isolated using µMACS mRNA Isolation kit (Miltenyi Biotec, Surrey, UK) 
following the manufacturer’s instructions. Cells were lysed by vigorously vortexing in lysis 
buffer, and cell lysate was removed by centrifuging in LysateClear columns at 13,000xg for 3 
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min. The cleared lysate was mixed with Oligo(dT) MicroBeads and magnetically retained in a 
MACS column placed in the magnetic field of a µMACS Separator, retaining the 
magnetically-labelled mRNA within the column. The column was washed with Lysis Buffer 
and Wash Buffer.  
2.11.2 cDNA synthesis from mRNA 
cDNA was synthesised using µMACS One-Step cDNA Synthesis Kit (Miltenyi Biotec) 
following the manufacturer’s instructions as follows: the column was washed twice with 
Equilibration/Wash Buffer and reconstituted Enzyme Mix was added to the column, followed 
by sealing solution to avoid evaporation, and incubated for 1 hour at 42°C. The column was 
rinsed twice in Equilibration/Wash Buffer and cDNA Release Solution was added to the 
column for 10 min before eluting the cDNA with 50µl cDNA Elution Buffer. cDNA was 
stored at -20°C until further analysis.   
2.11.3 qPCR assay  
qPCR was performed on a LightCycler 480 PCR machine (Roche, Basel, Switzerland) in 384 
well plates. The reaction mix was prepared with 2.5µl LightCycler 480 probes mastermix 
(Roche), up to 1.8µl cDNA, 0.35µl primer-limiting glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) Taqman probe and 0.35µl CD20 Taqman probe (Life 
Technologies), made up to a total reaction volume of 5µl with DEPC-treated water (Life 
Technologies). Cycle steps included a pre-incubation cycle at 95ºC for 10 min, 40 
amplification cycles at 95ºC (10 seconds), 60 ºC (1 min) and 72ºC (1 second), and a cooling 
cycle at 40ºC for 10 seconds.  
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2.11.4 Determination of relative gene expression 
Following qPCR, amplification curves were analysed using the LightCycler 480 software 
(Roche). The cycle threshold (Ct) values for the housekeeping gene (GAPDH) and the gene 
of interest (CD20) was determined and the difference between them calculated to generate the 
ΔCt value; this normalises the Ct value for each sample based on the level of GAPDH 
expression and accounts for variation in cDNA concentrations. The difference in ΔCt values 
was determined to obtain the ΔΔCt, using sorted B cell cDNA as a positive control for CD20 
expression. Finally, the fold change in CD20 expression (2^-ΔΔCt) was calculated to 
determine the relative gene expression for each sorted T cell subset.   
 
2.12 Antigen arrays 
The antigen arrays were conducted in Stockholm, Sweden within Professor Peter Nilsson’s 
laboratory (Science for Life Laboratory, Tomtebodavägen 23a, 171 65 Solna, Sweden). 
Antigen arrays used in this study were either on glass slides (planar arrays) or magnetic beads 
(suspension bead arrays) and the arrays were generated in-house. For an overview of the assay 
methodology see Fig. 2.1, and for an overview of the assay workflow see Fig. 2.2.  
 2.12.1 Antigens  
The antigens used this study, also known as PrESTs (protein epitope signature tags), were 
generated as part of the Human Protein Atlas (HPA) project using a whole genome 
bioinformatics approach. Antigens of 25-150 amino acids long (average length of 80 amino 
acids) representing predicted human proteins were designed based on the lowest sequence 




Figure 2.1 An autoantibody profiling assay workflow using planar or bead-based antigen 
arrays. Antigens representing human proteins are immobilised onto glass slides (planar) or 
magnetic beads (bead-based). The primary antibody is applied in the form of a biological fluid 
such as CSF, and bound antibody is detected using a fluorescently labelled anti-human 




excluded. The antigens were expressed in Escherichia coli Rosetta DE3 strain as fusion 
proteins with a His6-ABP tag, consisting of a hexahistidyl (His6) and albumin binding protein 
(ABP), to allow the antigens to be purified.   
 
2.12.2 Planar antigen arrays 
Planar antigen arrays, hosting 21,120 protein fragments immobilised onto glass slides, were 
used for unbiased screening of CSF from 6 individuals with CIS, and pooled CSF from 
RRMS or OND groups (6 CSF samples per pool). A smaller array hosting 384 protein 
fragments potentially linked to MS (such as CNS antigens) was also used for further 
exploration using the same samples individually rather than pooled.  
CSF samples diluted 1/4 (384 array) or 1/10 (21k array) in assay buffer (PBS + 0.1% tween + 
3% BSA + 160µg/ml His6-ABP; generated in-house) with chicken anti-His6-ABP IgY 
(1/40,000 dilution; Agrisera, Vannas, Sweden), were incubated for 30 min on a plate shaker 
(Grant Instruments, Cambridge, UK). Slides hosting immobilised protein fragments were 
washed in distilled H20 (dH20), 60µl of CSF was added and slides were incubated for 2 hours 
on a shaker at RT. Slides were washed in wash buffer (PBS + 0.1% tween, 2x5 min) and 
incubated in AlexaFluor 647 goat anti-human (H+L) IgG diluted 1/15,000 (life technologies, 
cat. A21445) on a shaker for 1h to detect bound human antibodies. To aid grid alignment 
prior to scanning, slides were co-stained with AlexaFluor 555 goat anti-hen IgG diluted 
1/60,000 (Molecular Probes, OR, USA) to detect bound His6-ABP tag-specific chicken 
antibodies.  Slides were washed 2x5 min in wash buffer, 1x5 min in PBS and were rinsed in 
deionised water prior to spinning dry. Slides were scanned to 10µm resolution in a microarray 
scanner (G2565BA; Agilent Technologies, Santa Clara, CA, USA) and analysed using 
64 
 
GenePix Pro v.5.1 (Molecular Devices, Sunnyvale, CA, USA). The top reactive antigens from 
the planar arrays, along with several potential autoantigens from the literature, were 
investigated further using suspension bead arrays (see Appendix IV for a list of antigens 
selected for further investigation using suspension bead arrays, and Appendix V for a list of 
established candidate autoantigens selected from the literature).  
2.12.3 Sample preparation for the suspension bead arrays  
A total of 235 banked CSF samples, diluted 1/50 in assay buffer (PBS + 0.1% tween + 3% 
BSA + 160µg/ml His6-ABP), were aliquoted into randomised destination wells using a liquid 
handling system (Freedom EVO150, Tecan, Männedorf, Switzerland). Three blank wells and 
three pooled wells (containing pooled CSF from every sample) were included on each plate. 
Plates were stored at -20ºC until required. 
 2.12.4 Generation of suspension bead arrays 
Antigens of interest, determined by both previous assays on planar arrays and potential 
disease relevance based on previously published literature, were covalently conjµgated to the 
free carboxyl groups on carboxylated microspheres as per manufacturer’s instructions 
(MagPlex-C, Luminex Corporation, Austin, TX). For each of the 301 unique bead IDs, 
750,000 beads per bead ID were brought to room temperature and distributed across 96 well 
plates (Greiner BioOne, Longwood, FL). Beads were washed and resuspended in phosphate 
buffer (0.1M NaH2PO4, pH 6.2) using a magnetic plate (Dexter) and a plate washer (EL406, 
Biotek, Winooski, VT). To activate the carboxyl sites on the beads, 50µl of activation 
solution, containing a 10mg/ml solution (0.5mg/well) of N-hydroxysµlfosuccinimide (NHS; 
Pierce, Rockford, IL) and 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride 
(EDC; Pierce), was added to the microspheres. Following 20 min incubation on a plate shaker 
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(Grant Bio), beads were washed twice in MES buffer (0.05M, pH 5.0). For the coupling 
reaction, 100µl of each antigen, diluted to 60µg/ml in MES buffer, were added to the 
microspheres and incubated for 2h on a plate shaker. The following control proteins were also 
coupled to beads: 4µg rabbit anti-human IgG, 4µg recombinant EBNA-1 protein (Tebu-Bio, 
Roskilde, Denmark) and 4µg His6-ABP. 
 2.12.5 Sample and coupling test  
A sample pool, generated by combining 1µl of each CSF sample, was used to test the 
conditions of the suspension bead array. Goat F(ab’)2 fragment anti-human IgG R-PE 
(5µg/ml; Invitrogen) was used at 1/750, but because the goat anti-human kappa (cat. no: 
2060-09) and lambda light chain R-PE antibodies (cat. no: 2070-09; Southern Biotech, 










Figure 2.2 Overview of assay workflow on planar and bead-based 
arrays. An initial unbiased discovery approach targeting 21,120 
antigens, followed by a screen of 384 potential target antigens, allowed a 
selection of potential autoantigens to be generated. These were further 
investigated using bead-based arrays in a verification phase using a 
larger sample size. 
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For the sample test, pooled CSF was diluted in assay buffer containing 160µg/ml His6-ABP 
with or without 5% milk and incubated for 1h on a shaker. Pooled CSF was incubated with 
5µl bead stock and primary antibodies (with a total volume of 50µl per well) for 1h on a 
shaker, and were washed 3x in 100µl wash buffer (PBS + 0.05% tween) using a magnetic 
plate and plate washer. The pooled CSF was then incubated with secondary antibodies for 30 
min on shaker and washed 3 times as previously described. Samples were resuspended in 
50µl and ran on a Luminex FlexMap 3D (Luminex Corporation, Austin, Texas, USA).  
For the coupling test, conjugation of the antigens to the beads was confirmed by detecting the 
His6-ABP tag on the antigens using chicken anti-His6-ABP (1/20,000 dilution; Agrisera) 
followed by R-PE-conjugated F(ab)2 fragment donkey anti-chicken IgY (1/1000; Jackson 
Immunoresearch Laboratories, West Grove, PA, USA). This allowed bead IDs with a median 
fluorescence intensity (MFI) below 30 to be excluded from further analysis, on the 
assumption that the conjugation step was unsuccessful. Some antigens such as EBNA-1 were 
purchased commercially rather than generated within the HPA; as such these proteins did not 
have a His6-ABP tag so no signal was expected. To ensure that the antigens were coupled to 
the correct bead IDs in the correct order, anti-human HPA antibodies against two antigens 
(MBP and anoctamin 2; ANO2) were used (1/1000) with a secondary R-PE anti-rabbit IgG 
antibody (1/2000; Jackson Immunoresearch Laboratories). 
2.12.6 Assays on suspension bead arrays 
Plates containing randomised CSF samples, pre-diluted in assay buffer, were thawed and 
incubated for 1h on a shaker. Following thorough sonication, 5µl of bead solution was added 
to each CSF sample and incubated on a shaker overnight. Beads were washed 3 times in wash 
buffer using a magnetic plate and plate washer, and were incubated in 0.2% paraformaldehyde 
(PFA; Sigma Aldrich) for 10 min to allow antibody cross-linking. Beads were washed and 
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incubated in anti-human IgG (1/750), anti-human kappa light chain (1/100) or anti-human 
lambda light chain (1/100) antibodies diluted in assay buffer (no milk) for 1h on shaker. 
Plates were washed 3 times in wash buffer with a final volume of 50µl per well and were ran 
on a Luminex FlexMap 3D.  
 2.12.7 Analysis of antigen array data 
Data were analysed in Microsoft Excel and GraphPad prism v7.0. Following quality control 
checks, involving evaluation of positive and negative controls and exclusion of beads and 
their corresponding protein conjugates with bead counts of less than 30 per well, an arbitrary 
cut-off threshold was applied to each sample, which was calculated as the MFI across the 
sample plus 0.5x, 4x or 10x median absolute deviation (MAD), depending on the assay. This 
accounted for variable background levels across samples.  
 
2.13 Statistics 
Statistical analyses were performed using GraphPad Prism v7.0 (GraphPad Software Inc., 
CA, USA). For analysis of ex vivo human data sets, median values were determined, and non-
parametric testing was used as these data were not normally distributed, although normal 
distribution was not tested for. Parametric testing was used for the analysis of in vitro cell 
culture data. Statistical comparisons with a P-value of P<0.05 or below were considered 
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Chapter 3: Characterising the B cell response in multiple sclerosis 
3.1 Introduction 
The evidence for a B cell-mediated component in MS pathogenesis is strong. B cells, 
plasmablasts and their antibody products are present in CNS compartments throughout the 
disease course where they correlate with pathogenesis and disease progression (Cepok et al., 
2005a; Winges et al., 2007). Despite this knowledge, the finer features of B cell biology in 
MS warrants further exploration. ASC have been identified within MS brain tissue, including 
in ectopic meningeal follicles; in an EAE model, long-lived EdU-labelled ASC were shown to 
persist in the inflamed CNS for up to five weeks, indicating that the CNS can provide ASC 
survival niches for extended periods of time (Serafini et al., 2007; Pollok et al., 2017). The 
clinical benefits of anti-CD20 therapies, mediated by depletion of mature B cells, suggest an 
active peripheral component, and it is known that B cells can exchange across the blood-brain 
barrier in either direction, potentially receiving stimulation in the periphery and in the CNS 
(von Budingen et al., 2012; Palanichamy et al., 2014a; Hauser et al., 2008; Kappos et al., 
2011). As such, the relative contributions of recently recruited peripheral B cells versus 
locally expanded B cells remains unclear. 
CSF analysis has identified an accumulation of IgM-IgD- class-switched B cells in MS, 
implicating selective memory B cell recruitment to the CNS, however, specific 
immunoglobulin isotypes of CSF B cell subsets have not been investigated (Cepok et al., 
2006). This may help to shed light on the origins of CSF B cells. ASC have also been 
identified in the CSF, and it has been reported that short-lived CD19+CD138+ASC are the 
major B cell effector subset during the course of MS (Cepok et al., 2005a). In contrast, 
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another study identified mature ASC as the major ASC population in MS CSF (Corcione et 
al., 2004). In addition to these inconsistencies, Cepok et al found that the frequency of CD19+ 
ASC, but not CD19- ASC, correlates with intrathecal IgG synthesis; however, several studies 
have identified clonal relationships between CSF ASC populations, implicating a continuum 
of B cell differentiation rather than the presence of distinct B cell pools (Ritchie et al., 2004; 
Winges et al., 2007). So, although the CSF B cell compartment in MS has been widely 
studied, further investigation may help to clarify the involvement of these populations with 
disease.  
In contrast to the widely reported peripheral blood Ig:Igratio of approximately 1. 6:1, Ig 
light chains are elevated in MS CSF (Zeman et al., 2012; Perez-Andres et al., 2010). This bias 
may have prognostic significance, as a lower ratio has recently been linked to increased 
conversion from CIS to CDMS (Voortman et al., 2017). Though a handful of studies have 
identified a biased Ig:Ig ratio on MS CSF B cells, the prevalence of this bias within and 
between MS groups is unclear, and its expression by CSF ASC, which are presumably 
responsible for their secretion, has not been investigated (Nowakowski et al., 2005; Vafaii and 
DiGiuseppe, 2014). 
The hypothesis of this chapter was that clonally expanded B lineage cells can be detected in 
MS CSF, and that the humoral response in MS begins with a restricted Ig response, which 




3.1.1 Chapter Objectives  
1. Characterise B cells and ASC from the peripheral blood of MS and healthy control 
groups  
2. Identify ASC in the CSF of individuals with different subtypes of MS (CIS, clinically 
definitive MS, MS on natalizumab treatment) in comparison to OND and ONID 
groups 
3. Determine immunoglobulin heavy and light chain expression in B cells and ASC in 
matched CSF and peripheral blood 
4. Determine the extent of IgIg bias on B cells and ASC, and compare this ratio 
between disease groups  
 
3.2 Results 
3.2.1 Characterisation of B cells and ASC in the blood and CSF 
Matched peripheral blood and CSF were received from individuals undergoing diagnostic or 
therapeutic lumbar puncture (LP), except for those coming off natalizumab, who were 
undergoing LP for JCV testing. The other individuals were stratified into disease groups 
following a formal diagnosis (Appendix I) with the following classifications: OND (n=17), 
ONID (n=7), CIS (n=10), MS (n=14) and NAT (n=14).  
PBMC from peripheral blood and cell pellets from the CSF were stained ex vivo for a series of 
characterisation markers and activation markers, to identify B cells and ASC, which were 
analysed by flow cytometry. For this, an appropriate gating strategy was determined. In the 
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peripheral blood, B cells were identified as CD19+CD20+ and ASC identified as 
CD27highCD38high within the CD19+ gate (Fig. 3.1A, blue arrows). The absence of circulating 
CD19- ASC was confirmed by gating on CD27highCD38high within the CD19- gate (Fig. 3.1A, 
red arrows), allowing CD19 to be used as a marker of peripheral blood ASC, in accordance 
with the literature, and for cleaner gating to be achieved (Mei et al., 2009; Yoshida et al., 
2010). Though CD138 is sometimes regarded as a plasma cell-specific marker, its expression 
is heterogeneous in peripheral blood plasmablasts and therefore cannot be used for their 
identification. This set of markers allowed subsequent gating for immunoglobulin light and 
heavy chain expression within these subsets.  
In the CSF, B cells were again identified as CD19+CD20+ (Fig. 3.1B). Based on previous 
studies that have identified heterogeneous CD19 expression on CSF ASC, CD19 was not used 
to identify these cells in the CSF; ASC were defined as CD27highCD38highCD138+, Despite 
the heterogeneous CD138 expression by peripheral blood ASC, previous reports have 
identified CSF ASC as CD138+, therefore this marker was included in the CSF ASC 





Figure 3.1 Gating strategy to identify B cells and ASC in the peripheral blood and
CSF. In the peripheral blood, B cells were identified as CD19+CD20+ (upper panel)
and ASC identified as CD27highCD38high within the CD19+ gate (middle panel) due to
the absence of CD19- antibody-secreting cells (lower panel) (A). In the CSF, B cells
were identified as CD19+CD20+ (upper panel) whereas ASC were defined as
CD27highCD38highCD138high (lower panel) (B). Gated on viable cells with doublets
excluded. Blue arrows represent gating used throughout, red arrows represent example





















































































































































Figure 3.1. Gating strategy to identify B cells and antibody-secreting cells in the
peripheral blood and CSF. In the peripheral blood, B cells were identified as
CD19+CD20+ (upper panel) and antibody-secreting cells identified as CD27highCD38high
within the CD19+ gate (middle panel) due to the absence of CD19- antibody-secreting cells
(lower panel) (A). In the CSF, B cells were identified as CD19+CD20+ (upper panel)
whereas antibody-secreting cells were defined as CD27highCD38highCD138high (lower panel)
(B). Gated on viable cells with doublets excluded. Blue arrows represent gating used
throughout, red arrows r t ex mple gating. FS; forward scatter.
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The gating strategy was validated by comparing marker expression between B cells and ASC 
(Fig. 3.2). Comparisons were made between those cells in the peripheral blood, rather than 
the CSF, since they were present at higher frequencies. This was achieved by gating on B 
cells and ASC respectively, and then creating a histogram for each marker to derive the MFI 
values. Although these MFI values were obtained from established gates, since these was 
required to first distinguish B cells and ASC prior to MFI analysis, comparison of MFI values 
for both cell populations allowed the relative expression levels of each marker to be 
determined and compared between populations. ASC expressed significantly lower levels of 
CD19 and CD20, and significantly higher levels of CD27, CD38 and CD138 compared to B 
cells (Fig. 3.2A, B). A strong distinguishing feature of ASC is their low surface and high 
intracellular Ig levels, with correspondingly high surface and low intracellular Ig in B cells; 
this phenomenon was observed using this gating strategy, thus confirming the ability to 











Figure 3.2 Features distinguishing ASC from CD19+CD20+ B cells in the
peripheral blood (i). Representative histograms (A) and analysis (B) of marker
expression intensity by peripheral blood B cells and ASC. Data are significant to ***
(P<0.001) or ** (P<0.01) using Mann-Whitney test (n=62). Values from all disease
















































































Figure 3.2 Features distinguishing ASC from CD19+CD20+ B cells in the peripheral
blood (i). Representative histograms (A) and analysis (B) of marker expression intensity by
peripheral blood B cells and ASC. Data are significant to *** (P<0.001) or ** (P<0.01) using
Mann-Whitney test (n=62). Values from all disease groups. Tukey box and whisker plot











































































Figure 3.3 Features distinguishing ASC from CD19+CD20+ B cells in the
peripheral blood (ii). Flow plots (A) and quantification (B) of surface (n=5) and
intracellular (n=9) Igκ and Igλ expression in CD19+CD20+ B cells and ASC. Data
are significant to ** (P<0.01) and *** (P<0.001) using Mann-Whitney test. Values
from all disease groups. Tukey box and whisker plot showing median values.
Figure 3.3 Features distinguishing ASC from CD19+CD20+ B cells in the peripheral
blood (ii). Flow plots (A) and quantification (B) of surface (n=5) and intracellular (n=9) Igκ
and Igλ expression in CD19+CD20+ B cells and AS . Data are significant to ** (P<0.01)
and *** (P<0.001) using Mann-Whitney test. Values from all disease groups. Tukey box
and whisker plot showing median values.
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3.2.2 B cells and ASC were elevated in MS CSF 
No significant differences were observed in the frequency of CD19+CD20+ B cells between 
OND (9.5%), ONID (13.4%), CIS (8.7%) and MS (9.9%) groups (Fig. 3.4A). However, the 
natalizumab (anti-4 integrin) group had significantly elevated frequencies (16.4%) compared 
to OND, CIS and MS groups. In the CSF, CIS (0.99%) and MS (1.07%) groups displayed 
elevated B cells compared to OND (0.33%) but not ONID (1.06%). In contrast, CSF B cells 
in the natalizumab group (0.16%) were significantly reduced compared to other MS groups. 
Frequencies of peripheral blood ASC were no different between groups, but in the CSF were 
significantly elevated in CIS (0.065%) compared to OND (0%), and MS (0.25%) compared to 
OND and natalizumab-treated individuals (0%) (Fig. 3.4B). CSF ASC appeared more 
elevated in MS than CIS, though this comparison was not statistically significant.   
In an effort to identify whether B cells and/or ASC in MS can be distinguished from 
OND/ONID control groups on the basis of marker expression, the expression of CD38 and 
CD27, both considered markers of activation, was compared between these groups. In the 
blood, there was no significant difference in CD38 or CD27 expression in B cells or ASC 
between groups (Fig. 3.5A). Similarly, analysis of these markers on CSF cells revealed little 
difference between groups, except in the post-natalizumab group, who demonstrated 
significantly elevated CD38 expression on B cells (Fig. 3.5B). Comparison of marker 
expression in CSF ASC between groups was difficult due to limited cell numbers (an arbitrary 





Figure 3.4 CD19+CD20+B cell and ASC frequencies in the blood and CSF of
individuals with neurological diseases. Investigation of the frequency of
CD19+CD20+ B cells (A) and ASC (B) as a percentage of total lymphocytes in the
blood and CSF of MS and control groups. Data are significant to * (P<0.05), **
(P<0.01) or *** (P<0.001) using Dunn’s multiple comparisons test. Tukey box and
whisker plot showing median values. OND; other neurological disease (n=17); ONID;
other neurological inflammatory disease (n=5), CIS; clinically isolated syndrome
(n=10), MS; multiple sclerosis (including relapsing-remitting and primary-







































































































































Figure 3.4 CD19+CD20+B cel and ASC fr qu ncies in the blood and CSF of individuals
with neurological diseases. Investigation of the frequen y of CD19+CD20+ B cells (A) and
ASC (B) as a percentage of total lymphocytes in the blood and CSF of MS and control groups.
Data are significant to * (P<0.05), ** (P<0.01) or *** (P<0.001) using Dunn’s multiple
comparisons test. Tukey box and whisker plot showing median values. OND; other
neurological disease (n=17); ONID; other neurological inflammatory disease (n=7), CIS;
clinically isolated syndrome (n=10), MS; multiple sclerosis (including relapsing-remitting and






















































































































































































Figure 3.5 Marker expression in MS B cells and ASC. MFI of CD38 and CD27
expressed by CD19+CD20+ B cells and ASC in the blood (A) and CSF (B) of MS
and control groups. Data are significant to * (P<0.05) and ** (P<0.01) using
Dunn’s multiple comparisons test. Tukey box and whisker plot showing median
values. OND (n=17), ONID (n=5), CIS (n=10), MS n=14), NAT (n=14).
Figure 3.5 Marker expression in MS B cells and ASC. MFI of CD38 and CD27
expressed by CD19+CD20+ B cells and ASC in the blood (A) and CSF (B) of MS and
control groups. Data are ignific nt to * (P<0.05) and ** 0.01) usi g Dunn’s multiple
comparison test. Tukey box and whisker plot showing median values. OND (n=17),
ONID (n=7), CIS (n=10), MS (n=14), NAT (n=14).
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3.2.3 CSF B cells and ASC show features of recent activation    
Since there was little difference in CD27 and CD38 expression between groups, I investigated 
whether the expression of these markers, in addition to the expression of IgG, may differ on B 
cells and/or ASC in the CSF compared to the peripheral blood (Fig. 3.6A). The results 
showed that both populations expressed significantly higher levels of CD27 (1.18 vs 3.39 for 
B cells, 17.6 vs 47.7 for ASC), and IgG (35.9 vs 78.9 for B cells, 145.5 vs 416.7 for ASC) in 
the CSF compared to those in the periphery (Fig. 3.6B). Interestingly however, levels of 
CD38 were decreased in CSF (1.28) vs peripheral (3.18) B cells but increased in CSF (161.6) 
vs peripheral (87.4) ASC. Finally, both B cells and ASC were significantly larger in size, 
measured by forward scatter, in the CSF compared to those in the periphery (Fig. 3.6C, D). 
 
3.2.4 Characterisation of CSF ASC populations 
Within the CSF, distinct ASC populations were identified based on differential expression of 
CD19 (Fig. 3.7A). This was performed by gating on total CSF ASC, as in Fig. 3.1B, and then 
gating on CD19. As a proportion of total ASC, CD19+ ASC were more common than CD19- 
ASC (64% vs 31%), though these proportions varied widely (Fig. 3.7B). This analysis was 
performed on CSF samples containing 10 or more ASC, as too few cells could easily bias the 
analysis (e.g. the presence of one CD19+ ASC would give an CD19+ ASC frequency is 
100%, whereas analysing samples containing a larger cell population would provide more 
reliable data). Though no difference was identified between the two ASC subsets in terms of 
frequencies, CD19- ASC expressed higher levels of CD138 compared to CD19+ ASC (Fig. 
3.7C). CD19- ASC also showed a trend for increased levels of CD27, CD38 and IgG 




Figure 3.6 CSF B cells and ASC show features of recent activation.
Representative histograms showing CD27, CD38 and IgG MFI values in
CD19+CD20+ B cells and antibody-secreting cells in the blood (grey) and CSF
(black) (A) and quantification of CD27, CD38 and IgG MFI values (B). Data are
significant to *** (P<0.001) using Mann-Whitney test (n= 12 to 62).
Representative flow plots (C) and comparison (D) of forward scatter in the blood
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Figure 3.6 CSF B cells and ASC show features of recent activation. Representative
histograms showing CD27, CD38 and IgG MFI values in CD19+CD20+ B cells and
antibody-secreting cells in the blood (grey) and CSF (black) (A) and quantification of
CD27, CD38 and IgG MFI values (B). Data are significant to *** (P<0.001) using Mann-
Whitney test (n= 12 to 62). Representative flow plots (C) and comparison (D) of forw rd






Figure 3.7 Identification of CD19+ and CD19- ASC subsets in MS CSF.
Representative plot of a CSF sample from an individual with MS, gated on viable
lymphocytes (A). Blue arrow represents gating. The proportion of CD19+ and
CD19- antibody-secreting cells in MS CSF (B). Data are significant to ***
(P<0.001) using Mann-Whitney test (n=15). Tukey box and whisker plot showing
median values. Differential expression of CD19 and CD138 (C) and CD27, CD38
and IgG (D) by CD19+ and CD19- ASC compared to CD19+CD20+ B cells in MS
CSF. Data are significant to ** (P<0.01) and *** (P<0.001) using Kruskal-Wallis






















































































































































































Figure 3.7 Identification of CD19+ and CD19- ASC subsets in MS CSF. Representative
plot of a CSF sample from an individual with MS, ted on viable lymph cytes (A). Blue
arrow represe s gating. The proportion of CD19+ and CD19- antibody- ecret ng cells in
MS CSF (B). Data are sig ificant to *** (P<0.001) using Mann-Whitney te t (n=15). Tukey
box and whisker plot showing median values. Differential expression of CD19 and CD138
(C) and CD27, CD38 and IgG (D) by CD19+ and CD19- ASC compared to CD19+CD20+
B cells in MS CSF. Data are significant to ** (P<0.01) and *** (P<0.001) using Kruskal-
Wallis test. Tukey box and whisker plots showing median values.
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3.2.5 B cell and ASC numbers correlate with CSF inflammation in MS  
lymphocyte counts, total FLC (kappa and lambda) and CXCL13 levels (Fig. 3.8). CSF 
lymphocyte counts (Fig. 3.8A) significantly correlated with the number of B cells (r = 0.88, p 
= <0.0001), CD19+ ASC (r = 0.75, p = <0.0001) and CD19- ASC (r = 0.70, p = <0.0001). 
Although the CSF FLC concentration (Fig. 3.8B) did not correlate with the CSF B cell 
frequency (r = 0.15, p = 0.36), it did correlate with CD19+ ASC (r = 0.36, p = 0.027) and 
CD19- ASC (r = 0.37, p = 0.022) frequencies. Finally, CSF CXCL13 levels (Fig. 3.8C) 
significantly correlated with the frequency of B cells (r = 0.5, p = 0.027), CD19+ ASC (r = 
0.58, p = 0.01) and CD19- ASC (r = 0.65, p = 0.0034).  
 
3.2.6 CSF ASC, but not B cells, are predominantly IgG+ in MS 
The correlation of ASC numbers with the CSF CXCL13 concentration could suggest 
increased ASC migration to the CSF, increased intrathecal generation due to higher B cell 
numbers, or both. To investigate the possible origins of B cells and ASC in the CSF, 
immunoglobulin isotype expression was determined. The results showed that in MS, CSF B 
cells are significantly biased towards IgG compared to those in the blood (blood: 13.27%, 
CSF: 31.82%) (Fig. 3.9A). This trend was also observed in OND and ONID controls (blood: 
11.28%, CSF: 29.57%). Though IgM-expressing B cells were decreased compared to the 
blood, IgM remained the dominant immunoglobulin isotype expressed by CSF B cells in both 
MS and control groups. In contrast to B cells, ASC in MS CSF were almost exclusively IgG+ 
(blood: 17.88%, CSF: 96.77%) with very little IgA, which is the dominant peripheral blood 




Figure 3.8. B cells and ASC correlate with inflammatory parameters in MS CSF. The
number of CD19+CD20+B cells , CD19+CD138+ASC and CD19-CD138+ ASC per ml CSF
was correlated with lymphocyte count per ml (A), FLC concentration (B) and CXCL13
concentration (C). Spearman correlation from all MS groups (lymphocyte count and FLC
concentration, n=38; CXCL13 concentration, n=19). Non-significant associations are shown in
grey font. Only matches with two positive values are displayed on the correlation plots, i.e.
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Figure 3.9 IgG is the dominant immunoglobulin isotype expressed by ASC, but not
CD19+CD20+B cells, in MS CSF. Representative flow plots from an individual with
MS, and corresponding quantification of immunoglobulin isotype expression in
CD19+CD20+ B cells (A) and ASC (B) in the blood and CSF of MS and control
(OND/ONID) groups. Data are significant to * (P<0.05), ** (P<0.01) and *** (P<0.001)








































































































































Figure 3.9 IgG is the dominant immunoglobulin isotype expressed by ASC, but not
CD19+CD20+B cells, in MS CSF. Representative flow plots from an individual with MS, and
corresponding quantification of immunoglobulin isotype expression in CD19+CD20+ B cells (A)
and ASC (B) in the blood and CSF of MS and control (OND/ONID) groups. Data are significant
to * (P<0.05), ** (P<0.01) and *** (P<0.001) using Mann-Whitney test (n=13-30 for peripheral
blood analysis, n= 2-11 for CSF analysis).
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3.2.7 CSF ASC, but not B cells, are Ig-biased in MS 
The predominance of IgG+ ASC in MS CSF could suggest these cells may have arisen 
following an antigen-specific response, however, it is known that IgG+ ASC express specific 
chemokines that may direct their homing to sites of inflammation (Kunkel and Butcher, 
2003). To provide more clues as to the origins of CSF ASC, and also B cells, Ig and Ig 
expression was analysed and compared to those in the periphery (Fig. 3.10B). Amongst MS 
groups, CSF B cells were no different in their IgIg ratio compared to peripheral blood B 
cells, except in the CIS group which displayed a slightly elevated Ig-bias (blood 1.44:1, CSF 
2.21:1) (Fig. 3.10B). MS CSF displayed a significantly biased IgIg ratio in ASC (blood 
1.12:1, CSF 9.33:1), with a trend towards this bias in CIS and following natalizumab 
treatment, which unfortunately was hampered by low sample numbers (Fig. 3.10C). In ONID 
but not MS CSF, the ASC IgIg ratio was biased in either direction (range 0.13:1 – 3.73:1). 
Analysis of the IgIg ratio within CD19+ and CD19- CSF ASC populations demonstrated 
that CD19- ASC are preferentially associated with a stronger Ig bias than CD19+ ASC 
(15.5:1 vs 4.6:1, respectively), although both ASC populations are clearly biased towards Ig 









Figure 3.10 Elevated kappa light chain expression by ASC, but not CD19+CD20+
B cells, in MS CSF. Representative flow plots show the Ig:Ig ratio of
CD19+CD20+ B cells and ASC in the blood (upper plots), compared to the CSF
(lower plots), in an individual with MS (A). Quantification of kappa and lambda light
chain ratios of CD19+CD20+B cells and ASC in the blood (B) and CSF (C). Data are
significant to * (P<0.05) and *** (P<0.001) using Mann-Whitney test (n=5-17 for
peripheral blood analysis, n= 1-9 for CSF analysis). The median Ig:Ig ratio in













































































































































































Figure 3.10 Elevated kappa light chain expression by ASC, but not CD19+CD20+ B
cells, in MS CSF. Representative flow plots show the Ig:Ig ratio of CD19+CD20+ B cells
and ASC in the blood (upper plots), compared to the CSF (lower plots), in an individual with
MS (A). Quantification of kappa and lambda light chain ratios of CD19+CD20+B cells and
ASC in the blood (B) and SF (C). Data are significant to * (P<0.05) and *** (P<0.001)
using Mann-Whitney test (n= -17 for peripheral blood analysis, n= 1-9 for CSF analysis). The
median Ig:Ig ratio in CD19+ and CD19- CSF ASC in MS (D). Comparisons were not
significant using Mann-Whitney test (n=7).
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The IgIg ratios on CSF B cells or ASC were compared to the CSF FLC IgIg ratio 
within each MS CSF sample, cell numbers permitting. An arbitrary minimum of 10 cells were 
chosen to be required for analysis, as unlike with MFI analysis where the entire population 
was analysed, this analysis required the cells to be further subdivided into Ig and Ig 
populations before the ratio was obtai ned. FLC testing was blindly performed by an external 
company (The Binding Site, Birmingham) on CSF which was banked and stored at -80℃ 
following removal of CSF cells. Results showed that the FLC IgIg ratio did not correlate 
with the frequency of CD19+CD20+ B cells in the CSF (r = 0.12, p = 0.55) (Fig. 3.11A). 
However, within the IgG+ B cell population there appeared to be an association with the FLC 
IgIg ratio in some of the samples (r = 0.19, p = 0.51) (Fig. 3.11B). The Ig bias observed 
in some IgG+ B cells did not appear to be specific to any particular MS subtype, and was seen 
in samples from CIS (15.5:1, 7:1), established MS (5.6:1) and natalizumab-treated individuals 
(5.75:1). Finally, it was shown that the FLC ratio correlated significantly with the CSF ASC 
IgIg ratio (r = 0.65, p = 0.03) (Fig. 3.11C). Comparison of the CSF FLC IgIg ratio 
between disease groups demonstrated significantly elevated ratios in all MS groups compared 
to OND (1:1), with CIS (12.5:1), MS (6.3:1) and natalizumab (4:1), thus indicating the 








Figure 3.11 The ASC Ig:Ig ratio correlates with the FLC ratio in MS CSF.
Relationship between the Ig:Ig ratio on CD19+CD20+ B cells (A), CD19+CD20+IgG+ B























































































































































Figure 3.12 Comparison of the CSF FLC Ig:Ig ratio between disease groups. The CSF
FLC Ig:Ig ratio in control groups (OND, ONID) and MS groups (CIS, MS, NAT). Data are
significant to * (P<0.05), or ** (P<0.01) using Dunn’s multiple comparisons test. Tukey box



































3.2.8 Serial CSF analysis of B cell and ASC populations 
An informative approach into the B cell response in MS is to analyse repeat CSF samples 
from the same individual; this could provide some information on the dynamics of the B cell 
response rather than a momentary snapshot offered by single sample analysis. Since LPs are 
performed as part of the diagnostic pathway for people with suspected neurological diseases, 
obtaining repeat samples is difficult in this context. However, in one individual who had 
recently ceased natalizumab therapy, a repeat LP was obtained, allowing comparison between 
the initial CSF sample (referred to as ‘day 0’) with a follow up sample obtained 62 days later.  
(Fig. 3.13). The CSF samples were analysed for B cell and ASC frequency, IgIg ratio and 
FLC concentration. Compared to the day 0 sample, the day 62 sample displayed a more than 
four-fold increase in the proportion of ASC (0.7% to 2.9%); in contrast, a similar proportion 
of B cells was observed between samples (0.8% vs 1.0%), despite the hugely increased CSF 
cellularity (Fig. 3.13A). The IgIg ratio in CSF B cells was 5.8:1 on first LP, compared to 
2.2:1 on the second LP (Fig. 3.13B). In CSF ASC, the IgIg ratio was more than 28:1 (i.e. 
28 Ig-expressing cells but no Ig-expressing cells were identified) on first LP, which was 










Figure 3.13 Increased frequency and kappa light chain bias of ASC, but not
CD19+CD20+ B cells, in the CSF of an individual with MS following cessation of
natalizumab therapy. Frequency of CD19+CD20+ B cells and ASC as a percentage
of total CSF lymphocytes in an individual with MS on first (day 0; left plots) and
second (day 62; right plots) lumbar puncture following cessation of natalizumab
therapy (A). The Igκ:Igλ ratio of CD19+CD20+ B cells and ASC was compared on
first and second lumbar puncture (B). Natalizumab treatment was stopped prior to the































































































































































































Figure 3.13 Increased frequency and kappa light cha n bias of ASC, but not
CD19+CD20+ B c lls, in th CSF of an individual with MS following cessation of
natalizumab therapy. Frequency of CD19+CD20+ B cells and ASC as a percentage of total
CSF lymphocytes in an individual with MS on first (day 0; left plots) and second (day 62; right
plots) lumbar puncture following cessation of natalizumab therapy (A). The Igκ:Igλ ratio of
CD19+CD20+ B cells and ASC was compared on first and second lumbar puncture (B).




Despite decades of research, the CS F B cell compartment in MS remains largely elusive. In 
this chapter, the frequency and phenotype of CSF B cells and ASC, and their possible 
association with MS pathogenesis, was investigated. 
 
3.3.1 Features and frequencies of CSF B lineage cells 
Based on previous studies, peripheral ASC can be distinguished from B cells through their 
increased CD27, CD38 and CD138, and decreased CD19 and CD20 expression (Fig. 3.1A, B) 
(Ellebedy et al., 2016; Fink, 2012). This was supported by observations in this chapter by 
comparing MFI values to differentiate these populations (Fig. 3.2).  
Peripheral ASC express low levels of CD19, and since the absence of peripheral CD19- ASC 
was confirmed in this chapter, it can be assumed that these circulating CD19+ ASC are 
plasmablasts (Fig. 3.1A, Fig. 3.2). Plasmablasts are recently generated cells that survive for 
up to a week in the periphery before apoptosis or migration to stromal niches, where they 
undergo terminal differentiation into long-lived plasma cells; therefore, it is not surprising 
that these cells demonstrate low, but not negative, CD19 expression (Radbruch et al., 2006; 
Nutt et al., 2015; Ellebedy et al., 2016). As pointed out by others, circulating ASC are 
heterogeneous for CD138, therefore this marker cannot be relied upon to identify these cells 
in the periphery (Costes et al., 1999; Medina et al., 2002; Fink, 2012). This could reflect 
differences in the potential of plasmablasts to adhere to a niche and differentiate into plasma 
cells (McCarron et al., 2017). Despite this heterogeneity in peripheral ASC, those in the CSF 
were highly positive for CD138 (Fig. 3.1B); this was in accordance with other studies, which 
use CD138 to identify ASC in the CSF (Cepok et al., 2005a; Winges et al., 2007). This 
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phenomenon could reflect the strong survival potential of CSF ASC, possibly driven by CNS-
derived survival factors, which could in turn suggest that CSF ASC are derived from the CNS 
and not the periphery.  
Several key phenotypic features were confirmed between B cells and ASC (Fig. 3.2, Fig. 3.3), 
most notably the location of immunoglobulin, definitively distinguishing the differential 
phenotype of these cells and confirming the gating strategy.  
A significant increase in peripheral B cells was observed in the natalizumab group (Fig. 
3.4A). This mirrors previous observations of altered peripheral immune cell composition 
following natalizumab, which is particularly pronounced in B cells compared to other immune 
subsets (Planas et al., 2012; Warnke et al., 2015). This could be a due to a greater dependency 
of B cells on4 integrin, which when blocked leads to disrupted B cell homing and adhesion 
to niches (Warnke et al., 2015). In accordance with other studies, no differences were seen in 
peripheral blood B cells or ASC in MS or control groups (Cepok et al., 2005a; Harp et al., 
2007).  
Several studies have investigated the frequency of CSF B cells in MS. Although highly 
variable between individuals, this frequency generally constitutes around 4-5% of CSF 
lymphocytes (Cepok et al., 2001; Cepok et al., 2005a; Winges et al., 2007; Kuenz et al., 2008; 
Kowarik et al., 2012). In this chapter, CSF B cells were found to represent around 1% of CSF 
lymphocytes. Even using the mean (MS = 1.4%, CIS = 1.7%), as in previous studies, rather 
than the median (MS = 1.07%, CIS = 0.99%), my findings were still lower than previously 
described (Fig. 3.4A). Similarly, ASC have been reported to constitute 1.59-2% of total 
lymphocytes but in this chapter represented less than 1% of CSF lymphocytes (Fig. 3.4B) 
(Winges et al., 2007; Cepok et al., 2005a; Kowarik et al., 2012). These discrepancies may be 
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due to sample timing (e.g. the time from onset of symptoms to LP may differ between studies) 
or in sample processing. Rapid sample processing is critical as the number of viable CSF 
lymphocytes decreases significantly just 30 minutes following LP, but due to the clinical 
nature of these studies this is not always possible (de Graaf et al., 2011). CSF does not contain 
the appropriate factors to support long-term cell survival; this is particularly crucial for ASC, 
which are highly susceptible to apoptosis (Cenci and Sitia, 2007). Additionally, the already 
low cellularity of CSF makes these studies technically challenging. Despite these challenges, 
a significant elevation in CSF B cells was observed in CIS and MS groups compared to 
controls, consistent with previous studies (Cepok et al., 2005; Kuenz et al., 2008). 
Furthermore, CSF ASC were significantly elevated in MS compared to OND and 
natalizumab-treated groups, and in CIS compared to OND. In the group recently coming off 
natalizumab, CSF B cells and ASC were dramatically reduced but not absent, which could 
suggest that these cells have recently migrated to the CNS; alternatively, these cells may be 
CNS-resident and may reflect the failure of natalizumab to fully deplete these cells. 
Natalizumab can access the CSF, but at a 100- to 400-fold lower concentration than in the 
serum, and the persistence of OCB in 18% of individuals following 2 years of treatment 
suggests that CNS-resident B lineage cells may exist in these individuals (Harrer et al., 2015; 
Sehr et al., 2016; Mancuso et al., 2014). 
Different frequencies in the B cell compartment between groups may provide clues as to the 
dynamics of the B cell response in MS. Harp et al (2007) found elevated CSF B cell 
frequencies in CIS compared to CDMS (Harp et al., 2007). A similar (but not significant) 
trend was also observed in this chapter, and although the median values between CIS and 
CDMS were essentially the same, more CIS samples contained a higher frequency of B cells 
than MS samples (Fig. 3.4A). Conversely, in the CSF, a lower frequency of ASC was 
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identified in CIS compared to MS (Fig. 3.4B). With the assumption that those who have had 
more than one clinical attack (i.e. CDMS) are further along in the disease process than those 
who have had one clinical attack (i.e. CIS), this could reflect evolution of the B cell response 
during disease, beginning with an influx of peripheral B cells, some of which may 
differentiate into ASC and set up residence within the CNS. This may explain the elevated B 
cells but lower ASC in CIS, as survival niches for ASC have not been established yet, and the 
decreased B cells but elevated ASC in MS (Fig. 3.4B). Conversely, Kuenz et al (2008) 
observed no significant difference in CSF B cell frequency between CIS or RRMS groups, 
although there was an increase in comparison to progressive MS, which was also shown by 
Wurth et al (2017) (Kuenz et al., 2008; Wurth et al., 2017). This could suggest that the B cell 
response in progressive MS is more compartmentalised within the CNS, consistent with the 
findings of ectopic follicles in progressive MS brains and the lower frequency of gadolinium-
enhancing lesions, suggestive of fewer breaches of the BBB (Serafini et al., 2004; Magliozzi 
et al., 2007; Pikor et al., 2017; Pérez-Cerdá et al., 2016). With this in mind, a limitation of this 
chapter is that the CDMS group contained individuals with both RRMS and PPMS; larger 
sample sizes would allow these groups to be separated so that a more detailed investigation 
could be conducted.   
An attractive therapeutic approach in MS is the specific targeting of pathogenic immune cell 
populations that may contribute to disease; therefore, comparing the features of B cell 
populations between disease groups may be beneficial. In this chapter, the expression of 
CD27 and CD38 in B cells and ASC were compared between disease groups (Fig. 3.5A, B). 
CD27 is a marker of memory B (and T) cells and its elevation in soluble form has been linked 
with a higher relapse rate; similarly, the ectoenzyme CD38 is associated with increased 
proliferation, and both markers have been used to define activation (Agematsu et al., 1997; 
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van der Vuurst de Vries et al., 2017; Funaro et al., 1997). No significant differences were 
observed in peripheral or CSF marker expression between disease groups, except in the 
natalizumab group, which displayed elevated CD38 expression on CSF B cells (Fig. 3.5A, B). 
To my knowledge, this phenomenon has not previously been reported. Natalizumab is known 
to perturb the peripheral B cell compartment by promoting the release of haematopoietic 
progenitor cells from the bone marrow; this may also occur in MS CNS, as ASC are highly 
dependent on 4 integrin for adherence to survival niches (Planas et al., 2012; Khan et al., 
2016). In the mature B cell compartment, CD38 is highly expressed on germinal centre and 
post-germinal centre B cells, where it protects against apoptosis by upregulating bcl-2 proto-
oncogenes (Zupo et al., 1994; Kumagai et al., 1995). Low levels of natalizumab can cross the 
BBB and may therefore disrupt CNS B cell development; however, a survival advantage by 
germinal centre B cells expressing high levels of CD38 may result in their over-representation 
in the CNS, due to the concomitant depletion of memory B cells by natalizumab, which 
express low levels of CD38 (Harrer et al., 2015; Sanz et al., 2008). This scenario is also in 
line with the detection of CD38high centroblasts in MS CSF, which are normally found within 
secondary lymphoid organs, and also supports the concept of the MS CNS as a B cell-
fostering environment (Corcione et al., 2004, Pollok et al., 2017).  
Data in this chapter demonstrated that CSF B cells and ASC display elevated CD27, IgG and 
increased size compared to their peripheral blood counterparts (Fig. 3.6A, B). Although this 
does not necessarily link these cells to disease pathogenesis, these features are suggestive of 
recent activation. In an investigation of the human B cell response following an 
immunological challenge, Ellebedy et al (2016) identified recently activated, antigen-specific 
B cells and ASC in the periphery (Ellebedy et al., 2016). In comparison to naïve B cells, 
recently activated B cells expressed elevated levels of CD27, which was even higher in 
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circulating ASC, 7 days after immunisation. Using forward scatter as a measure of cell size, 
Ellebedy et al (2016) also found that activated B cells were increased in size compared to 
naïve B cells (Ellebedy et al., 2016). This data therefore suggests that CSF B cells and ASC 
are recently activated. Increased IgG expression in CSF B cells and ASC was also observed 
compared to their peripheral blood counterparts. This compares to findings by Sandberg et al 
(1986), who showed that CSF B cells from those with MS secreted higher levels of IgG than 
peripheral blood B cells, suggesting that these cells may be highly activated in the CSF 
(Sandberg et al., 1986).   
Although CD38 expression was increased in CSF ASC compared to those in the blood, 
suggesting a higher level of activation, the converse was true for CSF B cells, which 
expressed lower CD38 than those in the blood (Fig. 3.6A, B). Although this appears to 
contradict the idea that CSF B cells are more activated than those in the periphery, B cell 
maturation into memory B cells is associated with downregulation of CD38, therefore this 
phenomenon could result from the increased proportion of memory B cells in the CSF (Perez-
Andres et al., 2010; Flores-Montero et al., 2016). Taken together, the features of CSF B cells 
and ASC in MS compared to those in the periphery suggest a highly activated phenotype.  
Previous studies have disagreed on the frequencies of CD19- ASC in the CSF. Where some 
studies describe this population as largely absent, Corcione and co-authors (2004) identified 
CD19- ASC as the dominant ASC subset in MS CSF (Corcione et al., 2004; Cepok et al., 
2005a; Kuenz et al., 2008). Additionally, Winges et al (2007) showed that CD19- ASC 
contribute a significant proportion (11±2%) of the CSF ASC population (Winges et al., 2007). 
In agreement with most previous studies, data from this chapter identified CD19+ ASC as the 
dominant ASC subset, constituting 64% of CSF ASC, although this frequency was highly 
variable (Fig. 3.7A, B). Some of the discrepancies in previous studies could have been due to 
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low cell numbers skewing the analysis, or differential survival of these populations in CSF 
following LP; for example, CD19- ASC dislodged from their survival niche will undergo 
rapid apoptosis, probably before CD19+ ASC, as they are dependent on continual pro-
survival signals from the niche (Radbruch et al., 2006). Detection of CD19- ASC supports 
evidence for a continuum of ASC development in the MS CNS, since these cells are non-
migratory and non-proliferating, indicating their in situ generation (Odendahl et al., 2005; 
Radbruch et al., 2006). 
It is considered that mature ASC display a CD19- phenotype due to their gradual 
downregulation throughout the differentiation from B cell to long-lived plasma cell. This is 
supported by evidence that long-lived bone marrow ASC with a lifespan of over 40 years do 
not express CD19 (Halliley et al., 2015). In addition, ASC were shown to persist in the 
inflamed mouse CNS over a period of 5 weeks, and non-proliferating CD19- ASC have also 
been identified in MS brain lesions (Corcione et al., 2004; Pollok et al., 2017). Not only did 
the ASC populations identified in this chapter differ in their expression of CD19, suggesting 
different stages of differentiation, but ASC of a mature phenotype appeared to express higher 
levels of CD138, CD27, CD38 and IgG than CD19+ ASC (Fig. 3.7C, D). Caraux et al (2010) 
showed that in peripheral blood ASC, elevated CD38, CD27 and cytoplasmic 
immunoglobulin was seen in CD138+ ASC compared to CD138- ASC, suggesting that these 
markers could be a feature of increasing differentiation to a terminal ASC phenotype (Caraux 
et al., 2010; Perez-Andres et al., 2010). APRIL, a ligand for CD138, is critical for the 
transition of circulating plasmablasts to plasma cells following arrival at bone marrow niches; 
indeed, circulating plasmablasts in APRIL-deficient mice fail to become established within 
survival niches (Belnoue et al., 2008). It is considered that higher CD138 expression reflects a 
greater survival advantage, and that CD138 therefore mediates selection of mature ASC; 
99 
 
therefore, the elevated CD138 expression by mature ASC may allow greater responsiveness to 
the survival factor APRIL, and extracellular matrix molecules, which are ligands for CD138 
(McCarron et al., 2017). 
 
3.3.2 CSF B lineage cells correlate with inflammatory parameters  
In agreement with previous observations, findings from this chapter demonstrated a strong 
correlation between the frequency of CSF B cells and ASC with the CSF lymphocyte count 
and CSF CXCL13 concentration (Fig. 3.8A-C) (Krumbholz et al., 2006; Kowarik et al., 2012; 
Puthenparampil et al., 2017). CXCL13 is markedly increased in the CNS during EAE, and its 
expression has been identified in ectopic follicle-like structures in EAE CNS tissue (Serafini 
et al., 2004; Magliozzi et al., 2004). Inflammatory cytokines such as lymphotoxin- and 
TNFcan induce CXCL13 expression; therefore, exacerbation of inflammation by infiltrating 
peripheral lymphocytes may lead to elevated CXCL13 expression and B cell retention within 
the CNS (Irani, 2016). However, an association between ASC and CXCL13 does not 
necessarily reflect their increased migration to the CNS; it is possible that ASC may instead 
arise from the differentiation of recruited peripheral B cells within ectopic CNS follicles.  
In this chapter, both CD19+ and CD19- ASC frequencies significantly correlated with CSF 
FLC (Fig. 3.8B). This is hardly surprising, since FLC are a by-product of rapid antibody 
production (Solling et al., 1981). The lack of correlation with CSF B cells potentially suggests 
that only a small proportion of these cells are disease-specific and as a whole are not 




3.3.3 CSF B cells, but not ASC, are largely peripherally derived 
Lymphocyte recruitment is not necessarily driven by antigen, as both antigen-specific and 
non-antigen specific lymphocytes are often observed at sites of inflammation (Ely et al., 2003; 
Chen et al., 2005). As inflammation subsides, non-antigen specific bystander lymphocytes are 
removed whereas the antigen-specific lymphocytes are retained (Zhang and Lakkis, 2015). In 
this chapter, comparison of the immunoglobulin isotype of CSF B cells to those in the 
periphery was performed to obtain clues as to the dynamics of B cell migration in MS. The 
similar immunoglobulin profile between peripheral blood and CSF B cells (Fig. 3.9A) implies 
that most of these cells are derived from the periphery. Indeed, sequencing studies have 
shown that CSF B cells are largely peripherally derived in that founding CNS B cell clones 
are often found within cervical lymph nodes, and that this immune response then evolves and 
continues within the CNS, since more mature clones are often found there (Stern et al., 2014).  
Increased CSF IgG+ B cells agrees with previous reports that class-switched B cells are 
enriched within the CSF during neuroinflammation, however in both studies, non-
inflammatory controls were not analysed (Cepok et al., 2006; Eggers et al., 2017). In this 
chapter, elevated CSF IgG+ B cells was observed for both MS and control groups, including 
non-inflammatory controls, suggesting that the increased proportion of memory B cells in the 
CSF is at least in part a biological phenomenon that is not specific to inflammation (Fig. 
3.9B). Much like how memory T cells are preferentially found in the normal and inflamed 
CSF, it appears that memory B cells also show this trend; this is likely due to differential 
expression of chemokine and adhesion receptors that allow memory lymphocytes to enter 
non-lymphoid tissues (de Graaf et al., 2011). It was also found that CSF B cells were 
generally not Ig-biased, and that this phenotype was comparable to peripheral blood B cells; 
this was true for all disease groups except for CIS, which showed a small increase, and 
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although not significant, clearly some individuals coming off natalizumab also showed an Ig 
bias, suggesting a level of clonal expansion of CSF B cells in some individuals (Fig. 3.10A, 
B). Overall, the majority of CSF B cells in MS appear to be peripherally derived based on 
their similar immunoglobulin heavy and light chain expression. 
In the periphery, most ASC are derived from mucosal responses and are therefore IgA+; 
however in the CSF, the overwhelming majority of these cells express IgG (Fig. 3.9B) (Mei et 
al., 2009). This striking difference to the peripheral blood profile has been suggested by CSF 
analysis in sequencing studies, and the fact that most CSF antibody in MS is IgG1; this 
phenomenon could therefore indicate clonal expansion of IgG+ ASC (Zeman et al.,2012; von 
Budingen et al., 2012; Stern et al., 2014). However, as the immunoglobulin isotype is also 
related to the homing capability of ASC, it is possible that CSF ASC have non-specifically 
migrated from the periphery and are not directly related to MS pathogenesis. Migration of 
peripherally derived ASC has been observed in NMO, where IgG+CXCR3+ plasmablasts are 
elevated in the periphery and enriched in the CSF during relapse (Chihara et al., 2013). 
Similarly, in a mouse model of viral encephalomyelitis, CXCR3+ plasmablasts were 
expanded in the draining cervical lymph nodes prior to their accumulation in the CNS, 
supporting the concept of peripheral expansion of antigen-specific plasmablasts prior to CNS 
infiltration (Marques et al., 2011).  
 
3.3.4 CSF ASC, but not B cells, show features of clonal expansion   
In this chapter, the frequency of CSF IgG+ ASC was increased in the MS group compared to 
the control group, where IgA+ ASC were increased in comparison (Fig. 3.9B). Despite the 
limited sample size, it is possible that this phenomenon reflects at least some peripheral ASC 
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migration in these individuals, since IgA is the dominant isotype in the periphery. The ASC 
Ig:Igratio was elevated in MS to varying degrees (Fig. 3.10A-C). In two ONID samples, 
CSF ASC were biased in both directions (Ig-biased or Ig-biased), which could reflect 
expansion towards the disease-causing agent; however, in MS, all of the individuals were Ig-
biased. This bias was also observed in an individual following natalizumab cessation (Fig. 
3.10C). Since natalizumab blocks lymphocyte trafficking into the CNS, an obvious 
explanation is that at least some clonally expanded ASC are CNS-resident and remain 
unaffected by natalizumab therapy; this has also been suggested by the observation of residual 
OCB in 40% of natalizumab cases (Mancuso et al., 2014). 
A light chain bias suggests antigen-driven selection, which could occur if CSF ASC are 
retained and fostered within the CNS. The novel observation that CD19- ASC are generally 
more Ig-biased than CD19+ ASC indicates that this population possess a more limited 
antigen diversity, and may therefore have been generated from an earlier CNS response (Fig. 
3.10D). As CD19- ASC are non-migratory, their presence in the CSF suggests they were 
dislodged from one of the limited number of CNS survival niches in favour of recently 
generated ASC, ending up in the CSF where their rapidly produced antibodies are detected 
prior to apoptosis (Radbruch et al., 2006). It is feasible to suggest that CNS survival niches 
are initially occupied by ASC generated earlier in the disease, and that with disease evolution, 
these cells may be out-competed by more recently generated CD19+ ASC, which have a 
broader antigen repertoire due to epitope and/or antigen spreading, therefore a lower IgIg 
ratio.  
Biologically, an elevated IgIg ratio suggests clonal expansion of B cells specific for an 
antigen inducing an IgG response, leading to a skewed light chain ratio. These data 
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demonstrate the intimate relationship between FLC and ASC by showing a strong correlation 
between the FLC IgIg ratio and the ASC IgIg ratio in the CSF, which was not observed 
for CSF B cells (3.11A-C). IgG+ CSF B cells also showed no correlation, however a small 
number of samples appeared to show some relationship, indicating some intrathecal 
expansion in these samples. A previous study showed that CSF B lineage cells are the source 
of CSF OCB by demonstrating a strong overlap between CSF cell immunoglobulin mRNA, 
and the Ig proteome from OCB (Obermeier et al., 2008). Observations in this chapter 
extended these findings by showing that CSF ASC, but not CSF B cells, are strongly related 
to secreted CSF immunoglobulin through their strong relationship with the FLC IgIg ratio.  
A hypothesis of this work was that the FLC IgIg ratio relates to the broadness of the 
humoral response in MS (Fig. 3.14). This suggests that the antibody response in MS spreads 
to additional epitopes and/or additional antigenic targets, becoming more diverse with time. 
This then presumably translates to disease duration; i.e. the disease begins with few (or even 
one) antigen specificities, and therefore a high FLC IgIg ratio, which progresses to a low 
ratio comparable to that in the periphery due to a broad array of targets. Therefore, it is 
possible that those with CIS, who have had one clinical relapse, have a higher FLC IgIg 
ratio than those with MS, who have experienced multiple clinical relapses. Comparison of the 
FLC IgIg ratio between disease groups revealed significant Ig bias in all MS groups 
compared to OND controls (Fig. 3.12). Despite the lack of a significance between CIS and 
MS, which could have been due to high variation and small group sizes, the CIS group shows 
a trend for an elevated ratio compared to the MS group (12.5:1 vs 6.3:1); additionally, the CIS 
group showed more significant difference against OND than the MS group, suggesting a 
greater increase compared to MS. Clearly, great variation exists within groups, which could 
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also represent the difficulty of categorising individuals as CIS or MS at diagnosis, since it is 
very difficult to estimate the duration of sub-clinical disease, which may have started years 
before clinical symptoms begin. As such, lack of a significant difference between CIS and MS 
does not necessarily invalidate the concept that the FLC IgIg ratio is associated with 
epitope/antigen spreading and/or disease progression, and further work is required to    
investigate this in a larger cohort.  
Figure 3.14 Proposed model for the spreading of the humoral response in MS. It was
hypothesised that the humoral response in MS is initiated against a single immunodominant
Ig-inducing antigen in all individuals (left panel). With increasing disease duration, a
combination of epitope spreading and the influx of peripheral B cells, which are retained within
the inflamed CNS, causes the presence of Ig-expressing antibodies in established MS (middle




Repeat CSF samples were investigated for their potential insight into the dynamics of CSF B 
cells and ASC. These were obtained from an individual coming off natalizumab therapy at 
day 0 (i.e. CSF obtained at first LP) and day 62. Despite the strikingly huge lymphocytic 
presence in the CSF, the CD19+CD20+ B cell population represented a similar frequency at 
both timepoints, possibly suggesting non-specific recruitment; in contrast, the ASC frequency 
had quadrupled on day 62, indicating their expansion (Fig. 3.13A). The high cellularity at day 
62 suggests an increase in CNS inflammation, and the preferential increase in ASC could 
indicate their active contribution to disease.  
The lower IgIg ratio in B cells on day 62 suggests a broader antibody repertoire, which in 
association with the increased cellularity suggests influx from the periphery (Fig. 3.13B). 
Conversely, ASC appear to display a higher Ig-bias in the presence of increased 
inflammation, based on both ASC and FLC ratios, suggesting an antigen-driven response by 
Ig-expressing ASC. Although these observations are based on low cellularity (for the ‘day 0’ 
sample) and are from only one individual, they provide some insight into B cell-related 
pathogenesis. Longitudinal analysis of the CSF antibody response would be required to fully 
investigate the dynamics of epitope and/or antigen spreading in MS, which is partly 
investigated in chapter 4, however as a final note, these data support the findings throughout 





3.4 Chapter Summary 
In summary, I identified and characterised both CD19+ and CD19- ASC populations in MS 
CSF, supporting the concept that the CNS is conducive to B cell survival and development.  
Phenotypic characterisation confirmed the distinct differences between these CSF ASC 
populations, which along with CSF B cells displayed an activated phenotype compared to 
their peripheral counterparts. These data support a pathological involvement of B cells and 
ASC in MS through their association with inflammation-related parameters, further 
supporting their depletion with anti-CD20 therapies (Hauser et al., 2008; Kappos et al., 2011; 
Krumbholz et al., 2014).  
The hypothesis of this chapter, that clonally expanded B lineage cells can be detected in MS 
CSF, was confirmed; CSF ASC appear to be clonally expanded, based on their predominant 
IgG expression, whereas CSF B cells appear to be largely non-selective and derived from the 
periphery, based on their similar immunoglobulin expression profiles between the periphery 
and CSF. Though no significant differences were observed between CIS and MS groups, the 
possibility remains that the IgIg ratio relates to epitope/antigen spreading, and thus 








INVESTIGATION OF CSF 




Chapter 4: Investigation of CSF antibody specificity in multiple 
sclerosis  
4.1. Introduction 
A hallmark of MS is the presence of CSF antibodies (Walsh and Tourtellotte, 1986, Kabat et 
al., 1950; Giovannoni, 2014). The key pathological feature of demyelination, and the 
induction and functional demyelinating properties of anti-myelin antibodies in EAE, has led 
to the extensive investigation of myelin antigens as primary autoantibody targets in human 
MS (Reindl et al., 1999; Walsh and Murray, 1998; Sadler et al., 1991; Marín et al., 2014). 
However, antibodies to non-myelin antigens have also been identified; these include damage-
related proteins, such as neurofilament light chains and neurofascin, inflammation-related 
proteins, such as prostaglandins and complement components, and microbial proteins, such as 
EBNA-1, human endogenous retroviruses (HERVs) and the so-called MRZ reaction towards 
measles, rubella and Varicella-zoster viruses (Puentes et al., 2017; Mathey et al., 2007; Farias 
et al., 2014; Santiago et al., 2010; Morandi et al., 2017; Derfuss et al., 2005; Chmielewska-
Badora et al., 2000).  
The strong Ig-bias by MS CSF antibodies, and the elevated Ig FLC concentration 
compared to controls, is suggestive of clonal expansion towards a common antigen; indeed, 
sequencing studies have demonstrated the presence of clonally expanded B cells and ASC in 
MS CNS (Lovato et al., 2011; Ligocki et al., 2010). However, despite decades of 
investigation, no single antigen has been identified thus far that is unique to MS, or that is 
commonly found within affected individuals (Levin et al., 2013; Hohlfeld et al., 2015a; 
Hohlfeld et al., 2015b). The broad antibody repertoire of MS contrasts with that of NMO, in 
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which a robust and specific CSF antibody response is mounted against the water channel 
aquaporin-4 (Takahashi et al., 2007). It is therefore possible that a unifying autoantigen 
responsible for the frequently observed Ig-bias in MS is yet to be identified. 
Proteomic techniques have revolutionised the search for candidate autoantigens, allowing 
high-throughput processing with the potential for hypotheses-free investigations. A 2014 
review identified 2D gel electrophoresis as the historical basis of proteomic analysis in MS, 
which has been largely superseded by shotgun mass spectrometry techniques, despite its 
limited use of samples (Farias et al., 2014). Although several studies have since utilised high-
density antigen arrays in the field of MS, large-scale analysis of the CSF autoantibody 
repertoire has not frequently been assessed using these methods and plenty of scope remains 
for further investigation (Somers et al., 2008; Häggmark et al., 2013; Bystrom et al., 2014; 
Quintana et al., 2014; Hecker et al., 2016; Ayoglu et al., 2016). High-density arrays allow the 
screening of large sample sizes and the analysis of large numbers of target antigens. 
Furthermore, the use of different array formats provides the opportunity to cross-validate 
findings of antigen reactivity. Large scale characterisation of the human proteome is a 
continuing initiative of the Human Protein Atlas (HPA) project (www.proteinatlas.org), 
which produces recombinant protein fragments for the systematic exploration of the human 
proteome (Sjoberg et al., 2016). These proteins represent sequences of lowest homology to 
other proteins and are validated using specific polyclonal antibodies (Sjoberg et al., 2016).  
In this chapter, we collaborated with Professor Peter Nilsson and colleagues in Stockholm to 
assess CSF antibody reactivity of MS and control groups using planar and bead-based array 
platforms, including using the largest available planar microarray platform to date, hosting 
HPA-validated antigens (Sjoberg et al., 2016). Additionally, a novel aspect of this project was 
the investigation of antigen reactivity by antibodies bearing kappa (Ig) and lambda (Ig) 
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light chains in MS CSF, with the aim of unravelling any potential differences in antigen 
reactivities, the identities of which may provide clues to their involvement in MS 
pathogenesis. The hypothesis of this chapter was that that antibodies bearing Iglight chain 
recognise a distinct antigen, which is responsible for the Ig bias in MS.     
 
4.1.1 Chapter Objectives  
1. Identify potential autoantigen targets recognised by CSF antibodies from MS (CIS, 
RRMS, PPMS and natalizumab-treated) and control (OND, ONID) groups using 
planar arrays 
2. Verify any observed autoantibody reactivity using bead-based antigen arrays 
3. Identify any differences in CSF reactivity across different disease groups 
4. Investigate whether antigen reactivity relates to FLC concentration and/or the 
Ig:Ig FLC ratio 
5. Determine whether common MS candidate autoantigens (MAG and MBP) are 
identified as antigen targets in MS CSF 
6. Assess whether certain antigens can induce a kappa-biased antibody response, and 





4.2.1 Unbiased assessment of CSF reactivity using planar 21k arrays 
The initial discovery phase was conducted using planar antigen arrays. The first array format 
employed 21,120 human protein fragments, termed ‘21k arrays’, allowing unbiased screening 
of 12,412 protein encoding genes.  
Due to the interest in potential autoantigens during the early phases of disease, CSF samples 
from six individuals with CIS were assessed for antigen reactivity using 21k arrays (Fig. 
4.1A). These samples were selected based on their strong FLC bias towards Ig(Appendix II 
table B) with a median ratio of 86:1, based on the hypothesis that these individuals 
demonstrate more antigen restriction and are earlier on in the disease course. For this phase of 
the study, pooled CSF from six RRMS and six OND individuals was also used (Fig. 4.1B). 
The RRMS samples used for planar arrays were also subject to selection bias; these were 
selected based on their non-biased Ig:Ig ratio (median 1.47:1) with the idea that these 
samples contain antibodies recognising multiple antigen specificities (Appendix II table B). 
As in previous studies by Professor Peter Nilsson and colleagues, an arbitrary threshold for 
each sample or group was determined to allow the number of antigens recognised, termed 
‘positive hits’, to be quantified (Fig. 4.2A). The threshold was set based on visual inspection 
of the antigen array data and a calculation was applied to allow distinction between positive 
and negative hits; this calculation was then applied to all samples. These cut-offs were 
sample-specific to account for the varying background reactivity between samples, allowing 
any antigen above this threshold to be identified as a positive hit. Defining a cut-off allowed 
the data to be transformed into binary values (1 or 0) to inform whether or not the cut-off 


























































Figure 4.1 CSF reactivity using 21k planar arrays (i). CSF samples from six CIS individuals
with a biased Igk:Igl FLC ratio (A), and pooled CSF from six RRMS individuals with a non-
biased Igk:Igl FLC ratio and six individuals with OND (B), were ran on large planar arrays to
determine reactivity towards 21,120 antigens. Dotted lines represent cut-offs determined for each
assay based on the level of background reactivity, and was calculated by multiplying the median
fluorescence intensity (MFI) of each group + 4x median absolute deviation (MAD). The rabbit
anti-human IgG control is shown at the end of each graph.
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Figure 4.2 CSF reactivity using 21k planar arrays (ii). The number of positive hits for
each sample was quantified following application of sample-specific cut-offs (A). Data
shows the median and range (for CIS group). Details of the positive hits shared between





rabbit anti-human IgG were omitted from these calculations, since it was expected that these 
would produce a positive hit, but negative controls such as empty beads (i.e. beads alone) or 
His6-ABP were included to ensure the calculated threshold was above these signals. 
Quantification of the positive hits between groups indicated that CIS and RRMS samples 
identified a higher number of hits compared to OND samples (Fig. 4.2A). Several antigens 
were identified as common targets between a number of samples and/or groups (Fig. 4.2B), 
and a number of positive hits with potential relevance to MS were also identified (Fig. 4.2C). 
 
 4.2.2 CSF reactivity using 384 planar arrays  
Following initial screening using 21k arrays, smaller arrays hosting 384 proteins were used 
(referred to as ‘384 arrays’). Although they are biased, since they host pre-determined 
proteins, the 384 arrays are more suited to screening a larger sample size. The 384 arrays can 
be custom designed based on organs or tissues of interest, or on diseases of interest, based on 
previously reported and/or suspected antigen targets associated with a certain disease; in this 
case, arrays hosting 384 antigens were selected, based on previous in-house studies by the 
collaborating laboratory. 
Six CSF samples from individuals with CIS (Fig. 4.3A), RRMS (Fig. 4.3B) and OND (Fig. 
4.3C) were applied to 384 planar arrays to reveal the MFI intensity profiles of each sample. 
Following application of sample-specific cut-offs, CIS samples (black dots) were found to 
identify a median of 12 (range 7-16) antigens, whereas RRMS samples (grey dots) identified 
12.5 (range 4-26) and OND samples (white dots) identified 4 (range 1-6; Fig. 4.4A). 
Collectively, the extent of antigen reactivity correlated significantly with total FLC (r= 0.807, 
p= <0.001) (Fig. 4.4B). Additionally, the Ig:Ig FLC ratio was collectively compared with 
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the number of positive hits recognised by each sample (Fig. 4.4C). This also revealed a 
significant correlation (r= 0.735, p= <0.001).  
In addition to calculating a threshold to define positive reactivity, high and low sample-
specific cut-offs were calculated, and a heat map generated to analyse reactivity towards 
common antigens between samples (Fig. 4.4D). This was performed based on the median 
reactivity per sample + 0.5x the median absolute deviation (MAD) for the lower cut-off (pink 
boxes), and the median reactivity per sample + 4x the MAD for the higher cut-off (red boxes). 
Several antigens common to more than one sample were identified, including interferon- 
inducible protein 27 (IFI27), B cell lymphoma/leukaemia 10 (BCL10) and phosphoglycerate 
mutase family member 5 (PGAM5), which were positively recognised by several CIS and 
RRMS CSF samples.   
Following this initial investigation, a total of 55 candidate target antigens were selected using 
both 21k and 384 planar arrays (Appendix IV), which were combined with a series of 
candidate MS target antigens identified from the literature (Appendix V) as well as those 
identified in-house to yield 301 antigen targets which were taken forward to the verification 












Figure 4.3 CSF reactivity on planar arrays towards 384 antigens (i). CSF samples from
six CIS (A), six RRMS (B) and six OND (C) individuals were ran on planar arrays to
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Figure 4.4 CSF reactivity on planar arrays towards 384 antigens (ii). The number of
positive hits for each CSF sample was quantified following application of arbitrary sample-
specific cut-offs, calculated by combining the median reactivity per sample + 0.5x the
median (A). Data shows the median and range, and were significant to * (P<0.05) using
Dunn’s multiple comparisons test. Spearman correlation of total CSF FLC (mg/L) (B) or the
FLC Ig:Ig ratio (C) compared to the number of positive hits obtained for CIS (black),
RRMS (grey) and OND (white) samples. Heatmap showing common antigen reactivities
(D). The heatmap was generated by calculating low and high sample-specific cut-offs by
combining the median reactivity per sample + 0.5x the median (low cut-off; pink) or

























































Figure 4.4 CSF reactivity on planar arrays towards 384 antigens (ii). The number of
positive hits for each CSF sample was quantified following application of arbitrary sample-
specific cut-offs, calculated by combining the median reactivity per sample + 0.5x the
median (A). Data shows the median and range, and were significant to * (P<0.05) using
Dunn’s multiple comparisons test. Spearman correlation of total CSF FLC (mg/l) (B) or the
FLC Ig:Ig ratio (C) compared to the number of positive hits obtained for CIS (black),
RRMS (grey) and OND (white) samples. Heatmap showing common antigen reactivities
(D). The heatmap was generated by calculating low and high sample-specific cut-offs by
combining the median reactivity per sample + 0.5x the median (low cut-off; pink) or
multiplying the median by 4 (high cut-off; red).
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4.2.3 Buffer and antibody optimisation     
Successful identification of reactive antigen targets relies on the measurement of a distinct 
signal which allows differentiation from the background signal. To optimise the assay 
conditions by reducing background signal, two assay buffers were tested; a standard buffer 
containing PBS + 0.1% tween, and the same buffer with 5% milk. The two assay buffers were 
compared for CSF pools using the anti-human IgG control, and demonstrated a modest signal 
reduction with the addition of 5% milk (Fig. 4.5). Controls used in these assays were ‘empty’ 
beads (i.e. beads which were not incubated with CSF) to show any non-specific signal derived 
from the beads, beads with anti-His6-ABP to demonstrate blocking of any exogenous ABP 
antibodies within CSF, and anti-human IgG as the positive control. Results demonstrated a 
level of total signal reduction with the addition of milk. 
For further optimisation, the anti-human Ig antibody was incubated with CSF pools in both 
buffers at a 1/100 (Fig. 4.6A) and 1/500 (Fig. 4.6B) dilution. Similarly, this process was 
repeated for the anti-human Ig antibody (Fig. 4.7A, B). Based on the lower signal intensity 
from the anti-human Ig antibody, and the loss in signal intensity at 1/500, a 1/100 dilution 
was selected for both antibodies. Because of the relatively low background reactivity 
observed in CSF, assay buffer without milk was selected for use in the suspension bead arrays 















Figure 4.5 Buffer optimisation using the anti-human IgG antibody. Reactivity of pooled
CSF using the anti-human IgG detection antibody in the presence of assay buffer with or
without 5% milk. The corresponding controls are shown on the right (grey bars). Controls used
were ‘empty’ beads (i.e. beads without CSF), beads with anti-His6-ABP (to demonstrate












































































Figure 4.6 Optimisation of anti-human kappa light chain antibody. Test of anti-κ light chain
antibody at 1/100 (A) and 1/500 (B) dilutions using pooled CSF, with or without the addition of



























































































Figure 4.7 Optimisation of anti-human lambda light chain antibody. Test of anti-λ light
chain antibody at 1/100 (A) and 1/500 (B) dilutions using pooled CSF, with or without the








































































































4.2.4 Quality control testing of the suspension bead array  
Suspension bead arrays were generated by first conjugating target antigens to magnetic beads 
labelled with a specific bead ID. To ensure pairing of the correct antigen with its 
corresponding bead ID, two antigens (MBP and ANO2) were selected and incubated with 
anti-MBP or anti-ANO2 antibodies. Binding to the correct bead IDs were confirmed, 
demonstrating successful pairings with the correct IDs and validating the bead IDs against 
their expected conjugated antigens (Fig. 4.8A). Incubation of antigen-conjugated beads with 
anti-rabbit IgG demonstrated reactivity for the correct bead IDs with no cross-reactivity with 
human antigens; similarly, non-specific binding was not observed following incubation of 
antigen-conjugated beads with anti-chicken IgY (Fig. 4.8B). The beads were also incubated 
with anti-His6-ABP antibody to demonstrate successful antigen conjugation, binding to the 
His6-ABP tagged to the antigens (Fig. 4.8C).  
Each bead ID was representative of a single antigen, and beads were pooled following 
conjugation. However, beads may have been lost during the conjugation process or they may 
have aggregated due to sticky antigens. Therefore, an important step was to assess the bead 
count corresponding to each antigen to ensure that conjugation was successful and that a high 
enough signal would be achieved. A low bead count would also mean low antigen levels in 
the assay which may misleadingly result in low signals, even in the presence of saturating 
antibody concentrations. For each antigen, the median number of beads were determined, and 
a minimum count of 30 beads was chosen as the cut-off (Fig. 4.9A). All except 8 beads 
passed the bead count test; these 8 bead IDs and their corresponding antigens were excluded 























Figure 4.8 Coupling test for the suspension bead array. Antibodies against two selected
bead IDs (MBP and ANO2) were used to ensure correct coupling to their corresponding IDs
(A). Anti-rabbit IgG and anti-chicken IgY antibodies were incubated with antigen-conjugated
beads for the negative control (B). The beads were incubated with an anti-His6-ABP antibody






















































Figure 4.9 Exclusion of antigens with low bead counts. As part of the analysis, the median
number of beads was determined for each antigen (A). A minimum cut-off of 30 beads per




Bead No. Gene Gene Description UniProt
25 CNTN2 Contactin 2 (axonal) Q02246
40 IFNLR1 Interferon, lambda receptor 1 Q8IU57
92 KIF15 Kinesin family member 15 Q9NS87
167 HERC2 HECT and RLD domain-containing E3 
ubiquitin protein ligase 2
O95714
201 ASTN1 Astrotactin 1 O14525
228 NCOA2 Nuclear receptor coactivator 2 Q15596
243 CNTN2 Contactin 2 (axonal) Q02246




Finally, for each suspension bead array, several quality control steps were assessed. Like the 
CSF samples, controls were processed in a randomised fashion to avoid any plate effects. 
Using the anti-human IgG detection antibody, the MFI values of empty beads and beads with 
anti-His6-ABP showed very little background reactivity, with median values of 27 and 23 
(Fig. 4.10A). The anti-human IgG-conjugated beads in the presence of CSF had a median 
MFI of 19,431, demonstrating the presence of CSF antibody which is detectable using this 
assay. The consistency between the controls and across CSF samples also demonstrated 
reliability of the assay.   
A final check after running CSF samples on the suspension bead array was to analyse the 
bead count for each CSF sample (Fig. 4.10B). This ensured consistent distribution between 
CSF samples to inform the reliability of the MFI values obtained from these beads during 
analysis. These analyses were performed for the anti-human IgG suspension bead array 
(shown in Fig. 4.10) and also for the anti-human Ig and anti-human Ig suspension bead 
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Figure 4.10 Quality controls for the anti-human IgG suspension bead array. Quality
controls employed for the suspension bead array assessed MFI values for the empty bead,
His6-ABP bead and the anti-human IgG bead in the presence of CSF (A). The same quality
controls were also performed for the Igκ and Igλ suspension bead arrays (data not shown). For
the anti-human IgG suspension bead array, the median number of beads incubated with each





























































4.2.5 Comparative antigen reactivity profiles between both array 
platforms  
As two alternative antigen array platforms, planar and bead-based, were used for this project, 
it was possible to compare the antigen reactivity of the same CSF sample using both 
technologies. The antigen reactivities of six CIS samples that were used on the 21k arrays 
were compared to reactivities using the bead-based arrays (Fig. 4.11). Antigens identified as a 
positive hit on the bead-array were then compared to the planar array data, and if positive 
using both methods, were coloured in red. In half of the samples (CIS 4, 5 and 6) almost all 
the antigens identified as positive on the bead-based array were also identified as positive on 
the planar array, even in weakly identified antigens. 
 
4.2.6 Comparative antigen reactivity profiles of repeat CSF samples    
To further investigate the reproducibility of these assays, comparison of antigen reactivity 
profiles of repeat CSF samples from the same individual, taken at different time points, were 
compared for two different individuals with MS, labelled CIS-1 and NAT-1 (Fig. 4.12A). 
Samples from CIS-1 were taken 418 days apart, whereas samples from NAT-1 were taken 62 
days apart. Very similar antigen reactivity profiles in terms of the magnitude of response and 
the identity of antigen targets were obtained for both samples; additionally, for each 
individual, comparison of MFI values from both samples revealed very strong correlations 











Figure 4.11 Consistent antigen reactivity profiles across both planar and bead-based array
platforms. For 6 individuals with CIS, antigen reactivity of CSF was compared for planar arrays
containing 21,120 antigens, and suspension bead arrays containing 301 antigens. Antigens
identified as a positive hit on both arrays are shown in red. Dotted lines represent sample-specific
cut-offs calculated as the median fluorescent intensity (MFI) plus 10x the median absolute
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Figure 4.12 Antigen reactivity of CSF samples from the same individual using the
suspension bead array. Reactivity of CSF from an individual with CIS (CIS-1) and an
individual with MS treated with natalizumab (NAT-1) taken at different time points (A). The
second L.P. was taken at 418 days (CIS-1) or 62 days (NAT-1) following initial L.P. Blue
represents the first L.P., orange represents the second L.P. Spearman correlation of antigen



































































































4.2.7 CSF reactivity using suspension bead arrays     
As in the planar arrays, the number of positive hits identified by each CSF sample was 
compared with the total FLC concentration (Fig. 4.13A) and the Ig:Ig ratio (Fig. 4.13B). 
Both of these parameters showed that no association with antigen reactivity was detectable. 
Data was grouped by disease classification to compare the number of positively recognised 
antigens for each sample; this analysis was performed for all three bead-based arrays which 
were carried out using different detection antibodies; anti-IgG (Fig. 4.14A), anti-Ig (Fig. 
4.14B) and anti-Ig (Fig. 4.14C). No distinct differences were apparent between disease 
groups in the number of positive hits recognised, and in contrast to the planar arrays, 
differential reactivity between MS groups and control groups was not observed; however, 
grouping these data by disease group revealed a slightly higher number of positive hits in the 
CIS group compared to OND (anti-Igassay) (Fig. 4.14C).  
 
4.2.8 Global CSF reactivity using suspension bead arrays 
To identify the top reactive antigens using the suspension bead arrays, the total number of 
positive hits identified across all CSF samples was determined for each assay using anti-IgG 
(Fig. 4.15A), anti-Ig (Fig. 4.15B) and anti-Ig (Fig. 4.15C) detection antibodies. Findings 
revealed that similar antigens were recognised using all three detection antibodies, with top 
antigens including EBNA-1, coiled-coil domain containing 85C (CCDC85C), and zinc finger 
protein 688 (ZNF688). In addition, Igand Igantibodies showed differential reactivity 
towards certain antigens; for example, CCDC85C was identified by Ig but not 














Figure 4.13 No correlation between FLC and reactivity parameters using the suspension
bead array. Spearman correlation of the total FLC concentration (mg/L) (A) and the Ig:Ig
FLC ratio (B) compared to the number of positive hits identified by each sample. The
positive hits were determined using sample-specific cut-offs which were calculated by
multiplying the MFI of each group + 10x median absolute deviation (MAD).
Controls were excluded from the analysis. Samples from MS groups only. 
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Individual Sample Reactivity Group Reactivity
Figure 4.14 Individual and grouped sample reactivity for the suspension bead arrays. The
number of positive hits per sample and per disease group were determined for the anti-IgG (A),
anti-Igκ (B) and anti-Igλ (C) suspension bead arrays. Tukey box and whisker plots showing
median values. Comparisons were significant to ** (P=0.01) using Dunn’s multiple
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Figure 4.15 Global antigen reactivity of IgG, Igκ and Igλ using suspension bead arrays.
Following the application of an arbitrary sample-specific cut-off value to define positive
antigen reactivity, the number of positive hits per antigen for the anti-IgG (A), anti-Igκ (B) and

















































4.2.9 Interrogation of candidate autoantigens     
For the anti-IgG bead array, the top twenty hits were evaluated for the frequency they were 
recognised (Fig. 4.16A). EBNA-1 was identified by over 87% of all CSF samples, with the 
following most antigenic proteins being CCDC85C and ZNF688, which were recognised by 
almost 50% of CSF samples. For the top six most antigenic proteins, which were all deemed 
positive hits in at least 20% of samples, their antigen reactivity profiles for each disease group 
was determined (Fig. 4.16B). Only EBNA-1 was differentially recognised between groups, 
showing significantly higher reactivity in all MS groups, particularly CIS, compared to OND 
controls. In conjunction with the higher EBNA-1 reactivity in MS, a higher proportion of MS 
samples (94.4 – 97.2%) showed positive reactivity following application of sample-specific 
cut-offs compared to OND (74.7%) and ONID (82.1%) samples (Fig. 4.16C).  
Antigen reactivity towards two major MS candidate autoantigens, MAG (Fig. 4.17A) and 
MBP (Fig. 4.17B), were also investigated. Three bead IDs were available for each of these, 
representing different parts of each protein. No significant reactivity was identified to any of 
these, although some individuals appeared to show some elevated antibody activity, 
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Figure 4.16 Top reactive antigens using anti-IgG in the suspension bead array. Top 20
reactive antigens recognised by CSF IgG in all disease groups (A). Antigens are listed alongside
their corresponding bead identification number, the frequency of hits and the percentage of CSF
samples identifying the antigen as a positive hit. Comparison of antigen reactivity between groups
for the 6 highest reactive antigens (B). Comparisons were significant to *** (P<0.05) and *
(P<0.01) using Dunn’s multiple comparisons test. Reactivity towards EBNA-1 was quantified and
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Figure 4.17 Absence of CSF IgG reactivity towards MAG and MBP proteins. Using the
suspension bead array, no significant reactivity of CSF IgG was observed in response to three
MAG proteins (A) or three MBP proteins (B) in any of the disease groups. Comparisons were









4.2.10 Differential light chain binding to antigens    
A question during this project was the antigen specificity of Ig and Iglight chains. Using 
the suspension bead array, reactivity of Ig- and Ig-expressing CSF antibodies was assessed 
and converted to an Ig:Igratio to identify whether a kappa bias could have been induced by 
any of these antigens (Fig. 4.18). Several antigens appeared to elicit such responses; notably 
EBNA-1, CCDC85C, ZNF688 and queuine tRNA-ribosyltransferase 1 (QTRT1). For each 
disease group, the Ig:Ig ratio was compared for each of these antigens (Fig. 4.19A). 
EBNA-1 elicited the strongest Ig bias, with the following median values: CIS (9.8:1), RRMS 
(7.6:1), PPMS (8.24:1), NAT (9.8:1), OND (5.8:1), ONID (5.4:1). Although the ratio was 
higher in MS groups than controls, this was not statistically significant. The relationship 
between the kappa and lambda light chain response was confirmed by correlation analysis, 
demonstrating that despite the higher kappa light chain reactivity towards these antigens, 



















Figure 4.18 Some antigens induce a kappa-biased antibody response. The Igκ:Igλ ratio,
calculated from the MFI for both Igκ and Igλ,was determined in response to each antigen
and compared across disease groups. Igκ:Igλ ratios of 10:1 or above are in red.
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Figure 4.19 Comparison of antigens between disease groups that induce a biased
kappa light chain response. The ratio of Igκ MFI to Igλ MFI in disease groups towards the
top four antigens demonstrating a biased kappa light chain response (A). Group comparisons
were not significant using Dunn’s multiple comparisons test. Relationship of Igκ and Igλ
reactivity for ZNF688, QTRT1, CCDC85C and EBNA-1 (B).
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4.3 Discussion  
4.3.1 A broad CSF antibody repertoire is an early feature of disease  
For the initial part of this chapter where 21k planar arrays were used, CSF samples were 
selected based on their diagnostic categorisation (CIS vs RRMS) and their CSF FLC Ig:Ig 
ratio to investigate potential spreading of the humoral response throughout the disease. As in 
chapter 3, a diagnosis of CIS was used to represent ‘early’ MS, as by definition, CIS is 
characterised by one clinical relapse at the time of diagnosis. Selecting CIS samples with a 
high FLC Ig:Ig ratio was intended to identify individuals with restricted antibody 
specificity to a limited number of antigens (due to the high Ig bias) and are therefore 
assumed to be at the earliest stages of the disease process. This was compared with RRMS 
samples with a low FLC Ig:Ig ratio, as by definition, RRMS represents individuals who 
have experienced more than one clinical relapse at diagnosis, and a less biased FLC Ig:Ig 
ratio potentially indicates broader spreading of the antibody response in MS (Fig. 3.14).  
Despite the selection bias of CSF samples used for the planar arrays, a key finding was the 
highly heterogeneous antibody responses between individuals. This was true using both 
planar (Fig. 4.1 – Fig. 4.4) and bead-based (Fig. 4.14 – Fig. 4.19) arrays, and was observed 
within and between disease groups. This is in line with findings from other studies using 
antigen arrays, and is clearly a fundamental feature of MS, demonstrating the complexity of 
the intrathecal antibody repertoire in this disease, even during apparently early stages 
(Haggmark et al., 2013; Quintana et al., 2014; Hecker et al., 2016; Ayoglu et al., 2016).    
An initial screen of six CIS samples using 21k planar arrays identified specificities that were 
highly unique to each individual (Fig. 4.1); this phenomenon was also observed using 384 
planar arrays (Fig. 4.3). Most CIS samples displayed reactivity towards multiple antigens, 
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although some CIS samples failed to respond to any antigens (Fig. 4.1A); this is an interesting 
observation, as differential CSF antibody responses could potentially allow disease outcomes 
to be distinguished. Reactivity towards multiple antigens was also observed in pooled and 
individual RRMS CSF (Fig. 4.1B, Fig. 4.3B); in contrast, pooled OND CSF effectively 
showed no reactivity on 21k planar arrays (Fig. 4.1B), and individual OND samples on 384 
arrays also showed little reactivity (Fig. 4.3C), demonstrating the relative absence of high 
affinity antibodies under normal physiological conditions, despite the presence of antibodies 
in the sample, as demonstrated by a positive signal for the rabbit anti-human IgG control (Fig. 
4.1B).  
 
 4.3.2 Identification of common antigens using planar arrays  
The identification of common target antigens between individuals may suggest common 
destructive processes mediated by the humoral response in MS. Despite the large variation 
between samples, quantification of the positive hits between groups following application of 
sample-specific cut-offs revealed several antigens common to more than one sample for both 
21k (Fig. 4.2B) and 384 (Fig. 4.4D) planar arrays. Of interest, reactivity towards 5'-
nucleotidase, cytosolic 1A (NT5C1A), identified as a positive hit on 21k planar arrays, has 
been observed previously (Fig. 4.2B); circulating autoantibodies to NT5C1A have been 
identified in 21% of MS cases (Lloyd 2016). However, its common association with other 
inflammatory or autoimmune conditions such as inclusion body myositis, systemic lupus 
erythematosus and Sjögren’s syndrome suggests this reactivity is a consequence of general 
inflammation, rather than a disease-specific phenomenon (Lloyd et al., 2016; Tawara et al., 
2017). Reactivity towards CCDC85C (Fig. 4.2B) in MS has also been observed previously. In 
a screen of SPMS plasma, 2 of 8 samples showed CCDC85C reactivity using the same planar 
141 
 
array platform as in this chapter (Sjoberg et al., 2016). CCDC85C is highly expressed in the 
cerebellum and is thought to play an important role in cortical development, therefore it is a 
potentially interesting neurological target (Mori et al., 2012; Uhlen et al., 2015). 
Common antigens were also identified using 384 planar arrays, where six CSF samples were 
included per disease group (Fig. 4.4D). Zinc finger protein 488 (ZNF488) is an 
oligodendrocyte-specific transcriptional regulator important for the maturation of 
oligodendrocytes, and its depletion leads to myelin gene downregulation and subsequent 
impairment of myelination (Wang et al., 2006). Other common targets included mitochondrial 
proteins, such as IFI27, PGAM5 and Acyl-CoA dehydrogenase family member 9, 
mitochondrial (ACAD9), and proteins involved in apoptosis, such as IFI27 and BCL10. Of 
note, increased PGAM5 activity was previously observed in MS serum compared to OND 
controls (Ayoglu et al., 2013; Ayoglu et al., 2016). The presence of autoantibodies against 
such proteins is suggestive of their increased abundance; many of these proteins are not 
normally accessible to antibodies as they are located intracellularly, but accumulation of dead 
cells following tissue damage and inflammation may lead to their release.  
 
 4.3.3 Identification of several antigens with potential relevance 
to MS pathology  
In addition to identifying several common antigens using planar arrays, several CNS-
associated proteins were identified (Fig. 4.2C). The nature of these targets may provide clues 
as to the pathological processes underpinning antibody-mediated damage in MS. 
Neuropeptide W (NPW) is a brain-associated antigen that is highly expressed throughout the 
CNS and is thought to play a role in energy homeostasis; its depletion may contribute to 
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dysregulation and energy failure, and is a potential mechanism of axonal injury (Takenoya et 
al., 2012; Haider, 2015). In this chapter, reactivity was also observed towards FBJ murine 
osteosarcoma viral oncogene homolog B (FOSB) in pooled RRMS CSF. FOSB is a proto-
oncogene which has previously been identified as part of an autoimmunity signature due to its 
involvement in regulating the matrix metalloproteinase (MMP) pathway by activating tissue 
inhibitor of metalloproteinase-1 (TIMP-1); its dysregulation contributes to enhanced 
lymphocyte trafficking through the BBB and promotes tissue destruction in the CNS (Botelho 
et al., 1998; Mandel et al., 2004; Mirshafiey and Kianiaslani, 2013). Increased reactivity was 
also observed towards phosphomannomutase-1 (PMM1); this glycosylation factor is 
upregulated in the MS brain, particularly in acute lesions compared to chronic active lesions, 
therefore its over-abundance may lend itself to becoming an autoimmune target (Tajouri et al., 
2003). Another interesting target was syntaphilin, released as a stress-response to prohibit 
mitochondria transport and provide a stable source of adenosine triphosphate (ATP) for 
neurons; accordingly, syntaphilin is increased in MS brains, therefore, autoantibody-mediated 
depletion of this molecule may contribute to loss of compensatory mechanisms employed to 
preserve CNS function in MS (van den Berg et al., 2017; Mahad et al., 2009). Finally, 
reactivity towards the chloride channel ANO2 was observed on both planar and suspension 
bead arrays (Fig. 4.2C, Fig. 4.16A). A study analysing the reactivity of 2,169 plasma samples 
to 11,520 antigens demonstrated differential reactivity in MS towards ANO2, which was also 
associated with HLA-DRB1*15, and was present in MS brain tissue (Ayoglu et al., 2016). Its 
localisation on the cell membrane makes it freely accessible for autoimmune attack and its 
fundamental role in olfactory transduction may underpin the high frequency of olfactory 
dysfunction in MS, in which 70% of post-mortem olfactory bulbs show evidence of 
demyelination (Stephan et al., 2009; Pifferi et al., 2012; DeLuca et al., 2015). Consistent with 
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this, various olfactory family members, including OR10AG1 and OR1L3, were also identified 
as MS-associated autoimmune targets during the planar array screen, suggesting 
autoantibody-mediated damage as a contributor to olfactory dysfunction (Fig. 4.1A, Fig. 
4.2C).  
 
4.3.4 Strong reactivity of EBNA-1 using the suspension bead arrays  
Following on from the broad exploration using planar arrays, suspension bead arrays were 
employed to interrogate candidate autoantigens in MS, which were selected based on findings 
from the planar arrays in addition to a literature search (see Appendices IV and V). CSF 
reactivity of six CIS samples on both 21k planar arrays (Fig. 4.1) and the anti-human IgG 
suspension bead array (Fig. 4.11) identified comparable positive hits across both technologies, 
confirming the reproducibility of the suspension bead arrays. Additionally, the recognition of 
almost identical antigens by repeat CSF samples from two individuals using the suspension 
bead array confirmed this technical reproducibility (Fig. 4.12). These findings also offer an 
insight into the kinetics of the humoral response in MS, which are particularly striking 
considering the long duration between LPs (62 days and 418 days respectively); this not only 
indicates a level of stability in the antigens recognised over time, but also suggests very slow 
evolution of the humoral response in at least some individuals (Fig. 4.12). Considering that a 
broad antibody response is already established at the time of CIS, it therefore appears likely 
that at this stage, the humoral response has already been in progress for many years before the 
onset of clinical symptoms.   
Comparison of the number of positive hits identified across individual samples using the 
suspension bead arrays showed a high level of variation, regardless of the disease group, and 
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appeared to show little distinction between disease groups (Fig. 4.14A). When these samples 
were grouped according to their disease categorisation, significantly increased reactivity was 
observed in CIS compared to OND using the anti-Ig detection antibody, but apart from this, 
little difference was observed overall (Fig. 4.14B). This contrasts with the planar arrays, 
which showed a clear distinction between disease groups, and suggests a limitation of the 
bead array technology. It is possible that the bead arrays were subjected to higher levels of 
non-specific antibody binding due to their overnight incubation with CSF, compared to the 2-
hour incubation using planar arrays. It may also have been the case that most of the 301 
antigens used in the suspension bead arrays did not allow enough distinction between MS and 
control groups, whereas the higher number of antigens used in the planar arrays allowed 
greater differences to be observed. Although steps were performed to optimise the assay (Fig. 
4.6 – 4.8) and to eliminate bead IDs with low counts (Fig. 4.9, Fig. 4.10), time limitations 
prevented further exploration of this issue.  
Despite the apparent lack of differential reactivity between MS and control groups using the 
suspension bead arrays, identifying the top reactive antigens allowed for their more detailed 
investigation as potential autoantigens. Almost every positive hit identified by CSF IgG was 
also identified by Ig and Igantibodies, since targets identified by IgG (Fig. 4.15A) were 
also collectively identified by Ig and Igantibodies (Fig. 4.15B, C). This suggests that most 
CSF antibodies are IgG, as the Ig and Igantibodies would also represent targets identified 
by other heavy chain specificities. For the top reactive antigens recognised using suspension 
bead arrays, some were also identified as potential autoantigens using the planar arrays, such 
as CCDC85C and QTRT1, and interestingly, some antigens were preferentially recognised by 
Ig, whereas others were preferentially recognised by Ig (Fig. 4.15). Although the presence 
of a broad antibody repertoire is clear, the strongly Ig-biased repertoire in MS CSF suggests 
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that one or more of the antigens preferentially recognised by Ig may be specific MS 
autoantigens.  
EBV is the strongest infectious agent linked to MS pathogenesis. Anti-EBNA-1 antibodies are 
elevated in MS serum and CSF compared to controls, and increased EBNA-1 reactivity of MS 
antibodies has been widely demonstrated in other antigen array studies (Santiago et al., 2010; 
Nociti et al., 2010; Lindsey et al., 2010; Hecker et al., 2016; Ayoglu et al., 2016). In this 
chapter, EBNA-1 was by far the most frequently identified of the 301 candidate autoantigens 
analysed using the suspension bead arrays; this was true using the anti-IgG detection antibody 
(Fig. 4.16) and the anti-Ig and anti-Ig antibodies (data not shown). This has also been 
shown by other antigen array studies, such as by Hecker et al, who identified EBNA-1 as the 
strongest candidate autoantigen using arrays hosting 3,991 peptides; importantly, these 
peptides were not synthesised by the HPA, demonstrating reproducible findings with different 
technologies (Hecker et al., 2016; Ayoglu et al., 2016).  
CSF IgG from all MS groups was significantly higher than the OND group, however, the lack 
of a significant difference over ONID controls indicates a degree of elevated EBNA-1 
reactivity during inflammation. This may be due to the exaggerated inflammatory activity in 
the CNS; a significant proportion (up to 2%) of the peripheral lymphocyte pool is specific for 
EBV, and broad antibody repertoires are a common feature of inflammatory neurological 
conditions, where around 80% of intrathecal antibody is not specific for the causative agent 
(Bonnan, 2014; Hatton et al., 2014). Nevertheless, the frequency of EBNA-1 positive CSF 




The distinctions between MS and controls are not dramatic because EBV seropositivity in the 
general population is 80-95%, but is thought to be present in over 99%, if not 100%, of those 
with MS (Pakpoor et al., 2013; Burnard et al., 2017). This increased EBV prevalence of 
around 20% in MS compared to controls is comparable to findings from this chapter, albeit 
with a slightly lower sensitivity using the arrays, since the average frequency in all MS groups 
was 95.4% compared to 74.7% in the OND group (Fig. 4.16C). These comparable frequencies 
to those in the literature demonstrates the reliability of these arrays and, importantly, implicate 
the involvement of EBV in MS. Unfortunately, however, these findings do not confirm that 
the elevated anti-EBNA-1 antibodies in MS are CSF-derived; as serum titres to EBNA-1 are 
elevated in MS, the lack of matched serum samples in this chapter means that the source of 
this elevated CSF reactivity cannot be confirmed. It therefore cannot be ruled out that the 
elevated anti-EBNA-1 antibody titre in the CSF is serum-derived, particularly under 
inflammatory conditions when the BBB may be compromised.  
 
 4.3.5 The Igbias in relation to antibody reactivity 
A key question of this thesis was whether the Ig:Ig FLC ratio has relevance to MS 
pathogenesis. In this study it was postulated that the level of bias could reflect the extent of 
oligoclonality, with a low bias reflecting a broader range of antigen specificities, indicative of 
disease progression, and a high bias reflecting a restricted antibody response. Despite the 
large variations between individuals within each disease classification, comparable levels of 
antibody reactivity were observed in both CIS and RRMS using planar arrays (Fig. 4.2A, Fig. 
4.4A). The similar antigen reactivity between Ig-biased CIS CSF and unbiased RRMS CSF 
suggests that at diagnosis, the humoral response is well-developed and features multiple 
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antigen targets recognised by antibodies bearing both Ig and Ig The similar level of 
reactivity between CIS and RRMS on 21k planar arrays was confirmed by demonstrating a 
significant correlation between antigen reactivity and CSF FLC concentration (Fig. 4.4B), and 
therefore antibody concentration; this confirms that increased antibody synthesis, for example 
during inflammation, leads to more diverse antigen recognition by CSF antibodies. As CSF 
FLC are prognostic indicators of disease severity, with increased levels predicting CIS 
conversion to MS and correlating with disability accumulation, its association with the 
number of antigen targets recognised by MS CSF suggests that the latter is also pathologically 
relevant (Makshakov et al., 2015). The relationship between total FLC and positive hits was 
not reproduced using suspension bead arrays (Fig. 4.13A), which was likely due to technical 
issues causing a lack of distinction between MS and control samples, as discussed.  
In addition to the clear relationship between FLC concentration and antibody reactivity, these 
arrays appeared to demonstrate some relationship between the number of hits and the FLC 
ratio (Fig. 4.4C). This is in contrast to what was expected, since increased antigen reactivity 
has been shown to relate to disease progression, and it would be hypothesised that CSF with a 
high Ig:Ig ratio would have fewer antibody specificities as this is related to a less severe 
disease course (Quintana et al., 2014; Rathbone et al., 2018). However, the comparison 
between the Ig:Ig FLC ratio and antibody reactivity may have been obscured by the 
misrepresentation of total antibody reactivity on the arrays; i.e. it is unlikely that every single 
antibody reactivity in the CSF will be represented on these arrays, so any differential antibody 
reactivity may not be accurately represented. Additionally, the analysis was performed on 
small sample sizes and may have been skewed by one CSF sample with a particularly high 
Ig ratio, since removal of this sample causes loss of significance. As this question has never 
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before been investigated, further work is required to elucidate the antigen reactivities of CSF 
samples with high and low ratios.   
In addition to MS, biased light chain usage is a feature of several autoimmune conditions 
including Hashimoto thyroiditis, Sjögren’s disease and rheumatoid arthritis, implicating an 
Ig or Ig preference in autoantibody formation (Chen et al., 2006; Nakayama et al., 2012; 
Gottenberg et al., 2007; Barnridge et al., 2014). In this chapter, several antigens were 
identified that preferentially induce an Ig-biased antibody response (Fig. 4.18, 4.19). This 
analysis was performed by calculating the ratio between the Ig MFI and Ig MFI for each 
antigen. For the top antigens inducing an Ig-biased response, increasing levels of kappa-
bearing antibodies was generally associated with a proportional increase in lambda-bearing 
antibodies, suggesting that the kappa bias towards these antigens could represent a biological 
phenomenon rather than pathological monoclonal expansion (Fig. 4.19B). The strongest bias 
identified was towards EBNA-1 at a median ratio of 8.5:1 in all MS groups; however, the 
kappa bias towards EBNA-1, and several other antigens, was also observed in controls (Fig. 
4.18, Fig. 4.19). Although the peripheral blood Ig:Ig ratio is approximately 1.6:1 in favour 
of Ig, light chain bias in healthy donors has been observed towards certain antigens, 
particularly small antigens with limited epitopes (Perez-Andres et al., 2010; Smith et al., 
2016). Indeed, this has been shown to be the case for EBNA-1 reactivity in the serum of 
healthy donors, which has a median ratio of 7.6:1 (Smith et al., 2016). This bias is considered 
to be caused by reactivity towards a highly antigenic part of the protein which carries a 
glycine-alanine repeat domain (Rumpold et al., 1987). Despite the significant hindrance of 
antibody diffusion into the brain, at least in part due to the widespread distribution of high 
affinity neonatal Fc receptors (FcRn), normal CSF contains a very low but detectable 
concentration of passively transferred serum-derived antibodies under physiological 
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conditions (Okun et al., 2010; Wolak et al., 2015; Diamond et al., 2013). This is also 
supported by the scarcity of CSF B cells and ASC in OND CSF, as identified by ourselves 
and others, which is indicative of these antibodies being peripherally derived (Cepok et al., 
2005a; Kuenz et al., 2008). Therefore, the kappa bias towards certain antigens in OND is 
likely a physiological phenomenon which would have been observed in the serum; this is in 
conjunction with the overall CSF FLC Ig:Ig ratio in OND controls being closely related to 
the serum FLC ratio (Perez-Andres et al., 2010). In conclusion, the widely reported IgFLC 
bias in MS CSF is likely a consequence of B cell activation and expansion towards an antigen 
with limited epitopes, and it remains possible that one or several kappa bias-inducing 
antigen(s) identified in this chapter is responsible for the increased IgFLC in MS CSF (Fig. 
4.19). 
 
4.3.6 Technical considerations  
Despite the identification of several antigens with potential relevance to MS pathogenesis, this 
study, and many others, have failed to identify a single unifying autoantigen linked to MS. 
Even if such antigen does not exist, discrepancies in the literature regarding other antigens, 
notably the classic MS autoantigens of the myelin sheath, are widespread. Data in this chapter 
did not identify any significant differential reactivity towards MBP or MAG proteins in MS, 
despite the elevated reactivity in some samples (Fig. 4.17). Other microarray studies have 
shown contrasting evidence for antibody reactivity towards myelin proteins; notably, while 
Ayoglu et al (2013) did not observe preferential binding by MS antibodies, Hecker et al 
(2013) observed significantly elevated reactivity in MS compared to OND (Hecker et al., 
2016; Ayoglu et al., 2013). Inconsistencies throughout published literature may be partly due 
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to the source and format of the antigens used. Antigens produced in bacterial expression 
systems, such as E. coli as in this study, are not subjected to the same range and complexity of 
post-translational modifications as in eukaryotic cells and their structure may not be 
sufficiently representative of the native form to allow autoantibody binding. Additionally, 
protein modification may occur spontaneously or in response to environmental triggers, such 
as inflammation, and may alter various aspects of protein structure and function which may 
subsequently alter protein antigenicity (Doyle and Mamula, 2012). For example, MBP 
ordinarily contains several post-translational modifications, and aberrant post-translational 
modifications in MBP from MS brains has been identified; in addition, studies have 
demonstrated that MOG reactivity is conformation dependent, requiring correct folding for 
antibody binding (Kim et al., 2003; Harauz et al., 2009; Zhang et al., 2012; O'Connor et al., 
2007; Menge et al., 2011). As such, autoantibodies towards modified antigens may not be 
identified using this approach.   
In addition to these considerations, protein length may also affect the outcome of these assays. 
Different antibody reactivity to full-length proteins and protein fragments was observed in a 
study using the same antigens and planar array platform as in this chapter (Sjoberg et al., 
2016). The antigens used this chapter were 25-150 amino acids long (average length of 80) 
and thus do not necessarily represent the full length native protein. Therefore, protein folding 
may be altered, and normally exposed epitopes may be hidden, or normally hidden epitopes 
may be exposed. Conformational epitopes, comprising discontinuous amino acid sequences 
brought together by protein folding, make up most epitopes recognised by antibodies and 
could also be disrupted, which could potentially abrogate antibody binding (Barlow et al., 
1986; Sivalingam and Shepherd, 2012). Therefore, many technical aspects must be considered 
in the interpretation of array data.   
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4.4 Chapter Summary 
This chapter confirmed that the intrathecal antibody response in MS is highly variable within 
and between disease subtypes. Whether the antibody response in early MS is more restricted 
than in those with established disease still remains to be elucidated, since there was no 
apparent difference in antibody reactivity between CSF with a high Ig:Igratio and a low 
Ig:Igratio. However, this relies on the assumption that all CSF antibody reactivities are 
represented on these arrays, which may not be the case considering the technical limitations of 
this technology, and requires further investigation.  
Importantly, this chapter identified several common candidate autoantigens in MS, and also 
identified several antigens of potential relevance to MS pathology. The strongest antigen 
recognised was EBNA-1, which in combination with its elevated frequency in MS compared 
to control groups, and its preference for inducing Ig-bearing antibodies, could mean it is at 
least partly responsible for inducing the FLC Ig:Igbias in MS CSF.  
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Chapter 5: Investigation of the phenotype and function of CD20+ 
T cells in multiple sclerosis and controls 
5.1. Introduction 
CD20 is a highly conserved cell-surface phosphoprotein identified in 1980 as one of the first 
human B cell markers (Stashenko et al., 1980; Tedder and Engel, 1994). CD20 belongs to the 
membrane-spanning 4 domains, subfamily A (MS4A) family of molecules and contains four 
transmembrane regions which form multimeric complexes on the cell surface (Tedder and 
Engel, 1994; Liang et al., 2001). This molecule is expressed at high levels by over 95% of B 
cells, and is present from the pre-B cell stage up until their terminal differentiation into ASC 
(Klein et al., 2013). The widespread expression of CD20 has led to its use as a highly 
effective therapeutic target in MS, with a single course of rituximab inducing rapid and 
complete depletion of peripheral CD20+ B cells, leading to a significant reduction in relapses 
and brain lesions (Hauser et al., 2008). Rituximab mediates a significant reduction (90%) in 
CSF B cells, though intriguingly, there is also a marked reduction (55%) in CSF T cells 
(Cross et al., 2006). Moreover, in EAE, a largely T cell-mediated disease, rituximab 
administration ameliorates disease in transgenic mice expressing human CD20 (Monson et 
al., 2011).  
The identification of T cells expressing CD20, and the findings that these cells are skewed 
towards a pro-inflammatory memory phenotype, has led to their investigation as a possible 
pathogenic subset in several diseases (Hultin et al., 1993; Wilk et al., 2009, Palanichamy et 
al., 2014b; de Bruyn et al., 2015; Alunno et al., 2016). The depletion of these cells by 
rituximab in rheumatoid arthritis and MS, followed by improved clinical features, implies a 
153 
 
possible link with disease (Wilk et al., 2009; Palanichamy et al., 2014b; Alunno et al., 2016). 
Reports on the frequency of these cells in the blood of those with MS are contradictory, with 
one study reporting elevated frequencies in MS, and others reporting similar frequencies to 
OND controls (Palanichamy et al., 2014b; Holley et al., 2014; Schuh et al., 2016). In addition, 
Th17-like characteristics of CD20+ T cells have been reported by some (Eggleton et al., 2011; 
Holley et al., 2014) but not others (Wilk et al., 2009; de Bruyn et al., 2015).  
The question of how CD20+ T cells acquire CD20 has been investigated previously, with 
conflicting results. Data exists for the expression of CD20 mRNA by these cells, however 
another study suggested that CD20 is acquired through trogocytosis; the transfer of cell 
membrane fragments, including surface molecules, to other cells following interaction (Wilk 
et al., 2009; Palanichamy et al., 2014b; Schuh et al. 2016; de Bruyn et al., 2015). Therefore, 
further investigation into this elusive subset is required to further understand their biology and 
potential role in disease.  
Based on the hypothesis that CD20+ T cells are a pro-inflammatory population which are 
present in MS CSF, I sought to first investigate the phenotype and frequency of CD20+ T 
cells in MS and control groups in both the peripheral blood and CSF. The functional aspects 
of CD20+ T cell biology were investigated to ascertain any possible functions in disease 
pathogenesis by culturing purified CD20+ and CD20- T cells from healthy subjects. 
 
5.1.1. Chapter Objectives 
1. Confirm the phenotype of CD20+ T cells in the blood of healthy donors 
2. Investigate the frequency of CD20+ T cells in CSF and blood from MS and OND 
groups and determine their phenotype using a selection of markers  
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3. Investigate the proliferation and survival of sorted CD20+ T cells from healthy 
subjects in vitro 
4. Determine expression of selected surface and intracellular markers  
5. Determine whether CD20+ T cells possess cytotoxic function  
6. Investigate the antigen specificity of CD20+ T cells using tetramers containing 
common viral peptides    
 
5.2 Results 
5.2.1 Identification of CD20+ T cells in the peripheral blood  
A gating strategy was established to identify CD20+ T cells within T cell subsets. Because of 
interference with compensation, which can cause problems particularly when identifying rare 
cells, a CD4+ antibody was omitted from the panel and CD8- T cells were gated on as an 
equivalent subset. Although this was not necessarily ideal, it was preferable to prioritise the 
identification of CD20+ T cells. After gating on CD3+ viable lymphocytes, and CD8+ or 
CD8- T cells, CD45RA and CCR7 antibodies were used to gate naïve (CCR7+CD45RA+), 
central memory (CM; CCR7+CD45RA-) and effector memory (EM; CCR7-CD45RA-) 
subsets for the CD8- fraction, and naïve, CM, EM and revertant effector memory (EMRA; 
CCR7-CD45RA+) for the CD8+ fraction (Fig. 5.1A). Although CD4+ EMRA cells do exist, 
their frequencies were far too low to reliably identify CD20+ T cells from this subset (Moro-

















Figure 5.1 Gating strategy to identify CD20+ T cells within T cell subsets. Gating strategy
for determination of naïve (CCR7+CD45RA+), central memory (CM; CCR7+CD45RA-),
effector memory (EM; CCR7-CD45RA-) and revertant effector memory (EMRA; CCR7-
CD45RA+) T cell subsets within CD8- and CD8+ compartments (A). Gated on viable CD3+
lymphocytes with doublet exclusion. Gating strategy from a representative sample showing
CD20+ T cell frequencies in CD8- (B) and CD8+ (C) T cell subsets, and isotype control
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Figure 5.2 CD20+ T cells are enriched in memory T cell subsets in the peripheral
blood of healthy subjects. Percentage of CD20+ T cells within CD8- (A) and CD8+ (B)
T cell subsets. Data are significant to ** (P<0.01) and *** (P<0.01) using Dunn’s






























































CD3 was plotted against CD20 to identify CD20+ T cells in CD8- (Fig. 5.1B) and CD8+ 
subsets (Fig. 5.1C; upper panel of each Figure). An isotype control was used to set the gates 
at 0.5% positivity or less for each subset (lower panel of each Figure). Apart from CD20, 
where an isotype control was used, gates were set based on differential marker expression of 
each lymphocyte population.  
 
5.2.2 Frequency and stability of CD20+ T cell subsets in healthy 
subjects   
Using the gating strategy established in Figure 5.1, the frequency of CD20+ T cells using 
PBMC from healthy subjects was assessed. Within the CD8- population (Fig. 5.2A), CD20+ 
T cells were significantly increased in CM (2.5%) and EM (4.9%) subsets compared to the 
naïve subset (0.7%). A similar trend was observed in the CD8+ population (Fig. 5.2B), with 
CD20+ T cells preferentially exhibiting a CM (15.9%), EM (13.2%) and to a lesser extent 



























Figure 5.3 CD20+ T cells co-express CD3 and CD20 at the mRNA and protein level.
Sorted CD20+ T cells and CD20- T cells were analysed for their expression of CD20 by
qPCR in comparison to B cells (A). CD20 expression was normalised to the housekeeping
gene, GAPDH. Comparisons were not significant using Dunn’s multiple comparisons test
(n=2). Relative intensities of CD3 (B) and CD20 (C) expression determined by flow
cytometry. Data are significant to * (P<0.05) and *** (P<0.001) using Dunn’s multiple












































































































































Figure 5.4 Peripheral blood CD20+ T cell frequencies are stable in vivo across a
prolonged time period. Longitudinal analysis of CD20+ T cell frequencies within CD8- (A)


























































































































































































In addition to characterising their subset distribution, longitudinal assessment of the frequency 
of CD20+ T cells was achieved by repeat sampling from four donors (Fig. 5.4A, B). For both 
CD8- and CD8+ populations, their frequencies appeared to be relatively consistent with time. 
In addition to quantifying CD20+ T cells in the blood of healthy donors, their characteristics 
were also investigated. CD20 mRNA was detected for CD20+ T cells but not CD20- T cells, 
with around 80-85% less CD20 mRNA than in B cells; however, these findings were not 
significant, probably due to lack of replicates (Fig. 5.3A). Using the gating strategy from Fig. 
5.1, MFI values were obtained for CD3 and CD20, using CD20- (conventional) T cells and 
CD20+ B cells as a comparison. Comparable levels of CD3 was identified in both T cell 
subsets, which was significantly higher than CD20+ B cells, confirming the T cell nature of 
these cells (Fig. 5.3B); conversely, elevated CD20 expression was observed in CD20+ T cells 
compared to CD20- T cells, which was also lower than B cells (Fig. 5.3C).  
 
5.2.3 CD20+ T cells are present in the CSF of both MS and OND 
groups    
Matched peripheral blood and CSF was obtained from MS and OND groups (see Appendix 
III for demographics). The presence of CD20+ T cells and their subset distribution in 
matched blood and CSF is shown from a person with MS (Fig. 5.5A). This was subsequently 
quantified and compared to the subset distribution of CD20- T cells, and was calculated as the 
percentage of CD20+ or CD20- T cells within each major CD8- or CD8+ T cell subset (Fig. 
5.5B). Compared to CD20- T cells, peripheral CD20+ T cells were significantly over-
represented in the effector memory compartments and reduced in the naïve compartments in 
both CD8- and CD8+ subsets. For the CD8- subset, the effector bias in CD20+ T cells was 
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also observed in the CSF, where CD20- T cells displayed a central memory bias (Fig. 5.5B). 
No significant differences in subset distribution between CD20- and CD20+ T cells were 
observed for CD8+ cells in the CSF. 
The CD4:CD8 ratio represents the level of CD8 bias in a T cell population. In the peripheral 
blood, CD20- T cells were heavily biased towards CD8- (70.3% vs 28.2%), whereas CD20+ 
T cells displayed a CD8+ bias (41.7% CD8- vs 55.6% CD8+) (Fig. 5.5C). These findings 
were extended to the CSF, where the CD8- bias was retained for CD20- T cells, and the 








Figure 5.5 Identification of CD20+ T cells in the CSF. Representative gating strategy
showing subset distribution of CD20- and CD20+ T cells in the blood and CSF of MS and
OND groups (A). Tukey box and whisker plots showing the distribution of CD20- and
CD20+ T cells in naïve, central memory, effector memory and revertant effector memory (for
CD8+ T cells only) populations in the peripheral blood and CSF of OND and MS groups (B).
Data are significant to * (P<0.05), ** (P<0.01) and *** (P<0.001) using Mann-Whitney test
(n=12-13). Ratio of CD8- and CD8+ T cells for CD20- and CD20+ subsets in the blood and


















































































































































































































































































































































Figure 5.6 Frequency of CD20+ T cells within each T cell subset in the CSF and
peripheral blood of MS and OND disease groups. Tukey box and whisker plot showing
the frequency of CD20- and CD20+ T cells in the blood (A) and CSF (B) of MS and OND





















































































































In this chapter, the frequency of CD20+ T cells within each T cell subset was determined for 
both OND and MS groups (Fig. 5.6). Within the peripheral blood, there was no significant 
difference in the frequency of CD20+ T cells between MS and OND groups for both CD8- 
and CD8+ subsets (Fig. 5.6A). There was also little difference in the CSF, although OND 
CSF appeared to have a higher frequency of CD20+ T cells than MS CSF (Fig. 5.6B).  
 
5.2.4 CD20+ T cells express elevated IFN and CCR6 in the CSF 
Since CD20+ T cells in the CSF have not previously been phenotypically characterised, at 
least not in MS, it was investigated whether these cells might possess Th17-like features or 
other pro-inflammatory features. Intracellular cytokine (IFN and IL-17) and CCR6 
expression was assessed following 3 hours of ex vivo stimulation with PMA and ionomycin in 
the presence of brefeldin A. Marker expression was then analysed for total memory (TCM, TEM 
and TEMRA) cells within both CD20- and CD20+ T cell subsets.  
Elevated IFN expression was observed in peripheral CD8-CD20+ T cells in both OND and 
MS groups (Fig. 5.7A). In the CSF, IFN expression was increased in all cell populations and 
was again significantly elevated in CD20+ T cells in both MS and OND groups. Within the 
CD8+ T cell population, CD20+ T cells also secreted significantly elevated IFN in the 
peripheral blood and CSF of both MS and OND groups (Fig. 5.7B). In the CSF, virtually all 
CD8+CD20+ T cells expressed IFN. 
Very little IL-17 secretion was observed in CD20- or CD20+ T cells in the blood and CSF of 
MS and OND groups, though some high IL-17-secreting cells were observed (Fig. 5.8A, B). 
Within the CD8- compartment, no differential CCR6 expression in CD20- or CD20+ T cells 







Figure 5.7 CD20+ T cells express higher levels of IFNγ in the blood and CSF.
Representative flow plots and Tukey box and whisker plots showing the expression of IFNγ
in total memory CD20- and CD20+ T cells in CD8- (A) and CD8+ (B) subsets for MS and
OND groups. PBMC were stimulated for 3 hours with PMA and ionomycin. Data are
significant to * (P<0.05), ** (P<0.01) and *** (P<0.001) using Mann-Whitney test (n=6-7
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Figure 5.8 IL-17 expression in CD20+ T cells in the blood or CSF. Representative flow
plots and Tukey box and whisker plots showing the expression of IL-17 in total memory
CD20- and CD20+ T cells in CD8- (A) and CD8+ (B) subsets for MS and OND groups.
PBMC were stimulated for 3 hours with PMA and ionomycin. No significant comparisons
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Figure 5.9 CD20+CD8+ T cells in the CSF express higher levels of CCR6 than in the
peripheral blood. Representative flow plots and Tukey box and whisker plots showing the
expression of CCR6 in total memory CD20- and CD20+ T cells in CD8- (A) and CD8+ (B)
subsets for MS and OND groups. PBMC were stimulated for 3 hours with PMA and
ionomycin. Data are significant to ** (P<0.01) using Mann-Whitney test (n=6-7 samples per
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CD8+ T cells; however in the CSF, CD20+ T cells displayed significantly elevated CCR6 
expression in both MS and OND groups (Fig. 5.9B). 
5.2.5 CD20 is maintained by CD20+ T cells in culture, but is 
downregulated in the presence of PBMC 
The features of CD20+ T cells were investigated with a series of in vitro assays. Because 
CD20+ T cells are enriched within the CD8+ memory pool, CD8+CD20+ T cells were 
focussed on for these assays. Prior to cell sorting, the CD8+ memory preparation was 
enriched by first passing PBMC through a magnetic negative selection column and collecting 
the negative fraction (Fig. 5.10A). This fraction was then cell sorted, with CD8+, CD45RA- 
and CD20+ gates applied, and CD20- and CD20+ subsets collected (Fig. 5.10B). Analysis of 
CD20 expression immediately post-sort identified 79% positivity in the CD20+ subset (Fig. 
5.10C). 
To assess the stability of CD20 expression over a 4-day period, Cell Proliferation Dye-stained 
CD20+ T cells were cultured with or without Dynabeads® Human T-Activator CD3/CD28 
beads, or soluble tetrameric antibody (ImmunoCult™) to mimic physiological T cell 
activation, which was compared to CD20- T cells. CD20+ T cells maintained expression of 
CD20 for 4 days, regardless of whether they were unstimulated (77.7%) or stimulated via 
CD3/CD28 (Dynabeads® 75.8%, ImmunoCult™ 82.8%) (Fig. 5.11A, B). In the presence of 
PBMC, a significant reduction in CD20 expression was observed in all conditions 
(unstimulated 46.5%, Dynabeads® 38.2%, ImmunoCult™ 38.9%). Despite this reduction, 
CD20 was still maintained at significantly higher levels than CD20- T cells. CD20- T cells 





Figure 5.10 Isolation of peripheral CD20+ T cells from healthy subjects for in vitro
assays. Following enrichment of CD8+ memory T cells using magnetic bead isolation (A),
cells were subjected to fluorescence activated cell sorting (FACS) to isolate CD20+ and
CD20- T cell populations (B). Blue arrows represent gating. CD20 expression of sorted





























































Figure 5.11 CD20+ expression by CD20+ T cells is maintained in culture, but is
downregulated in the presence of PBMC. CD20 expression on CD20- (blue) and CD20+
(purple) cells, in the presence or absence of PBMC, was assessed after 4 days with or without
stimulation (A, B). CD20 expression on undivided and divided cells within each T cell
population, cultured in the presence of PBMC (C, D). CD20 expression on PBMC following
T cell culture (E). Data were significant to ** (P<0.01) and *** (P<0.001) using Bonferroni
test and show the mean  SEM (n=3 independent donors, duplicate wells). All other
comparisons were not significant. Gates were set to 1% positivity on unstimulated or
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increase in CD20 expression, particularly following stimulation (unstimulated 2.9%, 
Dynabeads® 8.8%, ImmunoCult™ 18.3%), however, this was not significant.  
To investigate whether CD20 was specifically being lost by proliferating cells, CD20 
expression was determined for undivided and divided cells following stimulation (Fig. 5.11C, 
D). This was achieved by gating on Cell Proliferation Dye-high cells (undivided) and on those 
that had lost Cell Proliferation Dye following proliferation (divided), then determining CD20 
expression for each population. Undivided CD20+ T cells retained significantly higher CD20 
expression than undivided CD20- T cells, however following proliferation, induced by either 
Dynabead® or ImmunoCult™ stimulation, CD20 was reduced by CD20+ T cells and 
increased by CD20- T cells (Fig. 5.11D). As such, no significant differences in CD20 
expression were seen between CD20+ T cells and CD20- T cells following proliferation.  
Finally, CD20 expression was investigated on PBMC following co-culture with sorted CD20- 
T cells and CD20+ T cells. This showed no significant differences in CD20 expression by 
PBMC for each condition (Fig. 5.11E).  
 
5.2.6 CD20+ T cells display diminished proliferative capacity  
The proliferative capacity of CD20+ T cells was assessed by determining the percentage of 
cells that had lost Cell Proliferation Dye following 4 days of culture. Results showed that 
CD20+ T cells displayed significantly diminished proliferative capabilities compared to 
CD20- T cells after both Dynabead® stimulation (30.9% CD20- vs 17.5% CD20+) and 
ImmunoCult™ stimulation (71.1% CD20- vs 40.9% CD20+) in the presence of PBMC (Fig. 
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Figure 5.12 CD20+ T cells display diminished proliferative capacity. Following 4 days of
culture with or without anti-CD3/CD28 stimulation, CD20- and CD20+ T cells were assessed
for proliferation (A, B). Data are significant to *** (P<0.001) using Bonferroni test and show
the mean  SEM (n=3 independent donors, duplicate wells). All other comparisons were not
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5.2.7 Altered marker expression by CD20+ T cells   
By analysing the expression of several markers on total CD8- and CD8+ memory cells, some 
interesting differences were observed between CD20- and CD20+ T cells (Fig. 5.13). These 
markers were selected based on their involvement in cell activation, cytotoxicity, immune 
checkpoint inhibition and chemokine responsiveness. Because of the high over-representation 
of CD20+ T cells in the memory compartment, naïve cells were excluded from this analysis to 
allow like-for-like comparisons between memory CD20- and memory CD20+ T cells. Gates 
were set for each subset on isotype control/fluorescence minus one (FMO) samples, which 
were then applied to the full panel. Of note, there was a significant reduction in CD38 
expression in both CD8- and CD8+ CD20+ T cell subsets, and a significant reduction in 
granzyme B expression in CD8+CD20+ T cells. In addition, significantly elevated PD-1 
expression was observed in CD8- and CD8+ memory CD20+ T cells. Investigation of 
intracellular cytokine expression demonstrated elevated IL-4 secretion by CD8-CD20+ T 
cells, however no other comparisons were significant (Fig. 5.14). 
 
5.2.8 CD20+ T cells express elevated PD-1  
The novel observation of significantly elevated PD-1 expression by CD20+ T cells was 
further investigated. Using isotype control staining, PD-1 expression was determined for total 
CD8- and CD8+ memory T cells (Fig. 5.15A); this expression was compared to that of naïve 
T cells, which was very low in comparison (Fig. 5.15B). For both CD8- and CD8+ subsets, 
PD-1 expression was significantly increased, although this was not observed for the MFI 
values (Fig. 5.15C). On further analysis, PD-1 expression on central memory and effector 












Figure 5.13 Investigation of marker expression by CD20+ T cells. Expression levels of
selected markers were analysed for CD20- and CD20+ T cells within the CD8- memory and
CD8+ memory compartments. Cells were stained ex vivo except for CTLA-4 and FAS
ligand, which were first stimulated for 3h using PMA and ionomycin in the presence of
brefeldin A. Staining was intracellular for granzyme A, granzyme B, granulysin and CTLA-




Figure 5.14 Investigation of cytokine expression by CD20+ T cells. Following 3h
stimulation with PMA and ionomycin in the presence of brefeldin A, cytokine expression
was analysed by intracellular staining. Data are significant to * (P<0.05) using Mann-






Figure 5.15 Elevated PD-1 expression in CD20+ memory subsets. Representative flow
plots showing PD-1 expression in resting memory (A) and naive (B) T cells. Tukey box and
whisker plots showing PD-1 expression and MFI values in CD8- and CD8+ total memory T
cells (C) and memory T cell subsets (D). Data are significant to * (P<0.05), ** (P<0.01) and
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Figure 5.16 Expression of cytotoxic molecules by CD20+ T cells. Representative
frequency histograms of intracellular perforin, granzyme B, granzyme A, granulysin and
FASL expression by CD20- (blue) and CD20+ (purple) T cells (A). Isotype control staining
is shown in grey. N; naïve T cells. Tukey box and whisker plots showing percent
expression of cytotoxic molecules in CD20- and CD20+ T cells within central memory,
effector memory and effector memory RA compartments (B). Data are significant to *










































































































































however there was a significantly increased MFI when comparing central memory CD8- 
subsets (Fig. 5.15D). For CD8+ T cells, PD-1 expression was significantly elevated within 
each memory subset, with the strongest increase in the central memory compartment; this was 
also reflected by a significantly increased MFI for central memory CD20+ T cells but no 
other memory subset (Fig. 5.15D). 
 
5.2.9 CD20+ T cells retain cytotoxic potential despite diminished 
cytotoxic marker expression   
The CD8+ memory bias of CD20+ T cells warranted further investigation into the cytotoxic 
functions of these cells, therefore, the ex vivo expression of cytotoxic molecules was 
investigated. Perforin expression was generally increased in CD8- memory but decreased in 
CD8+ memory subsets (Fig. 5.16A). Overall, perforin expression appeared to be increased in 
CM (especially CD8-) but decreased in EM and EMRA subsets (Fig. 5.16A, B). Granzyme B 
(second column) and granulysin (fourth column) expression was decreased in CD20+ T cells, 
which for both markers was significant in CD8+ effector memory and EMRA subsets. 
Granzyme A expression (third column) appeared slightly elevated in central memory subsets, 
which was significant for CD8-CD20+ T cells, and the low levels of FasL (fourth column) 
failed to show any differences between CD20- and CD20+ subsets.  
Following the observation of perturbed cytotoxic molecule expression in CD20+ T cells, the 
ability of these cells to degranulate in response to PMA and ionomycin stimulation was 
assessed over a 3-hour time course (Fig. 5.17A, B). This assay was performed by stimulating 
total PBMC, with subsequent gating to identify CD20- and CD20+ T cells, and identification 
of degranulation was achieved by analysing intracellular perforin and surface CD107a, also  
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known as LAMP-1, a functional marker of degranulation (Alter et al., 2004). Both CD20- and 
CD20+ T cells showed decreased perforin expression over the time course, which was 
associated with a concomitant increase in surface CD107a by both subsets, which appeared 
higher in CD20+ T cells (Fig. 5.17A, B).  
 
5.2.10 CD20+ T cells are present within the EBV-specific CD8+ T cell 
compartment    
Because of the high seroprevalence of EBV infection in the general population, and its strong 
association with MS, the EBV specificity of CD20+ T cells was investigated by tetramer 
staining (Hatton et al., 2014). Using PBMC, gates were applied to CD3+CD8+ T cells, which 
were split based on CD20 expression, and tetramer positive gates were applied based on FMO 
staining (Fig. 5.18A). Reactivity towards GLC and YVL, two common EBV lytic cycle 
peptides, were then analysed in three HLA-A*02-positive donors (Fig. 5.18B). CD20+ T cells 
displayed clear reactivity for EBV, and interestingly, appeared to represent a higher frequency 
of tetramer positive cells than CD20- T cells; however, a larger number of donors would be 













Figure 5.17 CD20+ T cells express cytolytic granules. Representative flow plots of perforin
and CD107a expression at 0 hours and 3 hours post-stimulation with PMA and ionomycin
(A). Kinetics of intracellular perforin and surface CD107a expression of memory T cells with
(purple) and without (blue) CD20 expression (B). Mean values  standard deviation (n=4).
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Figure 5.18 CD20+ T cells are present within the EBV-specific CD8+ T cell
compartment. Representative gating strategy to determine the frequency of EBV-specific T
cells, and comparison with FMO (A). From total viable lymphocytes with doublets
excluded, CD3+CD8+ cells were divided into CD20- and CD20+ and then assessed for
tetramer positivity. Flow plots and quantification of the frequency of CD3+CD8+CD20- or
CD3+CD8+CD20+ T cells from healthy HLA-A*02-positive donors that show specificity
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Despite their initial description 25 years ago, there has been recent interest in CD20+ T cells 
due to their reported associations with several inflammatory conditions, including MS (Hultin 
et al., 1993; Palanichamy et al., 2014b). In conjunction with previous reports, data from this 
chapter confirmed the presence of a T cell population in the blood and CSF that co-express 
low levels of CD20, secrete elevated levels of pro-inflammatory cytokines and are over-
represented in the CD8 memory compartment.  
 
5.3.1 Identification and characterisation of CD20+ T cells 
In this chapter, a gating strategy was established that clearly identified CD20+ T cells within 
peripheral blood T cell populations (Fig. 5.1A-C). CD20+ T cells have been shown to express 
lower levels of CD20 than B cells, and are sometimes referred to as CD20dim, therefore a 
bright fluorochrome (PE or Bv421 depending on the panel) was used for their identification. 
Isotype control staining (Fig. 5.1C) revealed very little non-specific staining, indicating that 
the gated cells truly express CD20, which has previously been contested (Henry et al., 2010). 
The expression of CD20 by T cells has been investigated by others. In a co-culture assay with 
B cell and T cell lines, de Bruyn and colleagues (2015) found that CD20 was acquired by 
around 30% of T cells following a 1-hour incubation, which was also associated with 
acquisition of HLA-DR (de Bruyn et al., 2015). In contrast, a more recent report demonstrated 
that CD20+ T cells do not display HLA-DR, or any other typical B cell molecules, suggesting 
that trogocytosis is not the reason for CD20 expression by these cells (Schuh et al., 2016). In 
addition, other studies have demonstrated low but detectable levels of CD20 mRNA in 
CD20+ T cells (Wilk et al., 2009; Palanichamy et al., 2014b; Schuh et al., 2016). Findings 
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from this chapter agree with others that CD20+ T cells transcribe CD20 at the gene level, 
implicating de novo CD20 synthesis as the primary (if not only) mechanism by which these 
cells express CD20 (Fig. 5.3A).  
Although the validity of the CD20+ T cell population was previously challenged, with the 
suggestion they may be an artefact of flow cytometry, the equivalent levels of CD3 expressed 
by CD20+ and CD20- T cells confirmed the T cell nature of these cells (Henry et al., 2010). 
Additionally, despite the lack of significance, the mRNA data mirrored the level of CD20 
surface expression by CD20+ T cells compared to B cells, which was around a tenth lower, 
suggesting that the mRNA data is reliable (Fig. 5.3A-C). This also compares to published 
data, where CD20+ B cells carried 10-15-fold higher levels of CD20 mRNA than CD20+ T 
cells; further to this, the lack of CD19 mRNA in CD20+ T cells, as demonstrated by others, 
confirms that these are truly T cells (Wilk et al., 2009; Schuh et al., 2016).    
 
5.3.2 Frequency and stability of CD20+ T cell populations in healthy 
donors  
That only memory T cells express CD20 suggests that it could be acquired following 
activation, and its absence on naïve T cells demonstrates that this population do not inherently 
express CD20 throughout their lifespan (Fig. 5.2, Fig. 5.5). The lower frequency of CD20+ T 
cells in the CD8+ EMRA subset compared to central and effector memory subsets indicates 
that CD20 is not a feature associated with terminal T cell differentiation. That CD20+ T cell 
frequencies are preferentially higher in the CD8+ than the CD8- population supports the 
previously reported CD8+ memory bias in these cells, and point to a cytotoxic role for these 
cells (Wilk et al., 2009; Schuh et al., 2016). The relatively stable frequencies of CD20+ T 
184 
 
cells observed over 28 days indicates either stable expression over time, or continual 
induction under homeostatic conditions (Fig. 5.4). Taken together, these data suggest that 
CD20 is a physiological marker induced by a specific event occurring only in memory cells, 
but which can also occur in any other memory T cell subset, leading to a heterogeneous 
CD20+ T cell population. 
 
5.3.3 CD20+ T cell frequencies in MS and controls  
In the periphery, the CD8- (i.e. CD4+):CD8+ ratio showed that CD20- T cells were heavily 
biased towards CD8- at approximately 2:1 (Fig. 5.5C), agreeing with published data 
(McBride 2017). This also validates the gating strategy for identifying CD4+ T cells using a 
CD3+CD8- phenotype instead of a CD3+CD4+ phenotype. Similar ratios between CD8- and 
CD8+ subsets were observed in CD20+ T cells, agreeing with previous findings, and 
confirming the CD8+ T cell bias in this cohort of individuals (Wilk et al., 2009). Data from 
this chapter also identified CD20+ T cells in the CSF, where they retained their subset 
composition and CD8-:CD8+ ratio compared to CD20+ T cells in the periphery; this 
similarity could suggest the absence of selective CD20+ T cell recruitment into the CSF 
(since the populations are comparable to the periphery), or that the stimuli responsible for 
inducing CD20 expression on T cells is also present in the CSF (Fig. 5.5). The presence of 
CD20+ T cells in MS CSF has also been reported recently; furthermore, these cells have been 
identified in chronic white matter lesions in MS brain tissue but not in control tissue, 
suggesting that these cells may contribute to disease (Schuh et al., 2016; Holley et al., 2014).  
Previous reports on the frequency of CD20+ T cells in MS peripheral blood have been 
conflicting (Palanichamy et al., 2014b; Holley et al., 2014; Schuh et al., 2016). Though 
185 
 
overall frequencies as a proportion of total T cells was not performed in this chapter, as 
analysis within each subset was favoured to omit any potential subset bias between 
individuals, I observed CD20+ T cells at similar frequencies within T cell subsets for both MS 
and OND groups (Fig. 5.6A). This agrees with two previous studies, but disagrees with 
Palanichamy et al (2014b), who found that peripheral CD20+ T cells are increased in MS 
(7.2%) compared to OND controls (5.4%) (Palanichamy et al., 2014b; Holley et al., 2014, 
Schuh et al., 2016). Considering the lack of association in other studies, this small increase 
seen by Palanichamy et al (2014b) could be a statistical artefact caused by biological 
variation, or alternatively, may be correct; as such, further work with a larger sample size 
(these studies analysed 8-12 samples per group) may shed more light on this.  
In this chapter, CD20+ T cells were identified in the CSF of both OND and MS groups where 
the CSF frequency, particularly in the OND group, appeared higher than their peripheral 
blood counterparts (Fig. 5.6). Furthermore, the frequency of CD20+ T cells in OND CSF 
appeared increased compared to MS CSF, with a significant difference observed in the CD8+ 
effector memory subset (Fig. 5.6B). Interestingly, the only other study which has investigated 
the frequency of CD20+ T cells in the CSF reported similar findings, with almost double the 
frequency in OND versus MS; this may therefore suggest that these cells are not positively 
associated with disease pathogenesis (Schuh et al., 2016).  
 
5.3.4 Phenotype of CD20+ T cells in the CSF 
Although several reports describe these cells as pro-inflammatory, elevated IFNfollowing 
stimulation has been reported by some (Holley et al., 2014; de Bruyn et al., 2015; Schuh et 
al., 2016) but not others (Wilk et al., 2009). It was confirmed in this chapter that CD20+ T 
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cells in the peripheral blood express elevated intracellular IFNin both CD8- and CD8+ 
subsets following PMA/ionomycin stimulation for 3 hours, which was higher in the CD8+ 
subset, in accordance with their cytotoxic role (Fig. 5.7). In the CSF, CD20+ T cells 
expressed even higher levels compared to those in the periphery, which was significantly 
higher than CD20- T cells for both CD8- and CD8+ subsets. The enhanced secretion of IFN 
by CSF CD20+ T cells may support a variety of pathological functions leading to 
exacerbation of disease activity, as seen in people with MS treated with IFN, potentially 
linking these cells with pathology (Vartanian et al., 1995; Panitch et al., 1987). However, the 
comparable levels of IFN between both MS and OND suggests that this is probably a general 
feature of these cells. It must also be considered that IFN can play protective roles in the 
CNS, such as ameliorating EAE severity and limiting T cell proliferation; therefore, it cannot 
be excluded that these cells play a protective role (Balashov et al., 1995; Chen et al., 2009).  
A previous report suggested that CD20+ T cells preferentially secrete IL-17 compared to 
CD20- T cells following 4-hour stimulation with PMA and ionomycin (Schuh et al., 2016). 
IL-17-secreting CD20+ T cells were also reportedly expanded in rheumatoid arthritis 
compared to controls, and IL-17+CD20+ T cells have been identified in MS brain tissue 
(Eggleton et al., 2011; Holley et al., 2014). In this chapter, very little IL-17 secretion was 
observed in both CD20- and CD20+ T cell subsets in both MS and OND groups after 3 hours 
of stimulation, although a slight elevation was observed in CSF OND CD8-CD20+ T cells 
(Fig. 5.8). In line with these findings, other studies, which also stimulated their cells for 4 
hours as in the study by Schuh et al (2016), failed to identify significantly elevated IL-17 
production from peripheral CD20+ T cells compared to CD20- T cells due to low cell 
frequencies (Wilk et al., 2009; Holley et al., 2014; de Bruyn et al., 2015). Although Schuh et 
al (2016) do not report the exact frequencies of IL-17+CD20+ T cells, they appear to be 
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around 3% for CD20+ T cells compared to around 1% for CD20- T cells, and represent the 
mean rather than the median, despite the absence of a normal distribution (Schuh et al., 2016). 
The presence of some high outliers, and the likelihood of low cell numbers as reported by 
others, may have caused this difference to be exaggerated.    
Within the CD8+ subset, CD20+ T cells in the CSF expressed higher levels of CCR6 than 
CD20- T cells, which was not observed in the peripheral blood (Fig. 5.9). This novel finding 
appears to suggest the active migration of these cells into the CSF, as CCR6 regulates the 
migration of T cells into the CNS (Yamazaki et al., 2008). The abrogation of CCR6 
ameliorates disease severity in EAE models, pointing to a possible pathological role of these 
cells, however as with IFN, the lack of distinction between OND and MS suggests that this 
increased expression is not necessarily an indicator of disease (Reboldi et al., 2009; Arellano 
et al., 2015). Conversely, an alternative phenomenon may exist in that CCR6+ T cells 
preferentially become CD20+ after entering the CSF. IFN-secreting T cells in the CSF is 
strongly associated with CCR6 expression, and it may be the elevated IFN secretion by 
CCR6+ CSF T cells that leads to CD20 induction, possibly as a protective response to limit 
immune cell activation, which could have serious consequences in the CNS (Restorick et al., 
2017).  
 
5.3.5 In vitro characterisation of CD20+ T cells  
The features of CD20+ T cells were further investigated with a series of in vitro assays 
following their isolation from the peripheral blood of healthy subjects (Fig. 5.10). In contrast 
to the conventional gating strategy established in Fig. 5.1, it was important for the gates to 
identify CD20+ and CD20- T cells to be set apart to reduce the risk of cross-contamination 
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between populations. Analysis of CD20 expression immediately following cell sorting 
suggested that only 79% CD20+ T cells expressed CD20; however, the difficulty to obtain 
truly separate peaks with no overlap is a likely artefact of analysing weakly expressed 
markers by flow cytometry. 
To investigate the dynamics of CD20 expression by T cells, CD20+ T cells were cultured in 
the presence or absence of PBMC with or without stimulation (Fig. 5.11). Extending a 
previous report that CD20 is maintained for 48 hours in culture, it was shown here that CD20 
expression was maintained for 4 days when cells were cultured in isolation; in addition, 
CD20- T cells remained CD20-negative. However, in the presence of PBMC, CD20 was lost 
by around 50% of CD20+ T cells; conversely, CD20 appeared to be upregulated by some 
CD20- T cells (Fig. 5.11A, B). This implies that CD20 is regulated by interaction with other 
cells, either directly through cell-cell contact or indirectly through cytokine signals. As the 
effects of CD20 loss were greater following stimulation, CD20 expression was analysed for 
both undivided and divided cells (Fig. 5.11C, D). Loss of CD20 by CD20+ T cells was 
observed following proliferation, with some increased CD20 expression by CD20- T cells, 
suggesting that CD20 could be modulated by cell proliferation. Thus, CD20 expression 
appears to be induced but also reversible. 
Although acquisition by trogocytosis was effectively ruled out based on the presence of CD20 
mRNA in CD20+ T cells, this was further confirmed by analysing CD20 expression on 
PBMC following co-culture with each T cell subset (Fig. 5.11E). Loss of CD20 by CD20+ T 
cells was not associated with increased expression by PBMC in the same co-culture; 
accordingly, acquisition of CD20 by CD20- T cells was not associated with decreased CD20 
expression by PBMC. This therefore suggests that CD20 is not transferred by trogocytosis, at 
least in this in vitro model. 
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Further supporting the concept that CD20 may be involved in cell proliferation, I 
demonstrated that CD20+ T cells displayed a diminished proliferative capacity compared to 
CD20- T cells (Fig. 5.12). T cell populations alone did not proliferate despite the addition of 
recombinant IL-2, possibly due to the low cell numbers used (20,000 per well). Of note, Wilk 
et al (2009) also demonstrated a diminished proliferative capacity of CD20+ T cells using a 
3H-thymidine incorporation assay (Wilk et al., 2009). The group also identified that CD20 is 
functional, as CD20+ T cells can mobilise calcium ions, and that these cells were four-fold 
more susceptible to activation-induced apoptosis than CD20- T cells (Wilk et al., 2009). 
These are interesting observations, because although the precise function of CD20 has not 
been determined and no natural ligand has been described thus far, its structure has been 
compared to that of an ion channel (Kanzaki et al., 1997). Consistent with this comparison, 
evidence suggests that CD20 plays a role in calcium conductance, as transfection of CD20 
cDNA into non-lymphoid cells induces calcium transmembrane conductance identical to that 
observed in B cells (Bubien et al., 1993). Calcium is known to play a role in cell death; 
increased cytosolic levels occur during apoptosis and very high levels can promote necrosis 
(Rizzuto et al., 2003). In B cells, CD20 cross-linking can induce calcium-dependent cell death 
via activation of caspase 3 (Hofmeister et al., 2000). Although a role for CD20 in activation-
induced apoptosis seems possible, observations in this chapter that CD20 is maintained on 
isolated CD20+ T cells suggests it is not directly involved in cell death, since these cells were 
still viable following 4 days of culture. Alternatively, CD20 may be a precursor of apoptosis, 




5.3.6 Marker expression by CD20+ T cells  
Marker expression and cytokine secretion were analysed in peripheral CD20+ T cells from 
healthy subjects to further characterise this population. As previously reported, decreased 
CD38 expression, and elevated IL-4 expression, were both observed (Fig. 5.13 & Fig. 5.14) 
(Wilk et al., 2009, Schuh et al., 2016). CD38 participates in many cellular functions such as 
signal transduction and calcium signalling; as an explanation to why CD20+ T cells express 
lower levels of CD38, Wilk et al (2009) hypothesised that CD20 may serve as an alternative 
calcium signalling molecule (Wilk et al., 2009). The elevated IL-4 expression observed in the 
CD8-CD20+ population is interesting, as its functions include promoting a Th2 response, 
which seems contradictory considering the elevated IFN secretion by these cells. Despite 
this, other Th2 cytokines (IL-5 and IL-13) were not elevated (Fig. 5.14), and the lack of 
significantly elevated CXCR5 in CD20+ T cells suggests that these cells do not provide B cell 
help in the context of functioning as follicular T cells. This then could suggest an alternative 
purpose for CD20+ T cell-derived IL-4. If CD20 plays a role in limiting T cell activation, IL-
4 may be simultaneously upregulated as a regulatory mechanism to counteract the 
proinflammatory features of these cells. Indeed, IL-4 is involved in regulating inflammation 
and promoting tissue repair, and in the CNS can protect against autoimmune demyelination 
(Choi and Reiser, 1998; Furlan et al., 1998; Luzina et al., 2012).  
Though not of statistical significance, there was a trend towards increased CD27 expression in 
CD8+CD20+ T cells, suggesting that these cells have been recently activated by antigen 
presenting cells (Borst et al., 2005). Contrary to previous findings, we did not observe any 
difference in CD69, CD25 or IL-10 in these cells (Wilk et al., 2009; Schuh et al., 2016). In 
this chapter, the over-representation of CD20+ T cells in the memory compartment was 
corrected for by comparing them to CD20- memory cells, rather than the whole CD20- T cell 
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population, so as not to bias the analysis; others did not do this, which may have led to 
apparent differences in these cells based on the fact they are memory cells, rather than the fact 
they express CD20 (Wilk et al., 2009; Schuh et al., 2016).  
The strongest difference was seen in PD-1 expression, where significantly elevated levels 
were observed by CD20+ T cells in both CD8- and CD8+ subsets (Fig. 5.13). On further 
interrogation, it was clear that this increased frequency was largely in the CD8+ central 
memory subset; this was also observed for the MFI value, also suggesting an increased 
intensity of expression (Fig. 5.15A-D). PD-1 is an immune checkpoint inhibitor which 
negatively regulates T cell responses, and although often associated with exhaustion, all T 
cells express PD-1 following activation (Sharpe and Pauken, 2018). Considering the features 
of CD20+ T cells, such as their functional cytokine-secreting capacity, it seems likely that 
these cells are highly activated rather than exhausted. 
As CD20+ T cells are biased towards a CD8 memory phenotype, the cytotoxic properties of 
these cells were investigated. Although perforin expression was greater in the CD8-CD20+ 
central memory compartment, demonstrating their increased cytotoxic potential compared to 
CD20- T cells, it was reduced in CD8+ effector memory and EMRA compartments (Fig. 
5.16A, B). Granzyme B expression was also significantly reduced, as was granulysin to a 
lesser extent, whereas granzyme A expression appeared similar to CD20- T cells. These 
features suggest that CD8-CD20+ T cells possess increased cytolytic potential compared to 
CD8-CD20- T cells, whereas CD8+CD20+ T cells may have recently purged their cytolytic 
contents due their decreased expression of perforin. Despite these features, degranulation 
assays indicated that CD8+CD20+ T cells not only retain their cytolytic capacity, but the level 
of degranulation appeared even higher than in CD20- T cells (Fig. 5.17A, B). CD8-CD20+ T 
cells were also able to degranulate, as demonstrated by the increased surface expression of 
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CD107a over time, thus indicating a functional cytolytic response. These findings could 
indicate a different cytotoxic profile of CD20+ T cells compared to conventional T cells; 
other granzymes (H, K and M) exist in humans which were not studied in this chapter, and 
their possible expression by CD20+ T cells could explain how these cells retain potent 
cytolytic capacity despite their significantly reduced granzyme B expression (Voskoboinik et 
al., 2015).   
The findings in this chapter of comparable IL-2 production (Fig. 5.14) and functional lytic 
capacity (Fig. 5.17) again suggest that these cells are not exhausted, despite their elevated PD-
1 expression, since these key functions are lost early in the exhaustion process (Wherry et al., 
2003). The ability to produce IL-2 also suggests that these cells have not undergone anergy in 
response to persistent antigen (Mescher et al., 2007). Based on the features of these cells 
identified thus far, it appears that CD20 expression is induced on highly activated memory T 
cells which show some functional loss but retain their cytokine-secreting capacity. 
 
5.3.7 EBV reactivity of CD20+ T cells 
The crucial anti-viral role of CD8+ T cells led to the investigation of antigen specificity in 
CD20+ T cells. Because of the high prevalence of EBV infection in the general population, 
and its strong association with MS, EBV reactivity was investigated (Almohmeed et al., 2013; 
Pakpoor et al., 2013; Laurence and Benito-Leon, 2017). Indeed, data in this chapter identified 
CD20+ T cells within the circulating EBV-specific CD8+ T cell pool of healthy donors, 
where they even appear to be enriched (Fig. 5.18). Although time constraints prevented 
further investigation into this phenomenon, one might speculate that, since these cells are 
involved in curtailing EBV infection during the lytic cycle (i.e. active replication) and appear 
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to enter the CSF, CD20+ T cells could play a role in controlling CNS viral responses under 
homeostatic conditions. Interestingly, a recent study revealed a decreased CD8+ T cell 
response to EBV lytic phase antigens at the onset of MS, which might lead to the 
accumulation of EBV-infected B cells in the CNS; the authors postulated this as a potential 
predisposing factor to the disease (Pender et al., 2017). Reduced frequency or a functional 
defect of CD20+ T cells in MS could therefore lead to inadequate viral clearance, potentially 
explaining a link with MS pathogenesis that remains to be explored.   
 
5.4 Chapter Summary 
Data in this chapter identify CD20+ T cells in the CSF, where they express significantly 
elevated IFNand CCR6, however no difference in frequencies were observed between MS 
and OND. These cells possess a highly activated phenotype but are limited in their cytotoxic 
potential due to reduced cytotoxic molecules, and proliferative capacity, possibly due to 
elevated PD-1 expression. These features suggest that CD20 may regulate activation and/or 
proliferation and may therefore play a protective role. So, although some studies have 
reported an increased frequency of these cells in several pathological conditions, such as MS, 
rheumatoid arthritis and ovarian cancer, a direct contributing effect has not yet been 
demonstrated and the possibility that they function to dampen the immune response in the 
presence of inflammation cannot be excluded (Palanichamy et al., 2014b; Eggleton et al., 












Chapter 6: General Discussion  
The contributions of B cells to MS pathogenesis remain unclear. Clonal B cell populations 
have been identified in multiple CNS compartments, where they show features of an antigen-
driven response through somatic hypermutation and VH4 segment bias (Baranzini et al., 
1999; Colombo et al., 2010; Lovato et al., 2011; Rounds et al., 2015). B cells can traffic 
between the CNS and periphery where they may undergo clonal expansion on both sides of 
the BBB; however, the relative contributions of recently recruited peripheral B cells versus 
CNS-expanded B cells remains unclear (von Budingen et al., 2012; Palanichamy et al., 
2014a). Furthermore, a pathogenic role for the humoral response in MS is also unclear. 
Intrathecal antibodies are a hallmark of MS, and anti-neuronal antibodies can cause neuronal 
damage or disease progression in animal models (Kabat et al., 1950; Puentes et al., 2017; 
Amor et al., 2014). However, the rapid clinical benefits mediated by anti-CD20 therapies 
suggests that B cells predominantly contribute to disease through antibody-independent 
mechanisms (Harp et al., 2010; Parker Harp et al., 2015; Hauser et al., 2008). Additionally, 
the possibility remains that the benefits of anti-CD20 therapies result from CD20+ T cell 
depletion rather than B cell depletion. In this thesis I attempted to address some of these 
unanswered questions by investigating multiple aspects of B cells in MS, including their 
phenotype and antibody repertoire in the CSF. I also carried out investigations into the 
phenotype and function of CD20+ T cells in MS, control groups and healthy controls.  
 
6.1 What are the dynamics of the B cell response in MS? 
A summary schematic showing a model for the development of the humoral response in MS 
is shown in Fig. 6.1. In early MS, the humoral response is initiated following abnormal 
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recognition of self-antigen in the periphery (Stern et al., 2014). One or a small number of 
these autoreactive B cells then migrate to the CNS, arriving at the perivascular or 
leptomeningeal spaces. These cells will not be permitted into the CNS proper unless they are 
re-activated by autoreactive T cells expressing their cognate antigen, allowing their specific 
migration through the glia limitans where the humoral response against self is initiated 
(Engelhardt et al., 2017). Following local reactivation, these autoreactive B cells may also 
produce plasmablasts in the perivascular space. In addition to this, autoreactive peripheral 
plasmablasts generated from the initial reaction could also gain access to the CNS. At this 
stage, CSF antibodies are largely IgG as they are directed towards the initiating autoantigen, 
however, a low level of antibodies of alternative isotypes, with reactivity towards other 
antigens, may be detected due to their non-specific diffusion into the CSF. Based on the 
heterogeneous antigen reactivity of CSF from those with CIS, it appears that the initial stages 
of the humoral response in MS occur some time before clinical symptoms appear.  
During the early stages of disease it is likely that there is limited space for CNS residency. 
Ectopic lymphoid organ formation relies on the presence of other cell types and inflammatory 
cytokines, such as IL-17 and IL-22, and is generally associated with chronic inflammation 
(Zhang and Lu, 2012; Barone et al., 2015; Corsiero et al., 2016). Therefore, some of these 
CNS-specific memory B cells will then exit the CNS, probably via efferent lymphatics, where 
they can be detected in the periphery (Louveau et al., 2015b; von Budingen et al., 2012; 
Palanichamy et al., 2014a). Upon re-encounter with their cognate antigen in the secondary 
lymphoid organs, particularly the cervical lymph nodes, these cells will become re-activated 
and undergo subsequent germinal centre reactions, producing B cells with high affinity BCRs 
(Stern et al., 2014). Although this is a relatively small magnitude response, being highly 








may be still detected in the periphery, and resulting antibodies from this reaction may 
occasionally be detected in the periphery as a biased light chain ratio. These cells may then be 
permitted access to the CNS compartment once again, where their higher affinity for antigen 
may permit their retention, or they may again exit the CNS via efferent lymphatics. Repeated 
rounds of affinity maturation may eventually lead to divergence from the original initiating 
autoantigen, causing spreading of the antibody response to other epitopes and/or antigens as 
time progresses. 
 Despite this memory B cell enrichment, most B cells entering the CSF at time of diagnostic 
sampling appear to not be disease-specific and are likely present as a consequence of 
inflammatory activity, based on their similar immunoglobulin isotype to those in the 
periphery. The relatively high proportion of IgM+ B cells in MS CSF suggests that 
unswitched memory B cells and possibly naïve B cells also gain access to the CSF 
compartment; this is likely a consequence of inflammation and increased migratory activity at 
the BBB, in which pro-inflammatory cytokines disrupt endothelial cell-cell junctions 
Figure 6.1. Model for the development of the humoral response in multiple sclerosis. In 
early MS, autoreactive IgG+ B cells, which have been activated in the periphery against an 
unknown self-antigen migrate to the perivascular space (upper panel). Local reactivation by 
cognate T cells (not shown) leads to their re-activation where they may differentiate into 
plasmablasts or migrate into the CNS. Autoreactive IgG+ plasmablasts generated from the 
initial response in the periphery may also enter the CNS compartment with the aid of molecules 
such as MMPs. At this stage, only IgG antibodies are secreted within the CNS and CSF, 
leading to a strong Ig-bias, but bidirectional exchange of CNS-specific B cells and 
plasmablasts, and their prolonged stimulation on both sides of the BBB, allows evolution of the 
immune response. In established MS, inflammation at the blood-brain barrier generates a 
CXCL13 gradient and allows the influx of peripheral B cells of various antibody isotypes with 
multiple specificities, which may overcome the inflamed glia limitans and establish an 
increasingly diverse antibody response within the CNS (lower panel). These are often towards 
damage-associated antigens, such as neuronal and olfactory components (e.g. ANO2), and the 
resulting antibodies possess various heavy and light chain combinations, leading to a low 
Ig:Igratio. These infiltrating B cells may then set up residency within established CNS 
niches, which also permit the generation of long-lived plasma cells, although they may be out-







(Kermode et al., 1990; Minagar and Alexander, 2003). Indeed, B cell arrival at the inflamed 
CNS is facilitated by chemokines, particularly CXCL13; this thesis along with other studies 
have demonstrated the relationship between intrathecal CXCL13 and CSF B cell frequencies 
(Krumbholz et al., 2006; Kowarik et al., 2012; Puthenparampil et al., 2017). Inflammatory 
conditions also promote the formation and expansion of CNS survival niches, and elevated 
pro-inflammatory cytokines such as IL-6 promote plasma cell survival and maturation 
(Radbruch et al., 2006). Therefore, since the inflamed CNS is conducive for B cell survival, at 
least some of these IgM+ B cells may be retained, where they differentiate into ASC; in 
support of this, it has been shown that switched IgM+ B cells may undergo bidirectional 
exchange and affinity maturation in both peripheral and CNS compartments (Palanichamy et 
al., 2014a). This scenario may also apply to switched B cells expressing other 
immunoglobulin isotypes that are not specific for CNS antigens, and this sequence of events 
explains the heterogeneous antibody repertoire in MS, which recognises multiple ubiquitous 
targets that are not specific to the CNS (Brändle et al., 2016). Mechanisms favouring the 
retention and differentiation of B cells in the CNS could result from affinity for their specific 
antigen; animal studies have shown that high affinity germinal centre B cells have lower death 
rates compared to low affinity B cells, and that only those with high affinity for their antigen 
can differentiate into ASC (Phan et al., 2006; Anderson et al., 2009). Therefore, in the very 
early stages, only disease-specific B cells may be retained within the limited number of CNS 
survival niches, but with increasing duration, an increasing number of B cells with multiple 
specificities are retained. 
So, while the memory B cell response in established disease appears to be characterised by a 
relatively high turnover, the ASC response may be less dynamic, as suggested by the distinct 
differences in immunoglobulin isotypes between peripheral and CSF ASC. It also appears that 
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this isotype distribution is maintained throughout the disease course, as other studies 
identified almost all ASC as IgG+ in post-mortem MS brain tissue (Esiri, 1977, Stern et al., 
2014). Additionally, sequencing studies have demonstrated little clonal overlap between 
CD19+ B cells and CD138+ ASC in MS CSF, indicating that the CNS ASC compartment is 
largely sustained independently of B cells. Studies have shown that CD19+ B cell sequences 
are more diverse and contain less clonal populations than CD138+ ASC; in contrast, there are 
strong clonal relationships between CD19+ plasmablasts and CD19- plasma cells in MS CSF 
(Ritchie et al., 2004; Winges et al., 2007). This concept is supported by Vh segment analysis, 
showing that CSF ASC are strongly Vh4-biased, which is not always present in the IgG+ CSF 
B cell repertoire (Owens et al., 2007). In line with our own findings, which identified mature, 
IgG-biased CD19- ASC in MS CSF, this confirms that the MS CNS has the capacity to 
sustain an evolving B cell response. 
Although evidence demonstrates a strong CNS component of the ASC response, migration of 
peripheral ASC (i.e. plasmablasts) into the CNS remains a possibility (Piccio et al., 2010). In 
addition to CNS infiltration by B cells not specific to MS, this phenomenon could contribute 
to the broad reactivity of CSF antibodies. Furthermore, that CSF OCB are reduced or 
eliminated in around 45% of individuals treated with natalizumab indicates that antibody 
production is at least partly driven by peripherally-derived B-lineage cells (Mancuso et al., 
2014). Several studies have demonstrated evidence of clonally related ASC in both the CNS 
and peripheral blood, including the production of matched OCB and the identification of 
related sequences by deep sequencing in both compartments (Obermeier et al., 2008; Bankoti 
et al., 2014; Palanichamy et al., 2014a). Aside from the migration of IgG+ ASC to 
inflammatory sites, ASC can secrete MMP-2 and MMP-9 under inflammatory conditions, 
which are specifically required for the cleavage of dystroglycan at the BBB, permitting 
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migration across the parenchymal basement membrane (Kunkel and Butcher, 2003; Di 
Girolamo et al., 1998; Trocme et al., 1998; Agrawal et al., 2006; Song et al., 2015). 
Accordingly, CSF levels of MMP-9 significantly correlate with ASC frequency, and are 
increased during acute relapse, pointing to their possible migration into the CNS (Kuenz et 
al., 2008). Therefore, it seems likely that ASC, generated in the cervical lymph nodes from 
post-CNS B cells, could migrate to the CNS and continue the immune response (Stern et al., 
2014). 
 
6.2 Is the FLC Ig:Ig ratio a marker of epitope spreading in 
MS? 
A novel undertaking of this thesis was the investigation of the Ig:Ig ratio as a potential 
marker of epitope spreading in MS; a biological phenomenon in which the antibody repertoire 
becomes diversified following an initial dominant epitope-specific response (Vanderlugt and 
Miller, 2002). Several lines of evidence support B cell epitope spreading in MS. In a 
relapsing-remitting EAE model, interaction of MOG-reactive B cells with transgenic 
autoimmune T cells bearing a specific MOG peptide induced their expansion towards other 
MOG epitopes (Pollinger et al., 2009). In myelin proteolipid protein (PLP)-induced EAE, 
epitope spreading was shown to correlate with disease progression; the initial antibody 
response towards PLP expanded to multiple epitopes over the course of 67 days (Kidd et al., 
2008). In a study of childhood MS, consecutive serum antibody profiles indicated spreading 
of the immune response to CNS antigens up to twelve months after disease onset compared to 
those with a monophasic CNS event (Quintana et al., 2014). And finally, it was observed that 
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CSF containing a single band progressed to an oligoclonal response in MS but not in other 
conditions following subsequent LP (Davies et al., 2003). In addition, there is also evidence 
for T cell-mediated epitope spreading in both EAE and MS, which correlates with disease 
severity (Ellmerich et al., 2004; Davies et al., 2005).  
In this thesis, a biased Ig:Ig ratio of around 10:1 was identified in MS CSF. In contrast, a 
1977 study identified Ig-biased ASC in post-mortem MS brain tissue with an average ratio 
of 2.3:1 in active lesions; this significantly lower ratio compared to the relatively early 
(diagnostic) stages of MS, as investigated in this thesis, supports the concept of epitope 
spreading with disease progression (Esiri, 1977).  
The heterogeneous nature of MS and the benefits of early therapeutic intervention highlight 
the value of reliable prognostic markers in MS (Kappos et al., 2006; Comi et al., 2009; 
Ziemssen et al., 2015). Although some promising biomarkers have been identified thus far, 
such as CSF neurofilament light chains or chitinase 3-like 1, they appear to represent CNS 
damage, which may not necessarily be consistent with the disease course, and their ability to 
predict longer term disability remains to be seen (Canto et al., 2015;  Puentes et al., 2017; 
Soelberg Sorensen and Sellebjerg, 2016). Findings from this thesis that the CSF FLC Ig:Ig 
ratio is specifically elevated in MS groups compared to OND and ONID controls, is 
intrinsically linked to CSF ASC, and is stable following repeat sampling could make this an 
attractive potential biomarker. Although no significant difference in the FLC Ig:Ig ratio 
was seen between CIS and established MS in the small sample size used in this thesis, our 
larger study has shown a more marked difference, which was indicative of disease 
accumulation. It was shown that those with an FLC Ig:Ig ratio of >10:1 had significantly 
lower accumulation of disability at 5-year follow-up, as measured by EDSS, compared to 
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those with a ratio below 10:1 (Rathbone et al., 2018). These findings, which link antibody 
diversification with disease progression, agree with studies from the Monson group which 
used the accumulation of somatic hypermutations in MS CSF B cells to predict conversion 
from CIS to CDMS with 91% accuracy (Cameron et al., 2009; Ligocki et al., 2010).  
This scenario then suggests that Ig-expressing B cells, specific for an elusive common 
antigen, populate the CNS first due to their re-activation by antigen-specific T cells, where 
they differentiate into short-lived plasmablasts. Some of these cells then undergo terminal 
differentiation into long-lived plasma cells, where they cease migratory capacity and become 
dependent on the CNS niche for survival (Radbruch et al., 2006). With disease evolution, an 
expanding CNS B cell population will lead to competition from recently generated ASC for a 
space within the niche, and long-lived ASC may be expelled and replaced (Odendahl et al., 
2005). Findings in this thesis of CD19- ASC in MS CSF, which are generally more Ig-
biased than CD19+ ASC, support this hypothesis.  
 
6.3 What are the potential mechanisms of MS pathogenesis? 
Analysis of post-mortem MS brain tissue showed a Ig:Ig ratio of 2.3:1 in active lesions 
compared to a lower ratio of 1.6:1 in inactive lesions and non-lesional tissue (Esiri, 1977). 
This could suggest that re-appearance of the Ig-inducing antigen within the CNS contributes 
to acute inflammatory activity. Periodic reactivation of EBV within the CNS may account for 
this, which may also partly explain some of the discrepancies in the literature regarding the 
small proportion of individuals with intrathecal synthesis of anti-EBV antibodies (Bonnan, 
2014; Burnard et al., 2017). An anti-EBV response in MS is also supported by findings in this 
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thesis, which identified higher EBNA-1 reactivity in MS CSF compared to OND controls, in 
accordance with several other studies (Cepok et al., 2005b; Hecker et al., 2016; Ayoglu et al., 
2016). This could then support the concept of molecular mimicry, in which the Ig-biased 
response towards EBV cross-reacts with self-proteins; this could include the N-terminal of 
alpha B-crystallin, which is homologous to a region of EBNA-1 (Hecker et al., 2016).  
An interesting hypothesis relates to alpha B-crystallin, a small heat-shock protein and 
candidate MS autoantigen (van Noort et al., 1995). EBV infection of B cells has been shown 
to induce alpha B-crystallin expression, which is then presented via HLA-DR to T cells; 
furthermore, unlike other stress-induced heat-shock proteins, alpha B-crystallin is not 
constitutively expressed in human lymphoid tissues under normal conditions, but is found in 
all other animal species examined, potentially explaining why MS is a uniquely human 
disease (van Sechel et al., 1999). This constitutive lack of expression could prevent the 
formation of immunological tolerance towards alpha B-crystallin, which also serves as an 
immunodominant myelin antigen, where its presentation by EBV-infected B cells to 
autoreactive T cells may lead to CNS damage; accordingly, alpha B-crystallin accumulates in 
the MS brain (van Noort et al., 1995; van Noort et al., 2010; van Noort et al., 2012). This 
scenario is consistent with Pender’s hypothesis, in which defective clearance of EBV-infected 
B cells leads to their persistence and subsequent accumulation in the CNS (Pender, 2011; 
Pender et al., 2017). EBV preferentially infects memory B cells, and through altering the 
expression of chemokine receptors – for example, increasing CCR6 expression – may 
promote their migration to the CNS (Cepok et al., 2005b; Joseph et al., 2000; Nakayama et 
al., 2002; Reboldi et al., 2009). As shown in this thesis, the sustained elevation of CSF Ig 
following inhibition of lymphocyte trafficking with natalizumab indicates the long-term 
survival of ASC in these individuals, which is independent of peripheral B cell recruitment. 
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Similarly, another study found that Ig FLC was increased following intrathecal rituximab 
treatment, and that CSF B cells were not depleted, despite the significant reduction in 
peripheral B cells (Topping et al., 2016). This could implicate a role for EBV in transforming 
CNS-resident B cells and in maintaining the Ig-biased antibody response which persists in 
the absence of peripheral lymphocyte trafficking. Additionally, the preferential association of 
EBV-infected B cells with ectopic follicles in MS CNS could suggest that these follicles have 
resulted from their expansion (Serafini et al., 2007). ASC derived from infected memory B 
cells can sustain a functional EBV pool, and this differentiation activates the replicative cycle 
of EBV (Laichalk and Thorley-Lawson, 2005; Al Tabaa et al., 2009). Shedding of the virus 
from infected ASC may then infect memory B cells arriving from the periphery, leading to 
their subsequent transformation, and allowing their prolonged survival where they can 
provide co-stimulation to autoreactive T cells arriving at the CNS (Pender, 2011). 
 
6.4 Could CD20+ T cells be involved in MS pathology? 
Since CD20+ T cells are also depleted by rituximab, we asked whether these cells might be 
associated with MS pathogenesis (Wilk et al., 2009; Palanichamy et al., 2014b). The novel 
findings in this thesis that CD20+ T cells may enter the CSF, based on their elevated CCR6 
expression, where they retain their ability to secrete high levels of IFN, could indicate that 
these cells are pathogenic; however, their presence in OND CSF suggests that CD20+ T cells 
are likely part of a normal physiological response. Including the CSF and peripheral blood, as 
investigated in this thesis, CD20+ T cells have also been identified in other bodily 
compartments, such as the liver, lymph node, thymus, bone marrow, brain, synovial fluid and 
ascites (Algino et al., 1996; Wilk et al., 2009; Holley et al., 2014; de Bruyn et al., 2015; 
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Schuh et al., 2016). Features of these cells, including elevated IFN expression and reduced 
granzyme B and perforin expression, suggest they have recently been activated and have 
purged their cytolytic contents; although these cells still retain functional cytolytic capacity, 
their reduced proliferation and elevated PD-1 expression suggests that CD20 may act to limit 
potentially damaging T cell responses by curtailing activation. For example, in B cells, CD20 
becomes heavily phosphorylated following PMA stimulation, which occurs in conjunction 
with abnormally high intracellular calcium levels; CD20 on T cells is also associated with 
calcium flux, suggesting the two processes are related and that CD20 may modulate T cell 
functions in response to stimulation (Valentine et al., 1987; Genot et al., 1991; Wilk et al., 
2009). 
Another observation in this thesis was the apparent decrease in CD20+ T cells in MS CSF; 
interestingly, this was also observed in another study (Schuh et al., 2016). If CD20 expression 
is induced on highly activated T cells to limit their activation, their lower frequency in MS 
could suggest that this protective mechanism is faulty, leading to loss of control and 
exacerbated inflammation. Alternatively, the presence of CD20+ T cells may be a remnant of 
a prior anti-viral response, including towards EBV; this is in line with the observation that 
CD20+ T cells appear to be over-represented in the normal CD8+ memory T cell pool 
towards EBV lytic antigens. Interestingly, a recent study identified decreased CD8+ T cell 
responses to EBV lytic antigens in MS (Pender et al., 2017). It is therefore tempting to 
speculate that the defective response of MS T cells towards EBV-infected B cells manifests as 




6.5 A case for neuro-protective B cells in MS? 
The use of immunomodulators have offered insights into the role of immune cells in MS. 
Memory B cells are the major contributing B cell subset to MS pathogenesis, as demonstrated 
by their depletion observed with all current MS therapies, many of which were believed to act 
via T cell inhibition (Baker et al., 2017a; Baker et al., 2017b). In this instance, sparing naïve B 
cells may prove beneficial, since central tolerance checkpoints remain intact in MS and 
therefore autoreactive B cells will not be found in this pool (Kinnunen et al., 2013). It 
therefore seems important for new immunotherapies to consider sparing non-pathogenic 
subsets, particularly considering the potentially damaging consequences of widespread 
targeting of immune populations. A prime example is the increased inflammatory activity 
seen following depletion of BAFF and APRIL by atacicept in two MS clinical trials, where 
the harmful effects of blocking ASC function appears to indicate some protective function for 
these cells (Kappos et al., 2014; Sergott et al., 2015). Another therapeutic failure in MS 
resulted from TNF blockade; a seemingly contradictory outcome, considering the positive 
effects in RA and EAE (Lenercept MS study group, 1999; Moreland et al., 1997; Selmaj et 
al., 1991). Development of ectopic lymphoid structures, a characteristic pathological feature 
of RA, is abrogated following anti-TNF treatment, and in a mouse model of atherosclerosis, 
TNF was shown to be critical for tertiary lymphoid organ development (Canete et al., 2009; 
Furtado et al., 2014). Therefore, it can be speculated that the removal of ectopic lymphoid 
follicles by TNF blockade in MS also depletes protective ASC. Indeed, Matsumoto et al 
showed that protective compensatory mechanisms arise during inflammation to limit further 
damage (Matsumoto et al., 2014). It was demonstrated that in EAE but not control mice, 
plasmablasts generated in the draining lymph nodes following disease induction 
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predominantly expressed IL-10 and contributed to curtailing autoimmunity, and genetic 
ablation of the ASC transcription factors IRF4 and BLIMP-1 led to exacerbated disease 
(Matsumoto et al., 2014).  
In addition to a protective role via cytokine secretion, ASC may also secrete protective 
antibodies. It has also been shown that ASC generated from regulatory B10 cells rapidly 
produced polyreactive IgG and IgM antibodies which may promote the clearance of common 
antigens, such as those associated with apoptotic debris (Maseda et al., 2012; Schwartz‐Albiez 
et al., 2009). Natural autoreactive antibodies are reported to promote CNS repair via several 
mechanisms, such as preventing neuron apoptosis or activating intracellular repair-promoting 
signals in CNS cells; remyelinating antibodies have also been investigated clinically for their 
therapeutic potential (Paz Soldan et al., 2003; Wright et al., 2009; Eisen et al., 2017). B cells 
may also provide CNS protection under homeostatic conditions; it was recently shown that B 
cells are the predominant infiltrating lymphocyte subset in the developing mouse brain, where 
they promote oligodendrogenesis (Tanabe and Yamashita, 2018). These data collectively 
indicate that the balance between regulatory and pathogenic ASC may modulate disease 
severity and raise the possibility that regulatory ASC may generate protective antibodies in 
MS. 
In all, the heterogeneity of the B cell response, and their multiple and sometimes 
contradictory contributions to MS, raises the possibility that MS may be preferentially driven 
by certain lymphocyte subsets which varies between individuals. MS lesions demonstrate 
immunological heterogeneity between individuals, for example showing signs of T cell-
mediated (pattern I) or antibody-mediated (pattern II) damage, and these lesion patterns 
remained consistent in consecutive biopsies from the same individuals (Lucchinetti et al., 
2000; Metz et al., 2014). This implicates different pathological mechanisms between 
207 
 
individuals, and may allow for more targeted immunomodulators to be administered based on 
the underlying immunopathology; immunological heterogeneity may also explain the variable 
responses to anti-CD20 therapy, which although beneficial for many, some individuals 
continue to accumulate disability (Cross et al., 2006). As such, these variable 
immunophenotypes are an important consideration and may have important implications for 
the development of personalised therapies. 
 
6.6 Further Work  
Following on from this thesis, investigating the diagnostic and prognostic relevance of the 
CSF Ig:Ig ratio in a large cohort over an extended time period could determine the extent 
of its association with disability accumulation, and whether it has use as a biomarker in MS. 
Longitudinal analysis of the Ig:Ig ratio, for example, in response to relapse or infectious 
agents, may provide evidence of its involvement in epitope spreading and/or disease 
progression. Further investigating the CSF antibody reactivity of Ig and Ig in a larger 
cohort, against unconventional and full-length proteins, may help to identify the specificity of 
the dominant IgG antibodies found in MS. This could be achieved by immunohistochemistry 
of CSF antibodies on fresh-frozen MS brain sections and detection with anti-Ig or anti-Ig 
antibodies. Or, column purification of CSF IgG antibodies following incubation with MS 
brain lysate, and performing mass spectrometry on antibody-antigen complexes. 
Understanding the molecular trigger(s) of MS could allow the development of antigen-
specific tolerance mechanisms, antigen-specific adoptive immunotherapy or even vaccination. 
In relation to EBV, phase I clinical trials are currently underway into an EBV-specific 
adoptive immunotherapy in MS (Pender et al., 2014). The therapies involve expanding and 
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infusing EBV-specific T cells, as performed in a proof of principle study by Pender et al., and 
are reportedly showing positive results thus far (Pender et al., 2014; Pender, 2017).  
As discussed, the presence of B cells in MS CSF is not necessarily indicative of their 
involvement in disease; intracellular cytokine analysis by CSF B lineage cells could shed 
more light on the involvement of B cell subsets in MS. It is known that peripheral B cells in 
MS express lower IL-10 and higher pro-inflammatory cytokines such as IL-6 and GM-CSF, 
but the cytokine-secreting properties of CSF-derived B cells have not been explored thus far 
(Barr et al., 2012; Li et al., 2015; Guerrier et al., 2018). In line with this, developing safer and 
more focussed therapies which specifically deplete pathogenic memory B cells will 
potentially be important; future therapies may be able to predict disease progression and 
response to therapy based on the immunophenotype by analysing CSF or blood lymphocyte 
populations, for example, by using mass cytometry to analyse up to 42 parameters, or using 
next generation sequencing to identify disease-associated SNPs (Kay et al., 2016; Vrijenhoek 
et al., 2015). 
Finally, although this thesis unravelled several novel aspects of CD20+ T cell biology, many 
questions remain unanswered. The precise function of CD20 on T cells, if any, and its 
dynamics on these cells, remain elusive. Observations in this thesis suggest that CD20 is 
inducible in these cells; therefore, analysis of methylation status may inform whether CD20 is 
regulated at the epigenetic level. Importantly, a potential role for these cells in MS remains 
elusive; a larger scale study, including CSF analysis, and the response of these cells towards 
























Appendix I. Demographics for Chapter 3. Matched blood and CSF samples were 
obtained from MS groups and those with OND and ONID as controls. The median age and 
range and female to male sex ratio is shown where information was available.  
OND; other neurological disease, ONID; other neurological inflammatory disease, CIS; 
clinically isolated syndrome, NAT; MS patients recently ceasing natalizumab therapy. The 
MS group consisted of 9 RRMS and 5 PPMS cases.  






















Appendix II. Demographics and FLC data for Chapter 4. For the first part of the 
project using planar antigen arrays, six CSF samples from individuals with OND, CIS 
and RRMS were selected (A). The number of sample per group and median age and 
range is shown. MS samples were selected based on their high (CIS) or low (RRMS) 
Ig:Ig FLC ratios (B). CSF samples used in the second part of the project using 
suspension bead arrays (C). These samples were solely selected based on their 
diagnosis. The number of sample per group and median age and range is shown. The 




























Appendix III Demographics for Chapter 5. 
Appendix III. Demographics for Chapter 5. Matched blood and CSF samples were 
obtained from MS (2 CIS and 4 RRMS) and OND groups. The number of samples, 






















Appendix IV Positive hits identified using planar arrays were 























Appendix IV. Positive hits identified using planar arrays were selected for 
verification using suspension bead arrays. Based on the initial discovery phase, 
antigens were selected for the verification phase using suspension bead arrays. 























Appendix V Antigens from the literature were included in the 






















Appendix V. Antigens from the literature were included in the suspension bead 
arrays. Antigens identified in the literature, including those previously identified by the 
group, were selected for the verification phase using suspension bead arrays. Depending 
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